0000105770-21-000083.txt : 20211028 0000105770-21-000083.hdr.sgml : 20211028 20211028160125 ACCESSION NUMBER: 0000105770-21-000083 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 211358149 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-Q 1 wst-20210930.htm 10-Q wst-20210930
0000105770--12-312021Q3falsehttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member00001057702021-01-012021-09-30xbrli:shares00001057702021-10-18iso4217:USD00001057702021-07-012021-09-3000001057702020-07-012020-09-3000001057702020-01-012020-09-30iso4217:USDxbrli:shares00001057702021-09-3000001057702020-12-3100001057702019-12-3100001057702020-09-30xbrli:pure0000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300000105770srt:MinimumMember2021-01-012021-09-300000105770srt:MaximumMember2021-01-012021-09-300000105770wst:SmartDoseMember2013-06-300000105770wst:SmartDoseMember2021-09-300000105770wst:TermLoanDue2024Member2021-09-300000105770wst:TermLoanDue2024Member2020-12-310000105770wst:SeniorNotesDue2022Member2021-09-300000105770wst:SeniorNotesDue2022Member2020-12-310000105770wst:SeniorBNotesDue2024Member2021-09-300000105770wst:SeniorBNotesDue2024Member2020-12-310000105770wst:SeniorCNotesDue2027Member2021-09-300000105770wst:SeniorCNotesDue2027Member2020-12-310000105770wst:Revolvingcreditfacilitydue2024Member2021-09-300000105770us-gaap:LetterOfCreditMemberwst:Revolvingcreditfacilitydue2024Member2021-09-30iso4217:SGD0000105770currency:SGDus-gaap:ForwardContractsMember2020-12-310000105770currency:SGDus-gaap:ForwardContractsMember2021-09-300000105770us-gaap:ForwardContractsMembercurrency:USD2020-12-310000105770us-gaap:ForwardContractsMembercurrency:USD2021-09-300000105770us-gaap:ForeignExchangeForwardMember2021-01-012021-09-300000105770us-gaap:LongMembercurrency:USDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-300000105770us-gaap:ShortMembercurrency:USDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-30iso4217:EURiso4217:JPY0000105770currency:JPYus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-300000105770currency:JPYus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-300000105770currency:SGDus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-300000105770currency:SGDus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-09-300000105770currency:USDus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2019-12-310000105770currency:JPYus-gaap:CrossCurrencyInterestRateContractMember2019-12-310000105770currency:USDus-gaap:CrossCurrencyInterestRateContractMember2019-12-31utr:bbl0000105770us-gaap:OptionMember2017-11-012021-09-300000105770us-gaap:OptionMember2021-01-012021-09-30iso4217:USDwst:bbl0000105770us-gaap:OptionMember2021-09-300000105770us-gaap:ForeignCurrencyGainLossMember2021-07-012021-09-300000105770us-gaap:ForeignCurrencyGainLossMember2020-07-012020-09-300000105770us-gaap:ForeignCurrencyGainLossMember2021-01-012021-09-300000105770us-gaap:ForeignCurrencyGainLossMember2020-01-012020-09-300000105770us-gaap:FairValueHedgingMember2021-07-012021-09-300000105770us-gaap:FairValueHedgingMember2021-01-012021-09-300000105770us-gaap:FairValueHedgingMember2020-07-012020-09-300000105770us-gaap:FairValueHedgingMember2020-01-012020-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000105770us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000105770us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000105770us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300000105770us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000105770us-gaap:CashFlowHedgingMember2021-07-012021-09-300000105770us-gaap:CashFlowHedgingMember2020-07-012020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000105770us-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000105770us-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000105770wst:NetSalesMember2020-07-012020-09-300000105770wst:NetSalesMember2020-01-012020-09-300000105770us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000105770us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000105770us-gaap:CostOfSalesMember2020-01-012020-09-300000105770us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300000105770us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000105770us-gaap:CashFlowHedgingMember2021-01-012021-09-300000105770us-gaap:CashFlowHedgingMember2020-01-012020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000105770us-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000105770us-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000105770wst:NetSalesMember2021-07-012021-09-300000105770wst:NetSalesMember2021-01-012021-09-300000105770us-gaap:CostOfSalesMember2021-07-012021-09-300000105770us-gaap:CostOfSalesMember2020-07-012020-09-300000105770us-gaap:CostOfSalesMember2021-01-012021-09-300000105770us-gaap:InterestExpenseMember2021-07-012021-09-300000105770us-gaap:InterestExpenseMember2020-07-012020-09-300000105770us-gaap:InterestExpenseMember2021-01-012021-09-300000105770us-gaap:InterestExpenseMember2020-01-012020-09-300000105770us-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMember2021-07-012021-09-300000105770us-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMember2020-07-012020-09-300000105770us-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMember2021-01-012021-09-300000105770us-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMember2020-01-012020-09-300000105770us-gaap:NondesignatedMember2021-07-012021-09-300000105770us-gaap:NondesignatedMember2020-07-012020-09-300000105770us-gaap:NondesignatedMember2021-01-012021-09-300000105770us-gaap:NondesignatedMember2020-01-012020-09-300000105770us-gaap:FairValueInputsLevel1Member2021-09-300000105770us-gaap:FairValueInputsLevel2Member2021-09-300000105770us-gaap:FairValueInputsLevel3Member2021-09-300000105770us-gaap:ForeignExchangeContractMember2021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2021-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2021-09-300000105770us-gaap:CurrencySwapMember2021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2021-09-300000105770us-gaap:FairValueInputsLevel1Member2020-12-310000105770us-gaap:FairValueInputsLevel2Member2020-12-310000105770us-gaap:FairValueInputsLevel3Member2020-12-310000105770us-gaap:CurrencySwapMember2020-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2020-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2020-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2020-12-310000105770us-gaap:ForeignExchangeContractMember2020-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2020-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2020-12-310000105770srt:MinimumMemberwst:SalesProjectionsMember2021-09-300000105770wst:SalesProjectionsMembersrt:MaximumMember2021-09-300000105770srt:WeightedAverageMemberwst:SalesProjectionsMember2021-09-300000105770wst:ProbabilitiesOfSuccessfulFDAApprovalMembersrt:MinimumMember2021-09-300000105770wst:ProbabilitiesOfSuccessfulFDAApprovalMembersrt:MaximumMember2021-09-300000105770srt:MinimumMemberwst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember2021-09-300000105770srt:MaximumMemberwst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember2021-09-300000105770us-gaap:MeasurementInputDiscountRateMember2021-09-3000001057702020-01-012020-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:CommonStockMember2020-12-310000105770us-gaap:AdditionalPaidInCapitalMember2020-12-310000105770us-gaap:TreasuryStockMember2020-12-310000105770us-gaap:RetainedEarningsMember2020-12-310000105770us-gaap:RetainedEarningsMember2021-01-012021-03-3100001057702021-01-012021-03-310000105770us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000105770us-gaap:TreasuryStockMember2021-01-012021-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000105770us-gaap:CommonStockMember2021-03-310000105770us-gaap:AdditionalPaidInCapitalMember2021-03-310000105770us-gaap:TreasuryStockMember2021-03-310000105770us-gaap:RetainedEarningsMember2021-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100001057702021-03-310000105770us-gaap:RetainedEarningsMember2021-04-012021-06-3000001057702021-04-012021-06-300000105770us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000105770us-gaap:TreasuryStockMember2021-04-012021-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000105770us-gaap:CommonStockMember2021-06-300000105770us-gaap:AdditionalPaidInCapitalMember2021-06-300000105770us-gaap:TreasuryStockMember2021-06-300000105770us-gaap:RetainedEarningsMember2021-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000001057702021-06-300000105770us-gaap:RetainedEarningsMember2021-07-012021-09-300000105770us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000105770us-gaap:TreasuryStockMember2021-07-012021-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:CommonStockMember2021-09-300000105770us-gaap:AdditionalPaidInCapitalMember2021-09-300000105770us-gaap:TreasuryStockMember2021-09-300000105770us-gaap:RetainedEarningsMember2021-09-300000105770us-gaap:CommonStockMember2019-12-310000105770us-gaap:AdditionalPaidInCapitalMember2019-12-310000105770us-gaap:TreasuryStockMember2019-12-310000105770us-gaap:RetainedEarningsMember2019-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100001057702019-01-012019-12-310000105770us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000105770srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000105770us-gaap:RetainedEarningsMember2020-01-012020-03-3100001057702020-01-012020-03-310000105770us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000105770us-gaap:TreasuryStockMember2020-01-012020-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000105770us-gaap:CommonStockMember2020-03-310000105770us-gaap:AdditionalPaidInCapitalMember2020-03-310000105770us-gaap:TreasuryStockMember2020-03-310000105770us-gaap:RetainedEarningsMember2020-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100001057702020-03-310000105770us-gaap:RetainedEarningsMember2020-04-012020-06-3000001057702020-04-012020-06-300000105770us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000105770us-gaap:TreasuryStockMember2020-04-012020-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000105770us-gaap:CommonStockMember2020-06-300000105770us-gaap:AdditionalPaidInCapitalMember2020-06-300000105770us-gaap:TreasuryStockMember2020-06-300000105770us-gaap:RetainedEarningsMember2020-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000001057702020-06-300000105770us-gaap:RetainedEarningsMember2020-07-012020-09-300000105770us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000105770us-gaap:TreasuryStockMember2020-07-012020-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:CommonStockMember2020-09-300000105770us-gaap:AdditionalPaidInCapitalMember2020-09-300000105770us-gaap:TreasuryStockMember2020-09-300000105770us-gaap:RetainedEarningsMember2020-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000105770us-gaap:PerformanceSharesMember2021-01-012021-09-300000105770us-gaap:PerformanceSharesMember2021-09-300000105770us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000105770country:USus-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000105770country:USus-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000105770country:US2021-07-012021-09-300000105770country:US2020-07-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-07-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-07-012020-09-300000105770us-gaap:ForeignPlanMember2021-07-012021-09-300000105770us-gaap:ForeignPlanMember2020-07-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000105770country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000105770country:USus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000105770country:US2021-01-012021-09-300000105770country:US2020-01-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-09-300000105770us-gaap:ForeignPlanMember2021-01-012021-09-300000105770us-gaap:ForeignPlanMember2020-01-012020-09-300000105770wst:A2020RestructuringPlanMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2020-07-310000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2021-09-300000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2021-09-300000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2021-07-012021-09-300000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2021-07-012021-09-300000105770wst:A2020RestructuringPlanMember2020-07-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2020-12-310000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2020-12-310000105770wst:A2020RestructuringPlanMember2020-12-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2021-01-012021-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300000105770wst:A2020RestructuringPlanMember2021-01-012021-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2021-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2021-09-300000105770wst:A2020RestructuringPlanMember2021-09-300000105770wst:A2018RestructuringPlanMember2018-02-012018-02-280000105770wst:A2018RestructuringPlanMember2018-02-280000105770wst:A2018RestructuringPlanMember2021-09-300000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2020-12-310000105770wst:A2018RestructuringPlanMember2020-12-310000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2021-01-012021-09-300000105770wst:A2018RestructuringPlanMember2021-01-012021-09-300000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2021-09-300000105770wst:SmartDoseMember2021-07-012021-09-300000105770wst:SmartDoseMember2020-07-012020-09-300000105770wst:SmartDoseMember2020-01-012020-09-300000105770wst:SmartDoseMember2021-01-012021-09-30wst:segment0000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000105770us-gaap:IntersegmentEliminationMember2021-07-012021-09-300000105770us-gaap:IntersegmentEliminationMember2020-07-012020-09-300000105770us-gaap:IntersegmentEliminationMember2021-01-012021-09-300000105770us-gaap:IntersegmentEliminationMember2020-01-012020-09-300000105770us-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770us-gaap:OperatingSegmentsMember2020-07-012020-09-300000105770us-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770us-gaap:OperatingSegmentsMember2020-01-012020-09-300000105770us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000105770us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000105770us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000105770us-gaap:CorporateNonSegmentMember2020-01-012020-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania23-1210010
 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
530 Herman O. West Drive, Exton, PA
19341-0645
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.          Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                      Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑ Accelerated filer☐
Non-accelerated filer
☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                      ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
As of October 18, 2021, there were 74,079,715 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS
  Page
 
ITEM 1. 
 
 
 
 
 
ITEM 2.
ITEM 3.
ITEM 4.
   
 
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 6.
   
   

2
PART I. FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)

 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2021202020212020
Net sales$706.5 $548.0 $2,100.8 $1,566.7 
Cost of goods and services sold418.3 353.4 1,225.6 1,010.0 
Gross profit288.2 194.6 875.2 556.7 
Research and development13.1 12.5 39.1 34.0 
Selling, general and administrative expenses91.9 76.2 264.8 225.7 
Other expense (income) (Note 15)1.8 6.7 3.0 6.2 
Operating profit181.4 99.2 568.3 290.8 
Interest expense1.8 2.1 5.6 6.1 
Interest income(0.4)(0.2)(0.7)(1.2)
Other nonoperating (income) expense(1.1)(0.4)(3.6)(0.3)
Income before income taxes181.1 97.7 567.0 286.2 
Income tax expense12.0 21.1 73.0 52.1 
Equity in net income of affiliated companies(6.5)(5.7)(20.1)(13.7)
Net income$175.6 $82.3 $514.1 $247.8 
Net income per share:   
Basic$2.37 $1.11 $6.95 $3.35 
Diluted$2.31 $1.09 $6.78 $3.28 
Weighted average shares outstanding:    
Basic74.1 73.9 74.0 73.9 
Diluted76.0 75.8 75.8 75.6 

See accompanying notes to condensed consolidated financial statements.
3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2021202020212020
Net income$175.6 $82.3 $514.1 $247.8 
Other comprehensive (loss) income, net of tax:   
Foreign currency translation adjustments(24.2)29.4 (46.9)(4.9)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.2, $(0.1), $0.4, and $(1.2), respectively
0.4 (0.2)1.1 (4.0)
Net gain (loss) on derivatives, net of tax of $(0.4), $(0.2), $(0.4) and $(0.4), respectively
1.3 (0.9)0.7 (1.0)
Other comprehensive (loss) income, net of tax(22.5)28.3 (45.1)(9.9)
Comprehensive income$153.1 $110.6 $469.0 $237.9 

See accompanying notes to condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)September 30,
2021		December 31,
2020
ASSETS  
Current assets:  
Cash and cash equivalents$688.0 $615.5 
Accounts receivable, net476.4 385.3 
Inventories353.8 321.3 
Other current assets80.1 51.6 
Total current assets1,598.3 1,373.7 
Property, plant and equipment2,146.1 2,035.5 
Less: accumulated depreciation and amortization1,139.6 1,092.3 
Property, plant and equipment, net1,006.5 943.2 
Operating lease right-of-use assets58.5 68.3 
Investments in affiliated companies215.7 214.7 
Goodwill108.9 111.1 
Intangible assets, net26.1 30.5 
Deferred income taxes80.0 16.0 
Pension and other postretirement benefits17.0 12.9 
Other noncurrent assets31.6 23.4 
Total Assets$3,142.6 $2,793.8 
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$44.2 $2.3 
Accounts payable207.7 213.1 
Pension and other postretirement benefits2.4 2.3 
Accrued salaries, wages and benefits114.0 106.0 
Income taxes payable39.5 26.0 
Operating lease liabilities8.1 10.1 
Other current liabilities142.7 143.6 
Total current liabilities558.6 503.4 
Long-term debt209.9 252.9 
Deferred income taxes11.6 10.4 
Pension and other postretirement benefits52.1 57.5 
Operating lease liabilities53.4 60.4 
Deferred compensation benefits26.9 22.9 
Other long-term liabilities27.8 31.8 
Total Liabilities940.3 939.3 
Commitments and contingencies (Note 17)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
— — 
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.1 million and 74.0 million, respectively
18.8 18.8 
Capital in excess of par value251.2 267.3 
Retained earnings2,335.8 1,846.7 
Accumulated other comprehensive loss(155.7)(110.6)
Treasury stock, at cost (1.2 million and 1.3 million shares, respectively)
(247.8)(167.7)
Total Equity2,202.3 1,854.5 
Total Liabilities and Equity$3,142.6 $2,793.8 
See accompanying notes to condensed consolidated financial statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Nine Months Ended
September 30,
 20212020
Cash flows from operating activities:  
Net income$514.1 $247.8 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation84.6 77.3 
Amortization3.3 3.3 
Stock-based compensation27.5 27.6 
Pension settlement charge0.7 3.4 
Contingent consideration payments in excess of acquisition-date liability(1.0)(0.7)
Other non-cash items, net(17.5)(9.5)
Changes in assets and liabilities
(188.5)(25.4)
Net cash provided by operating activities423.2 323.8 
Cash flows from investing activities:  
Capital expenditures(176.9)(116.7)
Purchase of intangibles— (3.8)
Other, net1.2 (1.4)
Net cash used in investing activities(175.7)(121.9)
Cash flows from financing activities:  
Repayments of long-term debt(1.1)(1.7)
Dividend payments(37.8)(35.5)
Proceeds from stock-based compensation awards23.1 22.0 
Employee stock purchase plan contributions5.7 4.6 
Shares purchased under share repurchase programs(137.1)(115.5)
Shares repurchased for employee tax withholdings(14.7)(2.3)
Net cash used in financing activities(161.9)(128.4)
Effect of exchange rates on cash(13.1)6.8 
Net increase (decrease) in cash and cash equivalents72.5 80.3 
Cash, including cash equivalents at beginning of period615.5 439.1 
Cash, including cash equivalents at end of period$688.0 $519.4 

See accompanying notes to condensed consolidated financial statements.
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1:  Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2021, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Throughout the COVID-19 pandemic, production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.

Note 2:  New Accounting Standards

Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance, and where applicable, the Company has made contract amendments to reflect the removal of the LIBOR rate.

Note 3:  Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

7
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Biologics
40 %
32 %
40 %
29 %
Generics
 18 %
18 %
17 %
19 %
Pharma
24 %
27 %
24 %
28 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
High-Value Product Components
55 %
47 %
54 %
45 %
High-Value Product Delivery Devices
5 %
5 %
4 %
5 %
Standard Packaging
22 %
25 %
23 %
26 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Americas
45 %
49 %
45 %
49 %
Europe, Middle East, Africa
45 %
42 %
45 %
43 %
Asia Pacific
10 %
9 %
10 %
8 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2020$10.9 
Contract assets, September 30, 2021
12.8 
Change in contract assets - increase (decrease)$1.9 
Deferred income, December 31, 2020$(57.1)
Deferred income, September 30, 2021
(38.1)
Change in deferred income - decrease (increase)$19.0 

Starting in the third quarter of 2020, the Company entered into new capacity reservation agreements, which include the receipt of up-front cash. The decrease in the deferred income balance is primarily due to the revenue recognition associated with the capacity reservation agreements, which is to be recognized over the next 1 to 2 years.
8
During the nine months ended September 30, 2021, $30.0 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2021, there was $4.1 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $3.2 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.


Note 4:  Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2021202020212020
Net income$175.6 $82.3 $514.1 $247.8 
Weighted average common shares outstanding74.1 73.9 74.0 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.9 1.8 1.7 
Weighted average shares assuming dilution76.0 75.8 75.8 75.6 

During the three months ended September 30, 2021 and 2020, there were 0.0 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.0 million and 0.2 million antidilutive shares outstanding during the nine months ended September 30, 2021 and 2020, respectively.

In December 2020, we announced a share repurchase program for calendar-year 2021 authorizing the repurchase of up to 631,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2021. During the nine months ended September 30, 2021, we purchased 479,000 shares of our common stock under the program at a cost of $137.1 million, or an average price of $286.23 per share. This share repurchase program is expected to be completed by December 31, 2021.

Note 5:  Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2021		December 31,
2020
Raw materials$140.4 $133.5 
Work in process71.1 54.9 
Finished goods142.3 132.9 
 $353.8 $321.3 

9
Note 6:  Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating lease cost$3.3 $3.1 $9.5 $9.3 
Short-term lease cost0.4 0.3 0.9 0.6 
Variable lease cost1.1 1.2 3.3 2.8 
Total lease cost$4.8 $4.6 $13.7 $12.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2.9 $3.2 $9.2 $9.6 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $0.3 $0.8 $4.6 

As of September 30, 2021 and December 31, 2020, the weighted average remaining lease term for operating leases was 10.9 and 11.1 years, respectively.

As of September 30, 2021 and December 31, 2020, the weighted average discount rate was 3.67% and 3.68%, respectively.

10
Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20212020
2021 (remaining period as of )$3.0 $12.4 
202210.3 10.4 
20239.3 9.3 
20248.5 8.7 
20256.8 6.9 
Thereafter36.2 37.5 
74.1 85.2 
Less: imputed lease interest(12.6)(14.7)
Total lease liabilities$61.5 $70.5 

Note 7:  Affiliated Companies

At September 30, 2021 and December 31, 2020, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $207.1 million and $201.9 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $8.6 million and $12.8 million, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $34.0 million and $119.6 million for the three and nine months ended September 30, 2021, respectively, as compared to $36.6 million and $97.0 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the payable balance due to affiliates was $13.8 million and $33.6 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.8 million and $8.8 million, respectively, for the three and nine months ended September 30, 2021, as compared to $2.7 million and $7.7 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the receivable balance due from affiliates was $2.2 million and $1.4 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2020 Annual Report for additional details.

11
Note 8:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2021.
($ in millions)September 30,
2021		December 31,
2020
Term Loan, due December 31, 2024 (1.01%)
$86.6 $87.7 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
254.6 255.7 
Less: unamortized debt issuance costs0.5 0.5 
Total debt254.1 255.2 
Less: current portion of long-term debt44.2 2.3 
Long-term debt, net$209.9 $252.9 

Please refer to Note 8, Debt, to the consolidated financial statements in our 2020 Annual Report for additional details regarding our debt agreements.

Credit Agreement - Credit Facility

At September 30, 2021, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $297.6 million.

Credit Agreement Amendment - Term Loan

At September 30, 2021, we had $86.6 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $84.4 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Note 9:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2021 and December 31, 2020, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.

12
In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2021, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD28.8 — 24.0 
Yen6,131.7 24.6 27.7 
SGD28.7 17.8 3.0 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.4 billion ($86.1 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2021, we purchased several series of call options for a total of 596,367 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.

As of September 30, 2021, we had outstanding contracts to purchase 182,495 barrels of crude oil from October 2021 to March 2023, at a weighted-average strike price of $70.40 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2021 and December 31, 2020.

13
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of (Gain) Loss Recognized in Income for theAmount of (Gain) Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Fair Value Hedges:
Hedged item (intercompany loan)
$(5.9)$9.3 $(11.0)$25.1 Other expense (income)
Derivative designated as hedging instrument
5.9 (9.3)11.0 (25.1)Other expense (income)
Amount excluded from effectiveness testing
(0.9)(1.9)(2.1)(5.9)Other expense (income)
Total$(0.9)$(1.9)$(2.1)$(5.9)

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2021 and 2020 were $0.6 million, $1.9 million, and $1.3 million, $5.0 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.2)$(0.1)$0.1 $(0.7)Other expense (income)
Total$(0.2)$(0.1)$0.1 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$0.1 $(0.5)$0.1 $0.2 Net sales
Foreign currency hedge contracts1.4 — (0.3)0.1 Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$1.5 $(0.5)$(0.1)$0.4  
Net Investment Hedges:     
Cross-currency swap$0.6 $(3.0)$— $— Other expense (income)
Total$0.6 $(3.0)$— $—  
14
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.6)$2.8 $0.9 $(3.3)Other expense (income)
Total$(0.6)$2.8 $0.9 $(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$— $0.9 $(0.3)Net sales
Foreign currency hedge contracts(1.4)(0.3)1.2 (0.1)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(1.9)$(0.3)$2.3 $(0.2) 
Net Investment Hedges:     
Cross-currency swap$6.0 $(2.0)$— $— Other expense (income)
Total$6.0 $(2.0)$— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales$0.1 $0.2 $0.9 $(0.3)
Cost of goods and services sold(0.3)0.1 1.2 (0.1)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)0.1 (0.7)0.9 (3.3)

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Commodity call options$0.5 $0.1 $1.6 $0.3 Other expense (income)
Total$0.5 $0.1 $1.6 $0.3 

For the three and nine months ended September 30, 2021 and 2020, there was no material ineffectiveness related to our hedges.

15
Note 10:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$14.4 $14.4 $— $— 
Foreign currency contracts12.0 — 12.0 — 
Cross-currency swap2.2 — 2.2 — 
Commodity call options1.8 — 1.8 — 
 $30.4 $14.4 $16.0 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities15.7 15.7 — — 
Foreign currency contracts2.8 — 2.8 — 
 $22.0 $15.7 $2.8 $3.5 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.8 $12.8 $— $— 
Foreign currency contracts3.0 — 3.0 — 
Commodity call options0.3 0.3 
 $16.1 $12.8 $3.3 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities14.5 14.5 — — 
Cross-currency swap5.6 — 5.6 — 
Foreign currency contracts9.7 — 9.7 — 
 $33.4 $14.5 $15.3 $3.6 

16
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets and long-term liabilities, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. All derivatives are recognized on a gross basis as either assets or liabilities in the balance sheet.

Level 3 Fair Value Measurements

The fair value of the contingent consideration liability related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose® contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose® technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in an increase or decrease to the SmartDose® contingent consideration.

The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2019$3.3 
Increase in fair value recorded in earnings1.2 
Payments(0.9)
Balance, December 31, 20203.6 
Increase in fair value recorded in earnings0.9 
Payments(1.0)
Balance, September 30, 2021$3.5 

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.
17
The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2021, the estimated fair value of long-term debt was $220.3 million compared to a carrying amount of $209.9 million. At December 31, 2020, the estimated fair value of long-term debt was $265.7 million and the carrying amount was $252.9 million.

Note 11:  Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive income (loss) before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive income (loss)3.2 — 0.5 — 3.7 
Other comprehensive income (loss), net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2021202020212020
Gains (losses) on derivatives:
Foreign currency contracts$(0.1)$(0.3)$(1.1)$0.3 Net sales
Foreign currency contracts0.4 (0.1)(1.9)0.3 Cost of goods and services sold
Foreign currency contracts(0.9)1.1 (2.1)5.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(0.7)0.6 (5.4)5.4 
Tax benefit (expense)0.7 (0.3)2.2 (1.9)
Net of tax$— $0.3 $(3.2)$3.5 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.2 $0.4 (a)
Actuarial losses0.1 0.2 (0.1)— (a)
Settlements— (1.1)(0.7)(3.4)(a)
Total before tax0.2 (0.8)(0.6)(3.0)
Tax benefit (expense)(0.1)0.3 0.1 0.8 
Net of tax$0.1 $(0.5)$(0.5)$(2.2)
Total reclassifications for the period, net of tax$0.1 $(0.2)$(3.7)$1.3 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
18
Note 12: Shareholders’ Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 

19
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 

20
Note 13:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2021, there were 2,485,724 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2021, we granted 159,932 stock options at a weighted average exercise price of $277.23 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $63.72 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 0.7%; expected life of 5.6 years based on prior experience; stock volatility of 23.9% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2021, we granted 36,902 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $331.56 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2021, we granted 5,109 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $292.42 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Stock-based compensation expense was $11.4 million and $27.5 million for the three and nine months ended September 30, 2021, respectively. For the three and nine months ended September 30, 2020, stock-based compensation expense was $10.0 million and $27.6 million, respectively.

21
Note 14:  Benefit Plans

The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.1 $0.4 $— $— $0.1 $0.4 
Interest cost1.6 1.7 — — 1.6 1.7 
Expected return on assets(2.9)(2.8)— — (2.9)(2.8)
Amortization of prior service credit— 0.1 (0.1)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.5 0.4 (0.3)(0.6)0.2 (0.2)
Settlements— 1.1 — — — 1.1 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(0.9)$0.5 $(0.4)$(0.8)$(1.3)$(0.3)
International plans0.2 0.4 — — 0.2 0.4 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.9 $1.0 $— $— $0.9 $1.0 
Interest cost4.5 5.5 0.1 0.1 4.6 5.6 
Expected return on assets(9.0)(8.8)— — (9.0)(8.8)
Amortization of prior service credit0.1 0.1 (0.3)(0.5)(0.2)(0.4)
Recognized actuarial losses (gains)1.5 1.4 (1.2)(1.4)0.3 — 
Settlements0.7 3.4 — — 0.7 3.4 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(2.4)$1.5 $(1.4)$(1.8)$(3.8)$(0.3)
International plans1.1 1.1 — — 1.1 1.1 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 

During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

22
Note 15:  Other Expense (Income)

Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Restructuring and related charges$0.4 $4.5 $2.5 $4.5 
Fixed asset impairments and loss (gain) on sale of equipment0.2 0.9 0.6 7.2 
Contingent consideration0.1 0.8 0.9 0.9 
Foreign exchange transaction losses (gains)0.4 1.0 (2.5)(4.5)
Other items0.7 (0.5)1.5 (1.9)
Total other expense (income)$1.8 $6.7 $3.0 $6.2 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was originally expected to require restructuring and related charges of approximately $15 million to $17 million, with annualized savings being in the range of $3.5 million to $4.5 million. Due to the recent increase in customer demand, the Company will no longer proceed with certain portions of the plan, thus reducing the total expected charges to be approximately $9 million to $11 million. Similarly, annualized savings are now expected to be in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $7.1 million in restructuring and related charges associated with this plan.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2020$4.6 $— $4.6 
Charges1.0 1.5 2.5 
Cash payments(1.4)(0.9)(2.3)
Balance, September 30, 2021$4.2 $0.6 $4.8 

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2020$0.1 $0.1 
Cash payments(0.1)(0.1)
Balance, September 30, 2021$— $— 

23
Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Other Items

During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a net loss in our cost investment activity of $1.8 million, inclusive of an impairment charge of $2.2 million for one of the Company's cost investments. For the three and nine months ended September 30, 2020, there was no activity related to our cost investments.

During both the three and nine months ended September 30, 2021 and 2020, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information.

Note 16:  Income Taxes

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $12.0 million and $21.1 million for the three months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 6.6% and 21.6%, respectively. The provision for income taxes was $73.0 million and $52.1 million for the nine months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 12.9% and 18.2%, respectively. The reduction in effective tax rates for the three and nine months ended September 30, 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit.

Note 17:  Commitments and Contingencies

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2020 Annual Report.

Note 18:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

24
The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales:    
Proprietary Products$577.0 $421.5 $1,708.0 $1,194.5 
Contract-Manufactured Products129.7 126.6 393.2 372.5 
Intersegment sales elimination(0.2)(0.1)(0.4)(0.3)
Consolidated net sales$706.5 $548.0 $2,100.8 $1,566.7 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating profit (loss):
Proprietary Products$195.5 $107.5 $594.3 $312.9 
Contract-Manufactured Products16.8 18.8 51.9 52.1 
Total business and segment operating profit$212.3 $126.3 $646.2 $365.0 
Corporate and Unallocated
Stock-based compensation expense$(11.4)$(10.0)$(27.5)$(27.6)
Corporate general costs (1)(18.1)(12.4)(45.5)(39.5)
Unallocated Items:
Restructuring and severance related charges(0.3)(4.5)(2.5)(6.7)
Amortization of Acquisition-related Intangible Assets (2)(0.2)(0.2)(0.6)(0.4)
Cost investment activity(0.9)— (1.8)— 
Total Corporate and Unallocated(30.9)(27.1)(77.9)(74.2)
Total consolidated operating profit$181.4 $99.2 $568.3 $290.8 
Other expense, net0.3 1.5 1.3 4.6 
Income before income taxes$181.1 $97.7 $567.0 $286.2 

25
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other Expense (Income), for further discussion of these items.

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2020 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2020 Annual Report and in Part II, Item 1A of this Form 10-Q.

Throughout this section, references to “Notes” refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and additional medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.
26
Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

Impact of COVID-19

West has been actively monitoring the COVID-19 situation and its impact globally. Our primary objectives have remained the same throughout the pandemic: to support the safety of our team members and their families and continue to support patients around the world. Throughout the COVID-19 pandemic, our production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. Our capital and financial resources, including overall liquidity, remain strong. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders. However, we cannot predict the impact of the progression of the COVID-19 pandemic on future results due to a variety of factors, including the continued good health of our employees, the ability of suppliers to continue to operate and deliver, the ability of West and its customers to maintain operations, continued access to transportation resources, the changing needs and priorities of customers, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. We will continue to closely monitor the COVID-19 pandemic in order to ensure the safety of our people and our ability to serve our customers and patients worldwide.

2021 Financial Performance Summary

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2021:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
 Three months ended September 30, 2021 GAAP
$181.4 $12.0 $175.6 $2.31 
Unallocated items:
Restructuring and related charges0.3 0.1 0.2 — 
Amortization of acquisition-related intangible assets (2)
0.2 — 0.7 0.01 
Cost investment activity (3)
0.9 0.2 0.7 0.01 
Royalty acceleration (5)
— 20.4 (20.4)(0.27)
Three months ended September 30, 2021 adjusted amounts (non-U.S. GAAP)
$182.8 $32.7 $156.8 $2.06 

27
($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2021 GAAP
$568.3 $73.0 $514.1 $6.78 
Unallocated items:
Restructuring and related charges2.5 0.6 1.9 0.02 
Pension settlement (1)
— 0.2 0.6 0.01 
Amortization of acquisition-related intangible assets (2)
0.6 0.1 2.1 0.03 
Cost investment activity (3)
1.8 (0.1)1.9 0.02 
Tax law changes (4)
— 1.4 (1.4)(0.02)
Royalty acceleration (5)
— 20.4 (20.4)(0.27)
Nine months ended September 30, 2021 adjusted amounts (non-U.S. GAAP)
$573.2 $95.6 $498.8 $6.57 

During the three and nine months ended September 30, 2021, we recorded a tax benefit of $8.4 million and $26.9 million, respectively, associated with stock-based compensation.

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2020:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2020 GAAP
$99.2 $21.1 $82.3 $1.09 
Unallocated items:
Pension settlement (1)
— 0.3 0.8 0.01 
Restructuring and severance related charges4.5 1.1 3.4 0.04 
Amortization of acquisition-related intangible assets (2)
0.2 — 0.7 0.01 
Three months ended September 30, 2020 adjusted amounts (non-U.S. GAAP)
$103.9 $22.5 $87.2 $1.15 

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2020 GAAP
$290.8 $52.1 $247.8 $3.28 
Unallocated items:
Pension settlement (1)
— 0.8 2.6 0.03 
Restructuring and severance related charges6.7 1.7 5.0 0.06 
Amortization of acquisition-related intangible assets (2)
0.4 0.1 2.9 0.04 
Nine months ended September 30, 2020 adjusted amounts (non-U.S. GAAP)
$297.9 $54.7 $258.3 $3.41 

During the three and nine months ended September 30, 2020, we recorded a tax benefit of $2.0 million and $14.0 million, respectively, associated with stock-based compensation.

28
(1)The Company recorded a pension settlement charge within other nonoperating (income) expense, as it determined that normal-course lump-sum payments for our U.S. qualified, and in 2020 our non-qualified, defined benefit pension plan exceeded the threshold for settlement accounting.

(2)During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.5 million and $1.6 million, respectively, or amortization expense in association with an acquisition of increased ownership interest in Daikyo. During the three and nine months ended September 30, 2020 the Company recorded $0.2 million and $0.4 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2020, the Company recorded $0.5 million and $2.5 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

(3)During the three months ended September 30, 2021, we recorded a net loss on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded an impairment charge on one of our cost investments, partially offset by the gain on the sale of a cost investment.

(4)During the nine months ended September 30, 2021, the Company recorded a tax benefit of $1.4 million due to the impact of a United Kingdom tax law change enacted during the period.

(5)During the three and nine months ended September 30, 2021, the Company prepaid future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit.

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.

Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment, for the three months ended September 30, 2021 and 2020:
Three Months Ended
September 30,		Percentage Change
($ in millions)20212020As-ReportedOrganic
Proprietary Products$577.0 $421.5 36.9 %35.7 %
Contract-Manufactured Products129.7 126.6 2.4 %2.1 %
Intersegment sales elimination(0.2)(0.1)— — 
Consolidated net sales$706.5 $548.0 28.9 %27.9 %

Consolidated net sales increased by $158.5 million, or 28.9%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $5.5 million.
29
Excluding foreign currency translation effects, consolidated net sales for the three months ended September 30, 2021 increased by $153.0 million, or 27.9%, as compared to the same period in 2020.

Proprietary Products – Proprietary Products net sales increased by $155.5 million, or 36.9%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $5.0 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2021 increased by $150.5 million, or 35.7%, as compared to the same period in 2020, primarily due to growth in our high-value product offerings, including Westar®, NovaPure®, and FluroTec®-coated components. The three months ended September 30, 2021 included approximately $115 million in COVID-19 related activity for vaccines, antiviral treatments and treatment of underlying COVID-19 symptoms. The three months ended September 30, 2020 included approximately $32 million in COVID-19 related activity for antiviral treatments and treatment of underlying COVID-19 symptoms.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $3.1 million, or 2.4%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $0.5 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2021 increased by $2.6 million, or 2.1%, as compared to the same period in 2020, due to an increase in the sale of healthcare-related medical devices.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table presents net sales, consolidated and by reportable segment, for the nine months ended September 30, 2021 and 2020:
Nine Months Ended
September 30,		Percentage Change
($ in millions)20212020As-ReportedOrganic
Proprietary Products$1,708.0 $1,194.5 43.0 %38.1 %
Contract-Manufactured Products393.2 372.5 5.6 %3.1 %
Intersegment sales elimination(0.4)(0.3)— — 
Consolidated net sales$2,100.8 $1,566.7 34.1 %29.8 %

Consolidated net sales increased by $534.1 million, or 34.1%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $67.2 million. Excluding foreign currency translation effects, consolidated net sales for the nine months ended September 30, 2021 increased by $466.9 million, or 29.8%, as compared to the same period in 2020.

Proprietary Products – Proprietary Products net sales increased by $513.5 million, or 43.0%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $57.9 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2021 increased by $455.6 million, or 38.1%, as compared to the same period in 2020, primarily due to growth in our high-value product offerings, including Westar®, NovaPure®, Daikyo®, and FluroTec®-coated components. The nine months ended September 30, 2021 included approximately $335 million in COVID-19 related activity for vaccines, antiviral treatments and treatment of underlying COVID-19 symptoms. The nine months ended September 30, 2020 included approximately $52 million in COVID-19 related activity for antiviral treatments and treatment of underlying COVID-19 symptoms.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $20.7 million, or 5.6%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $9.3 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2021 increased by $11.4 million, or 3.1%, as compared to the same period in 2020, due to an increase in the sale of healthcare-related medical devices.
30
Gross Profit

The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Proprietary Products:  
Gross profit$267.3 $171.9 $811.5 $492.8 
Gross profit margin46.3 %40.8 %47.5 %41.3 %
Contract-Manufactured Products:   
Gross profit$20.9 $22.7 $63.7 $63.9 
Gross profit margin16.1 %17.9 %16.2 %17.2 %
Consolidated gross profit$288.2 $194.6 $875.2 $556.7 
Consolidated gross profit margin40.8 %35.5 %41.7 %35.5 %

Consolidated gross profit increased by $93.6 million, or 48.1%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.6 million for the three months ended September 30, 2021, as compared to the same period in 2020. Consolidated gross profit margin increased by 5.3 margin points for the three months ended September 30, 2021, as compared to the same period in 2020.

Consolidated gross profit increased by $318.5 million, or 57.2% for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $25.7 million for the nine months ended September 30, 2021, as compared to the same period in 2020. Consolidated gross profit margin increased by 6.2 margin points for the nine months ended September 30, 2021, as compared to the same period in 2020.

Proprietary Products - Proprietary Products gross profit increased by $95.4 million, or 55.5%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.5 million. Proprietary Products gross profit margin increased by 5.5 margin points for the three months ended September 30, 2021, as compared to the same periods in 2020, due to a favorable mix of products sold, sales price increases and production efficiencies, partially offset by increased overhead costs including compensation costs.

Proprietary Products gross profit increased by $318.7 million, or 64.7%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $23.9 million. Proprietary Products gross profit margin increased by 6.2 margin points for the nine months ended September 30, 2021, as compared to the same period in 2020, due to a favorable mix of products sold, sales price increases and production efficiencies, partially offset by increased overhead costs including compensation costs.

Contract-Manufactured Products - Contract-Manufactured Products gross profit decreased by $1.8 million, or 7.9%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $0.1 million. Contract-Manufactured Products gross profit margin decreased by 1.8 margin points for the three months ended September 30, 2021, as compared to the same period in 2020, due to unfavorable mix of products sold and timing of the pass-through of raw material price increases to customers.

31
Contract-Manufactured Products gross profit decreased by $0.2 million, or 0.3%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.8 million. Contract-Manufactured Products gross profit margin decreased by 1.0 margin points for the nine months ended September 30, 2021, as compared to the same period in 2020, due to unfavorable mix of products sold and timing of the pass-through of raw material price increases to customers, partially offset by production efficiencies.

Research and Development (“R&D”) Costs

The following table presents R&D costs, consolidated and by reportable segment:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Proprietary Products$13.1 $12.5 $39.1 $34.0 
Contract-Manufactured Products— — — — 
Consolidated R&D costs$13.1 $12.5 $39.1 $34.0 

Consolidated R&D costs increased by $0.6 million, or 4.8%, and $5.1 million, or 15.0%, for the three and nine months ended September 30, 2021, respectively, as compared to the same period in 2020. Efforts remain focused on the continued investment in self-injection systems development, fluid transfer admixture devices, elastomeric packaging components, and formulation development.

All of the R&D costs incurred during the three and nine months ended September 30, 2021 related to Proprietary Products.

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Proprietary Products$58.5 $50.6 $180.0 $144.7 
Contract-Manufactured Products3.9 3.7 11.4 11.4 
Corporate29.5 21.9 73.4 69.6 
Consolidated SG&A costs$91.9 $76.2 $264.8 $225.7 
SG&A as a % of net sales13.0 %13.9 %12.6 %14.4 %

Consolidated SG&A costs increased by $15.7 million, or 20.6%, for the three months ended September 30, 2021, as compared to the same period in 2020, due to an increase in compensation costs, costs related to professional services and an unfavorable foreign currency translation impact of $0.4 million.

Consolidated SG&A costs increased by $39.1 million, or 17.3%, for the nine months ended September 30, 2021, as compared to the same period in 2020, due to an increase in compensation costs and an unfavorable foreign currency translation impact of $4.5 million.

Proprietary Products - Proprietary Products SG&A costs increased by $7.9 million, or 15.6%, for the three months ended September 30, 2021, as compared to the same period in 2020. Proprietary Products SG&A costs increased primarily due to an increase in compensation costs and costs related to professional services.

32
Proprietary Products SG&A costs increased by $35.3 million, or 24.4%, for the nine months ended September 30, 2021, as compared to the same period in 2020. Proprietary Products SG&A costs increased primarily due to an increase in compensation costs, costs related to professional services and an unfavorable foreign currency translation impact of $4.2 million.

Contract-Manufactured Products - Contract-Manufactured Products SG&A costs increased by $0.2 million, or 5.4% for the three months ended September 30, 2021, as compared to the same period in 2020, and remained consistent for the nine months ended September 30, 2021, as compared to the same period in 2020.

Corporate - Corporate SG&A costs increased by $7.6 million, or 34.7%, for the three months ended September 30, 2021, as compared to the same period in 2020, primarily due to an increase in compensation costs and costs related to professional services.

Corporate SG&A costs increased by $3.8 million, or 5.5%, for the nine months ended September 30, 2021, as compared to the same period in 2020, primarily due to an increase in compensation costs and costs related to professional services.

Other Expense (Income)

The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:
Expense (Income) Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Proprietary Products$0.2 $1.3 $(1.9)$1.2 
Contract-Manufactured Products0.2 0.2 0.4 0.4 
Corporate and unallocated1.4 5.2 4.5 4.6 
Consolidated other expense$1.8 $6.7 $3.0 $6.2 

Other income and expense items, consisting of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, development and licensing income, contingent consideration, fixed asset impairments and miscellaneous income and charges, are generally recorded within segment results.

Consolidated other expense (income) changed by $4.9 million for the three months ended September 30, 2021, as compared to the same period in 2020, due to a decrease in restructuring and related charges, and fixed asset impairments recorded within the Proprietary Products segment, offset by a net loss recorded in the three months ended September 30, 2021 as a result of the sale one of the Company's cost investments.

Consolidated other expense (income) changed by $3.2 million for the nine months ended September 30, 2021, as compared to the same period in 2020, due to a decrease in restructuring and related charges, and fixed asset impairments recorded within the Proprietary Products segment, offset by a net loss recorded in the nine months ended September 30, 2021 as a result of activity related to the Company's cost investments.
33
Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Proprietary Products$195.5 $107.5 $594.3 $312.9 
Contract-Manufactured Products16.8 18.8 51.9 52.1 
Corporate(29.5)(22.4)(73.0)(67.1)
Adjusted consolidated operating profit$182.8 $103.9 $573.2 $297.9 
Adjusted consolidated operating profit margin25.9 %19.0 %27.3 %19.0 %
Unallocated items(1.4)(4.7)(4.9)(7.1)
Consolidated operating profit$181.4 $99.2 $568.3 $290.8 
Consolidated operating profit margin25.7 %18.1 %27.1 %18.6 %

Consolidated operating profit increased by $82.2 million, or 82.9%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.2 million for the three months ended September 30, 2021, as compared to the same period in 2020.

Consolidated operating profit increased by $277.5 million, or 95.4%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $20.8 million for the nine months ended September 30, 2021, as compared to the same period in 2020.

Proprietary Products - Proprietary Products operating profit increased by $88.0 million, or 81.9%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.1 million, due to the factors described above, most notably the sales increase in our high-value product offerings, inclusive of COVID-19 related activity.

Proprietary Products operating profit increased by $281.4 million, or 89.9%, for the nine months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $19.3 million, due to the factors described above, most notably due to the sales increase in our high-value product offerings, inclusive of COVID-19 related activity.

Contract-Manufactured Products - Contract-Manufactured Products operating profit decreased by $2.0 million, or 10.6%, for the three months ended September 30, 2021, as compared to the same period in 2020, including a favorable foreign currency translation impact of $0.1 million, due to the factors described above, most notably due an unfavorable mix of products sold and timing of the pass-through of raw material price increases to customers.

Contract-Manufactured Products operating profit decreased by $0.2 million, or 0.4%, for the nine months ended September 30, 2021, respectively, as compared to the same period in 2020, including a favorable foreign currency translation impact of $1.5 million, due to the factors described above.

Corporate- Corporate costs increased by $7.1 million, or 31.7%, for the three months ended September 30, 2021, as compared to the same period in 2020, due to the factors described above.

Corporate costs increased by $5.9 million, or 8.8%, for the nine months ended September 30, 2021, respectively, as compared to the same period in 2020, due to the factors described above.

34
Unallocated items – Other unallocated items during the three months ended September 30, 2021 consisted of $0.3 million in restructuring and related costs, $0.2 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020, and a net loss of $0.9 million on the sale of one of the Company's cost investments.

Other unallocated items during the nine months ended September 30, 2021 consisted of $2.5 million in restructuring and related costs, $0.6 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020, and a net loss in our cost investment activity of $1.8 million.

Other unallocated items during the three months ended September 30, 2020 consisted of $4.5 million in restructuring and related costs and $0.2 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020. Other unallocated items during the nine months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges, $2.2 million in severance related costs, and $0.4 million of amortization expense associated with an acquisition of an intangible asset. Please refer to Note 15, Other Expense (Income), for further discussion of these items.

Interest Expense, Net

The following table presents interest expense, net, by significant component:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Interest expense$2.7 $2.4 $7.6 $7.1 
Capitalized interest(0.9)(0.3)(2.0)(1.0)
Interest income(0.4)(0.2)(0.7)(1.2)
Interest expense, net$1.4 $1.9 $4.9 $4.9 

Interest expense, net, decreased by $0.5 million, or 26.3%, for the three months ended September 30, 2021, as compared to the same period in 2020, and remained consistent for the nine months ended September 30, 2021, as compared to the same period in 2020.

Other Nonoperating (Income) Expense

Other nonoperating (income) expense changed by $0.7 million for the three months ended September 30, 2021, as compared to the same period in 2020, primarily due to the pension settlement charge recorded in 2020. In the three months ended September 30, 2020, we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

Other nonoperating (income) expense changed by $3.3 million for the nine months ended September 30, 2021, as compared to the same period in 2020, primarily due to a reduction in the pension settlement charge and by a decrease in U.S. pension interest cost. In each nine month period, we determined that normal-course lump-sum payments for our U.S. qualified, and non-qualified in 2020, defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

Income Tax Expense
The provision for income taxes was $12.0 million and $21.1 million for the three months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 6.6% and 21.6%, respectively.

The decrease in the effective tax rate is primarily due to the Company's prepayment of future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit for the three months ended September 30, 2021.
35

The provision for income taxes was $73.0 million and $52.1 million for the nine months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 12.9% and 18.2%, respectively. The decrease in the effective tax rate is primarily due to the Company's prepayment of future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit for the nine months ended September 30, 2021.

Equity in Net Income of Affiliated Companies
Equity in net income of affiliated companies represents the contribution to earnings from our 49% ownership interest in Daikyo, and our 49% ownership interest in five companies majority-owned by a long-time partner located in Mexico. Please refer to Note 7, Affiliated Companies, for further discussion. Equity in net income of affiliated companies increased by $0.8 million for the three months ended September 30, 2021, as compared to the same period in 2020, due to favorable operating results at Daikyo and the Mexico affiliates.

Equity in net income of affiliated companies increased by $6.4 million for the nine months ended September 30, 2021, as compared to the same period in 2020, due to favorable operating results at Daikyo and the Mexico affiliates and reduction in amortization expense related to our increase in ownership interest in Daikyo of $0.9 million.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the nine months ended September 30:
($ in millions)20212020
Net cash provided by operating activities$423.2 $323.8 
Net cash used in investing activities$(175.7)$(121.9)
Net cash used in financing activities$(161.9)$(128.4)

Net Cash Provided by Operating Activities – Net cash provided by operating activities increased by $99.4 million for the nine months ended September 30, 2021, as compared to the same period in 2020, primarily due to improved operating results, offset by increases in working capital and timing of tax payments in 2021.

Net Cash Used in Investing Activities – Net cash used in investing activities increased by $53.8 million for the nine months ended September 30, 2021, as compared to the same period in 2020, due to the increase in capital expenditures in 2021 to meet customer demand.

Net Cash Used in Financing Activities – Net cash used in financing activities increased by $33.5 million for the nine months ended September 30, 2021, as compared to the same period in 2020, primarily due to increases in purchases under our share repurchases.

36
Liquidity and Capital Resources

The table below presents selected liquidity and capital measures:
($ in millions)September 30,
2021		December 31,
2020
Cash and cash equivalents$688.0 $615.5 
Accounts receivable, net$476.4 $385.3 
Inventories$353.8 $321.3 
Accounts payable$207.7 $213.1 
Debt$254.1 $255.2 
Equity$2,202.3 $1,854.5 
Working capital$1,039.7 $870.3 

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at September 30, 2021 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at September 30, 2021 included $234.2 million of cash held by subsidiaries within the U.S., and $453.8 million of cash held by subsidiaries outside of the U.S. During the nine months ended September 30, 2021, we purchased 479,000 shares of our common stock under the share repurchase program at a cost of $137.1 million, or an average price of $286.23 per share.

Working capital – Working capital at September 30, 2021 increased by $169.4 million, or 19.5%, as compared to December 31, 2020, which includes an unfavorable foreign currency translation impact of $18.9 million. Excluding the impact of currency exchange rates, cash and cash equivalents, accounts receivable, inventories, and total current liabilities increased by $85.5 million, $104.1 million, $42.1 million, and $66.4 million, respectively. The increase in accounts receivable was due to increased sales activity. The increase in inventories that occurred in the period was to ensure we have sufficient inventory on hand to support the needs of our customers. The increase in total current liabilities was primarily due to the reclassification of a portion of the Company's debt from long-term to short-term.

Debt and credit facilities – The $1.1 million decrease in total debt at September 30, 2021, as compared to December 31, 2020, resulted from debt repayments under our Term Loan.

Our sources of liquidity include our Credit Facility. At September 30, 2021, we had no outstanding borrowings under the Credit Facility. At September 30, 2021, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.4 million, was $297.6 million. We do not expect any significant limitations on our ability to access this source of funds.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2021, we were in compliance with all of our debt covenants.

We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

37

Commitments and Contractual Obligations

A table summarizing the amounts and estimated timing of future cash payments resulting from commitments and contractual obligations was provided in our 2020 Annual Report. During the three months ended September 30, 2021, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

At September 30, 2021, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2020 Annual Report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2020 Annual Report.

NEW ACCOUNTING STANDARDS

For information on new accounting standards that were issued but not yet adopted, during the three months ended September 30, 2021, and the impact, if any, on our financial position or results of operations, see Note 2, New Accounting Standards.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “plan,” “expect,” “believe,” “intend,” “will,” “estimate,” “continue” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:
•sales demand and our ability to meet that demand;
•competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;
38
•customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;
•interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customers’ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;
•the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;
•whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;
•the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Crystal Zenith prefilled syringes;
•average profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;
•maintaining or improving production efficiencies and overhead absorption;
•dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;
•the loss of key personnel or highly-skilled employees;
•the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;
•the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;
•the cost and progress of development, regulatory approval and marketing of new products;
•our ability to obtain and maintain licenses in any jurisdiction in which we do business;
•the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and
•the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.

This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2020 Annual Report as well as Part II, section 1A of this quarterly report.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

39
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2020 Annual Report.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls include some, but not all, components of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of September 30, 2021, our disclosure controls and procedures are effective.

Changes in Internal Controls
During the quarter ended September 30, 2021, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

None.

ITEM 1A.  RISK FACTORS

There are no material changes to the risk factors disclosed in Part I, Item 1A of our 2020 Annual Report.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended September 30, 2021, there were no purchases of our common stock made by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act.

ITEM 6.  EXHIBITS

The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

40
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer



October 28, 2021
41
EXHIBIT INDEX
Exhibit NumberDescription
3.1
3.2
4.1
4.2
4.3
4.4 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.1
10.10
10.36
31.1
31.2
32.1*
32.2*
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.


(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

* Furnished, not filed.
F-1
 EX-10.1 2 char1-1826719v3xlibortrans.htm EX-10.1 Document

LIBOR TRANSITION AMENDMENT
THIS LIBOR TRANSITION AMENDMENT (this “Agreement”), dated as of October 26, 2021 (the “Amendment Effective Date”), is entered into between WEST PHARMACEUTICAL SERVICES, INC., a Pennsylvania corporation (the “Company” or “Borrowers’ Representative”), and BANK OF AMERICA, N.A., as administrative agent (the “Administrative Agent”).
RECITALS
WHEREAS, the Company, the other borrowers party thereto (collectively with the “Borrowers” and each a “Borrower”), the lenders from time to time party thereto (the “Lenders”), and Bank of America, N.A., as Administrative Agent, have entered into that certain Credit Agreement dated as of March 28, 2019 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”);
WHEREAS, certain Loans under the Credit Agreement denominated in Sterling, Yen, and Euros (collectively, the “Impacted Currencies”) incur or are permitted to incur interest, fees, commissions or other amounts based on the London Interbank Offered Rate as administered by the ICE Benchmark Administration (“LIBOR”) in accordance with the terms of the Credit Agreement; and
WHEREAS, applicable parties under the Credit Agreement have determined in accordance with the Credit Agreement that LIBOR for the Impacted Currencies should be replaced with a successor rate in accordance with the Credit Agreement and, in connection therewith, the Administrative Agent has determined that certain conforming changes are necessary or advisable.
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.     Defined Terms. Capitalized terms used herein but not otherwise defined herein (including on any Appendix attached hereto) shall have the meanings provided to such terms in the Credit Agreement, as amended by this Agreement.
2.    Agreement. Notwithstanding any provision of the Credit Agreement or any other document related thereto (the “Loan Documents”) to the contrary, the parties hereto hereby agree that the terms set forth on Appendix A shall apply to the Impacted Currencies. For the avoidance of doubt, to the extent provisions in the Credit Agreement apply to the Impacted Currencies and such provisions are not specifically addressed by Appendix A, the provisions in the Credit Agreement shall continue to apply to the Impacted Currencies.
3.    Conflict with Loan Documents. In the event of any conflict between the terms of this Agreement and the terms of the Credit Agreement or the other Loan Documents, the terms hereof shall control.
4.    Conditions Precedent. This Agreement shall become effective upon receipt by the Administrative Agent of counterparts of this Agreement, properly executed by the Borrowers’ Representative and the Administrative Agent.
5.    Payment of Expenses. The Company agrees to reimburse the Administrative Agent for all reasonable and documented out-of-pocket costs and expenses of the Administrative Agent in
CHAR1\1826719v3

connection with the preparation, execution and delivery of this Agreement, including all reasonable fees and expenses of counsel to the Administrative Agent (paid directly to such counsel if requested by the Administrative Agent).
6.    Miscellaneous.
(a)The Loan Documents, and the obligations of the Borrowers under the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect according to their terms. This Agreement is a Loan Document.
(b)The Borrowers’ Representative (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of the Borrowers’ obligations under the Loan Documents and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge any Borrower’s obligations under the Loan Documents.
(c)The Borrowers’ Representative represents and warrants as follows:
(i)    It has taken all necessary corporate or other action to authorize the execution, delivery and performance of this Agreement.
(ii)    This Agreement has been duly executed and delivered by the Borrowers’ Representative and constitutes the legal, valid and binding obligation, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).
(iii)    No consent or authorization of, filing with or other act by or in respect of, any Governmental Authority or any other Person (including stockholders and creditors of the Borrowers) is required in connection with the execution, delivery, performance, validity or enforceability of this Agreement, except to the extent that such consent or authorization has been obtained or such filing or action has been completed prior to the date hereof.
(iv)    The execution and delivery of this Agreement does not violate any Requirement of Law or material Contractual Obligation of any Borrower or any of its Subsidiaries.
(iv)    Before and after giving effect to this Agreement, (A) the representations and warranties of each Borrower contained in Section 3 of the Credit Agreement or any other Loan Document are (i) with respect to representations and warranties that contain a materiality qualification or are qualified by Material Adverse Effect, true and correct and (ii) with respect to representations and warranties that do not contain a materiality qualification and are not qualified by Material Adverse Effect, true and correct in all material respects, except to the extent that such representations and warranties specifically refer to an earlier date, in which case such representations and warranties are (1) with respect to representations and warranties that contain a materiality qualification or are qualified by Material Adverse Effect, true and correct and (2) with respect to representations and warranties that do not contain a materiality qualification and are not
CHAR1\1826719v3

qualified by Material Adverse Effect, true and correct in all material respects, in each case, as of such earlier date; and (b) no Default or Event of Default exists.
(d)This Agreement may be in the form of an electronic record (in “.pdf” form or otherwise) and may be executed using electronic signatures, which shall be considered as originals and shall have the same legal effect, validity and enforceability as a paper record. This Agreement may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts shall be one and the same Agreement.  For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by the Administrative Agent of a manually signed Agreement which has been converted into electronic form (such as scanned into “.pdf” format), or an electronically signed Agreement converted into another format, for transmission, delivery and/or retention.
(e)Any provision of this Agreement held to be illegal, invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the legality, validity or enforceability of the remaining provisions hereof and the illegality, invalidity or unenforceability of a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
(f)The terms of the Credit Agreement with respect to governing law, submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.
[remainder of page intentionally left blank]

CHAR1\1826719v3

Each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.
BORROWERS’ REPRESENTATIVE:    WEST PHARMACEUTICAL SERVICES, INC.

By: /s/ Charles Witherspoon
Name: Charles Witherspoon
Title: Vice President and Treasurer

CHAR1\1826719v3

ADMINISTRATIVE AGENT:    BANK OF AMERICA, N.A.,
as Administrative Agent
By:/s/ Elizabeth Uribe
Name: Elizabeth Uribe
Title: Assistant Vice President


CHAR1\1826719v3

Appendix A

TERMS APPLICABLE TO ALTERNATIVE CURRENCY LOANS

1.    Defined Terms. The following terms shall have the meanings set forth below:
“Alternative Currency” means each of the following currencies: Sterling, Yen, and Euros.
“Alternative Currency Daily Rate” means, for any day, with respect to any extension of credit under the Credit Agreement denominated in Sterling, the rate per annum equal to SONIA determined pursuant to the definition thereof plus the SONIA Adjustment; provided, that, if any Alternative Currency Daily Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement. Any change in an Alternative Currency Daily Rate shall be effective from and including the date of such change without further notice.
“Alternative Currency Daily Rate Loan” means a Loan that bears interest at a rate based on the definition of “Alternative Currency Daily Rate.” All Alternative Currency Daily Rate Loans must be denominated in an Alternative Currency.
1“Alternative Currency Loan” means an Alternative Currency Daily Rate Loan or an Alternative Currency Term Rate Loan, as applicable.
“Alternative Currency Term Rate” means, for any Interest Period, with respect to any extension of credit under the Credit Agreement:
(a)denominated in Euros, the rate per annum equal to the Euro Interbank Offered Rate (“EURIBOR”), as published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) on the day that is two TARGET Days preceding the first day of such Interest Period with a term equivalent to such Interest Period; and
(b)denominated in Yen, the rate per annum equal to the Tokyo Interbank Offer Rate (“TIBOR”), as published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) on the day that is two Business Days preceding the first day of such Interest Period (or such other day as is generally treated as the rate fixing day by market practice in such interbank market, as determined by the Administrative Agent; provided that, to the extent such market practice is not administratively feasible for the Administrative Agent, then such date shall be such other day as otherwise reasonably determined by the Administrative Agent) with a term equivalent to such Interest Period;
provided, that, if any Alternative Currency Term Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.
CHAR1\1826719v3

“Alternative Currency Term Rate Loan” means a Loan that bears interest at a rate based on the definition of “Alternative Currency Term Rate.” All Alternative Currency Term Rate Loans must be denominated in an Alternative Currency.

1“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the laws of, or are in fact closed in, the state where the Administrative Agent’s Office is located; provided that
(a)    if such day relates to any interest rate settings as to an Alternative Currency Loan denominated in Euro or €STR Loan, any fundings, disbursements, settlements and payments in Euro in respect of any such Alternative Currency Loan or €STR Loan, as applicable, or any other dealings in Euro to be carried out pursuant to this Agreement in respect of any such Alternative Currency Loan or €STR Loan, as applicable, means a Business Day that is also a TARGET Day;
(b)    if such day relates to any interest rate settings as to an Alternative Currency Loan denominated in (i) Sterling, means a day other than a day banks are closed for general business in London because such day is a Saturday, Sunday or a legal holiday under the laws of the United Kingdom; and (ii) Yen, means a day other than when banks are closed for general business in Japan; and
(c)    if such day relates to any fundings, disbursements, settlements and payments in a currency other than Euro in respect of an Alternative Currency Loan denominated in a currency other than Euro, or any other dealings in any currency other than Euro to be carried out pursuant to this Agreement in respect of any such Alternative Currency Loan (other than any interest rate settings), means any such day on which banks are open for foreign exchange business in the principal financial center of the country of such currency.
“Committed Loan Notice” means a Notice of Borrowing, and such term shall be deemed to include the Committed Loan Notice attached hereto as Exhibit A.
“Conforming Changes” means, with respect to the use, administration of or any conventions associated with SONIA, EURIBOR, TIBOR, €STR or any proposed Successor Rate for any currency, any conforming changes to the definitions of “SONIA”, “EURIBOR”, “TIBOR”, “€STR”, “Interest Period”, timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters (including, for the avoidance of doubt, the definition of “Business Day”, timing of borrowing requests or prepayment, conversion or continuation notices and length of lookback periods) as may be appropriate, in the discretion of the Administrative Agent, to reflect the adoption and implementation of such applicable rate(s) and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice for such currency (or, if the Administrative Agent determines that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such rate for such currency exists, in such other manner of administration as the Administrative Agent determines is reasonably necessary in connection with the administration of this Agreement and any other Loan Document).
“Dollar” and “$” mean lawful money of the United States.
CHAR1\1826719v3

“EONIA-€STR Spread” means, with respect to any day:
(a)    the percentage rate per annum which is, or remains, published on that day as the “EONIA-€STR spread” by the European Central Bank; or
(b)    if no such rate is, or remains, published on that day, the percentage rate per annum which was the “EONIA-€STR spread” most recently published by the European Central Bank.
“€STR” means, in relation to any day, the applicable €STR Screen Rate for that day.
“€STR Loan” means a Euro Swing Line Loan that bears interest at a rate based on the definition of “Enhanced €STR”. All €STR Loans must be denominated in Euros.
“€STR Screen Rate” means the euro short-term rate administered by the European Central Bank (or any other person which takes over the administration of that rate) as published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent and the Swing Line Lender from time to time).
“Enhanced €STR” means, with respect to any day, the percentage rate per annum which is the equal to the sum of:
(a)    €STR; and
(b)    EONIA-€STR Spread,
and if that rate is less than zero, Enhanced €STR shall be deemed to be zero.
“Interest Payment Date” means, (a) as to any Alternative Currency Daily Rate Loan, the last Business Day of each March, June, September and December and the Termination Date, (b) as to any €STR Loan, the last Business Day of each calendar quarter and the Termination Date and (c) as to any Alternative Currency Term Rate Loan, the last day of each Interest Period applicable to such Loan; provided, however, that if any Interest Period for an Alternative Currency Term Rate Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest Period shall be Interest Payment Dates.
“Interest Period” means as to each Alternative Currency Term Rate Loan, the period commencing on the date such Alternative Currency Term Rate Loan is disbursed or converted to or continued as an Alternative Currency Term Rate Loan and ending on the date one, three or six months thereafter (in each case, subject to availability for the interest rate applicable to the relevant currency), as selected by the Borrowers’ Representative in its Committed Loan Notice; provided that:
(a)    any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless, in the case of an Alternative Currency Term Rate Loan, such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;
CHAR1\1826719v3

(b)    any Interest Period pertaining to an Alternative Currency Term Rate Loan that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and
(c)    no Interest Period shall extend beyond the applicable maturity date set forth in the Credit Agreement.
“Relevant Rate” means, with respect to any Loan denominated in (a) Sterling, SONIA, (b) Euros, EURIBOR, and (c) Yen, TIBOR, as applicable.
“SONIA” means, with respect to any applicable determination date, the Sterling Overnight Index Average Reference Rate published on the fifth Business Day preceding such date on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time); provided however that if such determination date is not a Business Day, SONIA means such rate that applied on the first Business Day immediately prior thereto.
“SONIA Adjustment” means, with respect to SONIA, 0.1193% per annum.
“Successor Rate” means the Successor Rate, LIBOR Successor Rate or any similar or analogous definition in the Credit Agreement.
“TARGET2” means the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which utilizes a single shared platform and which was launched on November 19, 2007.
“TARGET Day” means any day on which TARGET2 (or, if such payment system ceases to be operative, such other payment system, if any, determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro.
“Type” means, with respect to a Loan, its character as a Base Rate Loan, a LIBOR Loan, an Alternative Currency Daily Rate Loan, an Alternative Currency Term Rate Loan, or an €STR Loan.
2.    Terms Applicable to Alternative Currency Loans. From and after the Amendment Effective Date, the parties hereto agree as follows:
(a)    Alternative Currencies. (i) No Alternative Currency shall be considered a currency for which there is a published LIBOR rate, and (ii) any request for a new Loan denominated in an Alternative Currency, or to continue an existing Loan denominated in an Alternative Currency, shall be deemed to be a request for a new Loan bearing interest at the Alternative Currency Daily Rate, Alternative Currency Term Rate or Enhanced €STR, as applicable; provided, that, to the extent any Loan bearing interest at the LIBOR Rate is outstanding on the Amendment Effective Date, such Loan shall continue to bear interest at the LIBOR Rate until the end of the current Interest Period or payment period applicable to such Loan unless, in the case of a Loan that bears interest at a daily floating rate, such daily floating rate is no longer representative or being made available, in which case such Loan shall bear
CHAR1\1826719v3

interest at the applicable Alternative Currency Daily Rate or Enhanced €STR, as applicable, immediately upon the effectiveness of this Agreement.
(b)     References to LIBOR Rate and LIBOR Loans in the Credit Agreement and Loan Documents.
(i)     References to the LIBOR Rate and LIBOR Loans in provisions of the Credit Agreement and the other Loan Documents that are not specifically addressed herein (other than the definitions of LIBOR Rate and LIBOR Loan) shall be deemed to include Alternative Currency Daily Rates, Alternative Currency Term Rates, Alternative Currency Loans, Enhanced €STR and €STR Loans, as applicable; provided, that, references to the LIBOR Rate and LIBOR Loans in Section 2.01(d) of the Credit Agreement shall be deemed to be references to Enhanced €STR and €STR Loans, respectively.
(ii)     For purposes of any requirement for the Borrowers to compensate Lenders for losses in the Credit Agreement resulting from any continuation, conversion, payment or prepayment of any Alternative Currency Loan on a day other than the last day of any Interest Period (as defined in the Credit Agreement), references to the Interest Period (as defined in the Credit Agreement) shall be deemed to include any relevant interest payment date or payment period for an Alternative Currency Loan.
(c)     Interest Rates. The Administrative Agent does not warrant, nor accept responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to the rates in the definition of “Alternative Currency Daily Rate”, “Alternative Currency Term Rate”, “Enhanced €STR” or with respect to any rate (including, for the avoidance of doubt, the selection  of such rate and any related spread or other adjustment) that is an alternative or replacement for or successor to any such rate or the effect of any of the foregoing, or of any Conforming Changes.
(d)    Computation Dates. The Administrative Agent shall determine the Dollar Equivalent amounts of Borrowings and Loans denominated in Alternative Currencies. Such Dollar Equivalent shall become effective as of such Computation Date and shall be the Dollar Equivalent of such amounts until the next Computation Date to occur.
(e)    Borrowings and Continuations of Alternative Currency Loans. In addition to any other borrowing requirements set forth in the Credit Agreement:
(i)    Alternative Currency Loans. Each Borrowing of Alternative Currency Loans, and each continuation of an Alternative Currency Term Rate Loan shall be made upon the Borrowers’ Representative’s irrevocable notice to the Administrative Agent, which may be given by (A) telephone or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a Committed Loan Notice. Each such Committed Loan Notice must be received by the Administrative Agent not later than 11:00 a.m. (Eastern time) three Business Days (or five Business Days in the case of a Special Notice Currency) prior to the requested date of any Borrowing or, in the case of Alternative Currency Term Rate Loans, any continuation. Each Borrowing of or continuation of Alternative Currency Loans shall be in a principal amount of the Dollar Equivalent of $1,000,000 or a whole multiple of the
CHAR1\1826719v3

Dollar Equivalent of $100,000 in excess thereof. Each Committed Loan Notice shall specify (i) whether the applicable Borrower is requesting a Borrowing or a continuation of Alternative Currency Term Rate Loans, (ii) the requested date of the Borrowing or continuation, as the case may be (which shall be a Business Day), (iii) the currency and principal amount of Loans to be borrowed or continued, (iv) the Type of Loans to be borrowed, (v) if applicable, the duration of the Interest Period with respect thereto. If the Borrowers’ Representative fails to specify a currency in a Loan Notice requesting a Borrowing, then the Loans so requested shall be made in Dollars. If the Borrowers’ Representative fails to specify a Type of Loan in a Committed Loan Notice or if the Borrowers’ Representative fails to give a timely notice requesting a continuation, then the applicable Loans shall be made as Base Rate Loans denominated in Dollars; provided, however, that in the case of a failure to timely request a continuation of Alternative Currency Term Rate Loans, such Loans shall be continued as Alternative Currency Term Rate Loans in their original currency with an Interest Period of one (1) month. If the Borrowers’ Representative requests a Borrowing of or continuation of Alternative Currency Term Rate Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month. Except as otherwise specified in the Credit Agreement, no Alternative Currency Loan may be converted into or continued as a Loan denominated in a different currency, but instead must be repaid in the original currency of such Alternative Currency Loan and reborrowed in the other currency.
(ii)    Conforming Changes. With respect to any Alternative Currency Rate the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein, in the Credit Agreement or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement, the Credit Agreement or any other Loan Document; provided, that, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Borrowers and the Lenders reasonably promptly after such amendment becomes effective.
(iii)    Committed Loan Notice. For purposes of a Borrowing of Alternative Currency Loans, or a continuation of and Alternative Currency Term Rate Loan, the Borrowers shall use the Committed Loan Notice attached hereto as Exhibit A.
(f)    Euro Swing Line Loans. In addition to any other borrowing requirements set forth in the Credit Agreement,
    (i)    €STR Loans. Each Euro Swing Line Loan shall be an €STR Loan.
(ii)    Borrowing Procedures. Each Borrowing of Euro Swing Line Loans shall be made upon the German Borrower’s irrevocable notice to the Swing Line Lender and the Administrative Agent, which may be given by (A) telephone or (B) by a Committed Loan Notice; provided, that, any telephonic notice must be confirmed promptly by delivery to the Swing Line Lender and the Administrative Agent of a Committed Loan Notice. Each such Notice of Borrowing must be received by the Swing Line Lender and the Administrative Agent not later than 11:00 a.m. (London time) on the requested Borrowing Date, and shall specify (1) the amount to be borrowed, which shall be a
CHAR1\1826719v3

minimum principal amount of €500,000, and (2) the requested Borrowing Date, which shall be a Business Day. Promptly after receipt by the Swing Line Lender of any Committed Loan Notice, the Swing Line Lender will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Committed Loan Notice and, if not, the Swing Line Lender will notify the Administrative Agent (by telephone or in writing) of the contents thereof. Unless the Swing Line Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any Lender) prior to 12:00 p.m. (London time) on the date of the proposed Borrowing of Euro Swing Line Loans (A) directing the Swing Line Lender not to make such Euro Swing Line Loan as a result of the limitations set forth in the first proviso to the first sentence of Section 2.01(d)(i) of the Credit Agreement, or (B) that one or more of the applicable conditions specified in Section 4 of the Credit Agreement is not then satisfied, then, subject to the terms and conditions hereof, the Swing Line Lender will, not later than 1:00 p.m. (London time) on the Borrowing Date specified in such Committed Loan Notice, make the amount of its Euro Swing Line Loan available to the German Borrower.
(iii)    Conforming Changes. With respect to Enhanced €STR, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein, in the Credit Agreement or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement, the Credit Agreement or any other Loan Document; provided, that, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Borrower and the Lenders reasonably promptly after such amendment becomes effective.
    (iv)    Committed Loan Notice. For purposes of Borrowing a Euro Swing Line Loan, the German Borrower shall use the Committed Loan Notice attached hereto as Exhibit A.
(g)    Interest.
    (i)    Subject to the provisions of the Credit Agreement with respect to default interest, (x) each Alternative Currency Daily Rate Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Alternative Currency Daily Rate plus the Applicable Margin; (y) each Alternative Currency Term Rate Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Alternative Currency Term Rate for such Interest Period plus the Applicable Margin and (z) each Euro Swing Line Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to Enhanced €STR plus the Applicable Margin.
    (ii)    Interest on each Alternative Currency Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified the Credit Agreement. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any debtor relief law.
CHAR1\1826719v3

(h)     Computations. All computations of interest for Alternative Currency Loans shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed, or, in the case of interest in respect of Alternative Currency Loans as to which market practice differs from the foregoing, in accordance with such market practice. All other computations of fees and interest with respect to €STR Loans shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Alternative Currency Loan for the day on which the Alternative Currency Loan or €STR Loan is made, and shall not accrue on an Alternative Currency Loan or €STR Loan, or any portion thereof, for the day on which the Alternative Currency Loan or €STR Loan or such portion thereof is paid, provided that any Alternative Currency Loan or €STR Loan that is repaid on the same day on which it is made shall, subject to the terms of the Credit Agreement, bear interest for one day. Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.
(i)    Successor Rates. The provisions in the Credit Agreement addressing the replacement of a current Successor Rate for a currency shall be deemed to apply to Alternative Currency Loans and SONIA, TIBOR and EURIBOR, as applicable, and the related defined terms shall be deemed to include Sterling, Yen and Euros and SONIA, TIBOR and EURIBOR, as applicable.
CHAR1\1826719v3

Exhibit A

[FORM OF]
NOTICE OF BORROWING
(Alternative Currency Loans)

TO:    BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT

FROM: WEST PHARMACEUTICAL SERVICES, INC.
RE:    Credit Agreement dated as of March 28, 2019 by and among West Pharmaceutical Services, Inc. (the “Company”), certain subsidiaries of the Company party thereto (together with the Company, the “Borrowers” and each a “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and an Issuing Lender (as amended, restated, supplemented or otherwise modified from time to time, the “Agreement”). Capitalized terms used but not defined herein shall have the meanings given to them in the Agreement.
Pursuant to Section 2.01(c) or 2.04 of the Agreement, as applicable, the undersigned hereby makes the following request:
1.    This request is for (choose one):
☐A Borrowing of Revolver Loans
☐A Borrowing or Euro Swing Line Loans
☐A Continuation of Revolver Loans
---
1.    On              (a Business Day)
2.    In the amount of [$]             [in the following currency: _______].
3.    Comprised of:    ☐ Alternative Currency Daily Rate Loans
☐ Alternative Currency Term Rate Loans
☐ €STR Loans

4.    For Alternative Currency Term Rate Loans: with an Interest Period of __ month[s].
5.    On behalf of ____________________________ [insert name of applicable Borrower]
[With respect to such Borrowing, the Borrowers’ Representative hereby represents and warrants that (i) such request complies with the requirements of Section 2.01 of the Credit Agreement and (ii) each of the
CHAR1\1826719v3

conditions set forth in Section 4.02 of the Credit Agreement has been satisfied on and as of the date of such Borrowing.]1

[With respect to such Borrowing of Swing Line Loans, the Borrowers’ Representative hereby represents and warrants that (i) such request complies with the requirements of the first proviso to the first sentence of Section 2.01(c) or 2.01 (d) of the Credit Agreement, as applicable and (ii) each of the conditions set forth in Section 4.02 of the Credit Agreement has been satisfied on and as of the date of such Borrowing of Swing Line Loans.]2






[signature page follow]

1Include for Borrowings of Revolver Loans.
2Include for Borrowings of Swing Line Loans.
CHAR1\1826719v3

The undersigned certifies to the accuracy of the foregoing.
Date:
WEST PHARMACEUTICAL SERVICES, INC.,
as Borrowers’ Representative
By:    
Name:
Title:


CHAR1\1826719v3
 EX-31.1 3 ex311q32021.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: October 28, 2021

EX-31.2 4 ex312q32021.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: October 28, 2021

EX-32.1 5 ex321q32021.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: October 28, 2021

 EX-32.2 6 ex322q32021.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: October 28, 2021


 EX-101.SCH 7 wst-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Revenue - Contracts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2112105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2115106 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2417406 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Leases - Lease Weighted Average (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 2123108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2426412 - Disclosure - Debt - Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2127109 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2332307 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2136111 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2438418 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2439419 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2140112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2341309 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2442420 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2443421 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) link:presentationLink link:calculationLink link:definitionLink 2144113 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2445422 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2146114 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2347310 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2448423 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2449424 - Disclosure - Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2150115 - Disclosure - Other Expense (Income) link:presentationLink link:calculationLink link:definitionLink 2351311 - Disclosure - Other Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 2452425 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2453426 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2454427 - Disclosure - Other Expense (Income) - Other Items (Details) link:presentationLink link:calculationLink link:definitionLink 2155116 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2456428 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2157117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2158118 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2359312 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2460429 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 wst-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 wst-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 wst-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Position [Axis] Position [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Customer [Domain] Customer [Domain] Change in equity affiliate investment AOCI AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Actuarial losses Recognized actuarial losses (gains) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Letter of Credit Letter of Credit [Member] Pension settlement charge Pension Settlement Charge Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits. Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Total reclassifications for the period, net of tax Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Interest cost Defined Benefit Plan, Interest Cost Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Dividends declared Dividends, Common Stock, Cash Europe, Middle East, Africa EMEA [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Defined benefit pension and other postretirement plan adjustments, net of tax of $0.2, $(0.1), $0.4, and $(1.2), respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Pension and other postretirement benefits Liability, Defined Benefit Plan, Current Other noncurrent assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Sales Projections Sales Projections [Member] Sales Projections Segments [Axis] Segments [Axis] Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Dividend yield (in hundredths) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Shares available for issuance under the 2016 Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Stock volatility (in hundredths) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Level 3 Fair Value Measurements [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Increase in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Schedule of Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Effective income tax rate reconciliation, deduction, amount Effective Income Tax Rate Reconciliation, Deduction, Amount Fair Value Hedges Fair Value Hedging [Member] Document Fiscal Year Focus Document Fiscal Year Focus Amortization of Acquisition-related Intangible Assets Amortization of Intangible Assets Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Variable lease cost Variable Lease, Cost Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Net gain (loss) on derivatives, tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Cash Flow Hedges: Cash Flow Hedging [Member] Pension and other postretirement benefits Liability, Defined Benefit Plan, Noncurrent Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Award Type [Domain] Award Type [Domain] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Loss on sale of investments Gain (Loss) on Sale of Investments Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of net sales Concentration Risk, Percentage Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Issued Entity Address, City or Town Entity Address, City or Town Currency [Axis] Currency [Axis] Retained earnings Retained Earnings [Member] 2020 Restructuring Plan 2020 Restructuring Plan [Member] 2020 Restructuring Plan [Member] Contract with customer liability recognized Contract With Customer, Liability, Recognition Period Contract With Customer, Liability, Recognition Period Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Probabilities of Successful Execution of Agreement Probabilities of Successful Execution of Agreement [Member] Probabilities of Successful Execution of Agreement Prior service credit Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Generics Generics Customers [Member] Generics Customers [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Probabilities of Successful FDA Approval Probabilities of Successful FDA Approval [Member] Probabilities of Successful FDA Approval Entity Interactive Data Current Entity Interactive Data Current Line of credit Facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Basic (in dollars per share) Earnings Per Share, Basic Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Year three Lessee, Operating Lease, Liability, to be Paid, Year Three Revenue Revenue from Contract with Customer [Text Block] Amount receivable from affiliates Due from Affiliates Balance, beginning of period Balance, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Type Document Type Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Deferred compensation liabilities Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Geographic Concentration Risk Geographic Concentration Risk [Member] Entity Current Reporting Status Entity Current Reporting Status Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Pension and other postretirement benefits Assets for Plan Benefits, Defined Benefit Plan Operating cash flows from operating leases Operating Lease, Payments Changes in assets and liabilities Other Noncash Income (Expense) Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Deferred compensation assets Deferred Compensation Plan Assets Effect on future earnings, amount Effect on Future Earnings, Amount Long-term debt, gross Long-term Debt, Gross PSU payout, minimum (in hundredths) PVS Payout Minimum Percent of an employee's targeted award to be paid out, Minimum. Assets: Assets, Fair Value Disclosure [Abstract] Total debt Long-term Debt Total assets at fair value Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Development and licensing income [Line Items] Development and licensing income [Line Items] [Line Items] for Development and licensing income [Table] Document Transition Report Document Transition Report Impairment charge Other than Temporary Impairment Losses, Investments Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total Liabilities and Equity Liabilities and Equity Fixed asset impairments and loss (gain) on sale of equipment Other Asset Impairment Charges Americas Americas [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Deferred income, current Contract with Customer, Liability, Current Year five Lessee, Operating Lease, Liability, to be Paid, Year Five Capital in excess of par value Additional Paid in Capital LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Derivative [Line Items] Derivative [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Stock purchase program, cost of shares purchased Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Net Income Per Share Earnings Per Share [Text Block] Stock repurchase program, average price per share (in dollars per share) Treasury Stock Acquired, Average Cost Per Share International plans Foreign Plan [Member] Minimum Minimum [Member] Settlements Settlements Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other non-cash items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Gross profit Gross Profit Long-term line of credit Long-term Line of Credit Year two Lessee, Operating Lease, Liability, to be Paid, Year Two Total liabilities at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Selling, general and administrative expenses Selling, General and Administrative Expense Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Balance, December 31, 2020 Balance, September 30, 2021 Restructuring Reserve Trading Symbol Trading Symbol Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Amounts reclassified out from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Deferred income taxes Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] Corporate general costs General and Administrative Expense Restructuring Plan [Domain] Restructuring Plan [Domain] Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Debt Debt Disclosure [Text Block] Other charges Other Restructuring [Member] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Dividend payments Payments of Ordinary Dividends, Common Stock Inventories Inventory Disclosure [Text Block] Contingent consideration payments in excess of acquisition-date liability Payment for Contingent Consideration Liability, Operating Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of reportable segments Number of Reportable Segments Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Total lease liabilities Operating Lease, Liability Foreign exchange transaction losses (gains) Foreign Currency Transaction Gain (Loss), before Tax High-Value Product Delivery Devices Standard Packaging [Member] Standard Packaging [Member] Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.1 million and 74.0 million, respectively Common Stock, Value, Issued Other expense, net Nonoperating Income (Expense) Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Customer Concentration Risk Customer Concentration Risk [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other retirement benefits Other Postretirement Benefits Plan [Member] Performance Share Unit (PSUs) Performance Shares [Member] Commitments and contingencies (Note 17) Commitments and Contingencies Leases Lessee, Operating Leases [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Change in contract assets - increase (decrease) Contract With Customer, Asset, Increase (Decrease) Contract With Customer, Asset, Increase (Decrease) Remainder of fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Restructuring and related activities, period of implementation Restructuring and Related Activities, Period of Implementation Restructuring and Related Activities, Period of Implementation Options Held Options Held [Member] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Product Concentration Risk Product Concentration Risk [Member] Short Short [Member] Document Period End Date Document Period End Date Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Entity Registrant Name Entity Registrant Name Treasury stock, at cost (in shares) Treasury Stock, Shares Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Work in process Inventory, Work in Process, Net of Reserves Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Finished goods Inventory, Finished Goods, Net of Reserves Consolidation Items [Domain] Consolidation Items [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity: Equity [Abstract] Cash payments Payments for Restructuring Amount due and payable to affiliates Due to Affiliate Net gain (loss) on derivatives, net of tax of $(0.4), $(0.2), $(0.4) and $(0.4), respectively Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Measurement Input Type [Domain] Measurement Input Type [Domain] Effect of exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Common Stock Common Stock [Member] Fair value and net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Segment Information Segment Reporting Disclosure [Text Block] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Operating profit Operating profit Operating Income (Loss) Operating lease liabilities Operating Lease, Liability, Current Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Hedging Designation [Axis] Hedging Designation [Axis] Stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Capital in Excess of Par Value Additional Paid-in Capital [Member] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Cash and cash equivalents Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Treasury Stock Treasury Stock [Member] Deferred compensation benefits Deferred Compensation Liability, Classified, Noncurrent Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Derivative, notional amount Derivative, Notional Amount Other nonoperating (income) expense Other Nonoperating Income (Expense) Long-term debt, fair value Long-term Debt, Fair Value Other, net Payments for (Proceeds from) Other Investing Activities Other Financial Instruments [Abstract] Other Financial Instruments [Abstract] -- None. No documentation exists for this element. -- Capital expenditures Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total Liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Award Type [Axis] Award Type [Axis] Stock options, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] PSU payout, maximum (in hundredths) PVS Payout Maximum Percent of an employee's targeted award to be paid out, Maximum. Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Measurement Input Type [Axis] Measurement Input Type [Axis] Total Equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule Of Other Income And Expense, By Component Shares purchased under share repurchase programs Payments for Repurchase of Common Stock Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Interest income Investment Income, Net Operating lease liabilities Operating Lease, Liability, Noncurrent Interest expense Interest expense Interest Expense Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Operating Segments Operating Segments [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Accrued salaries, wages and benefits Other Employee-related Liabilities, Current Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Risk-free interest rate (in hundredths) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Carrying amount, equity-method investments Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Schedule of Changes in Level 3 Fair Value Measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Sales to affiliates Sales to Equity Method Investees Sales to Equity Method Investees Derivative contract term Derivative, Term of Contract Income tax expense Tax benefit (expense) Provision for income taxes Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Asia Pacific Asia Pacific [Member] Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Term Loan, due December 31, 2024 (1.01%) Term Loan Due 2024 Term Loan Due 2024 [Member] Term Loan Due 2024 Total current assets Assets, Current Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Operating leases liabilities payments due Lessee, Operating Lease, Liability, to be Paid Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Inventories Total inventories Inventory, Net Stock options, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Commodity call options Other Assets, Fair Value Disclosure Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Less: current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Small Business Entity Small Business Restructuring Plan [Axis] Restructuring Plan [Axis] Other Expense (Income) Other Income and Other Expense Disclosure [Text Block] Carrying amount, investments not accounted for under the equity method Equity Securities without Readily Determinable Fair Value, Amount Forward treasury locks Treasury Lock [Member] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Revenue Benchmark Revenue Benchmark [Member] High-Value Product Components High-Value Components [Member] High-Value Components [Member] Stock options, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Short-term lease cost Short-term Lease, Cost Activity related to stock -based compensation (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Year one Lessee, Operating Lease, Liability, to be Paid, Year One Pharma Pharma Customers [Member] Pharma Customers [Member] Other expense (income) Other Income Restructuring and related charges Charges Restructuring and Related Cost, Incurred Cost Activity related to stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Retirement Plan Type [Domain] Retirement Plan Type [Domain] Yen Japan, Yen Year four Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted Average Weighted Average [Member] Entity Address, State or Province Entity Address, State or Province Level 2 Fair Value, Inputs, Level 2 [Member] Defined benefit pension and other postretirement plan adjustments, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Deferred income, noncurrent Contract with Customer, Liability, Noncurrent Corporate and Unallocated Corporate, Non-Segment [Member] Development and licensing income [Table] Development and licensing income [Table] Development and licensing income [Table] Segment Reporting [Abstract] Segment Reporting [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Customer [Axis] Customer [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Benefit Plans Retirement Benefits [Text Block] Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Other comprehensive (loss) income, net of tax Other comprehensive (loss) income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Series A notes, due July 5, 2022 (3.67%) Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Total Assets Assets Common stock, shares authorized (in shares) Common Stock, Shares Authorized Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Geographical [Domain] Geographical [Domain] Net sales Net Sales [Member] Net sales member Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative Contract Type [Domain] Derivative Contract [Domain] Change in deferred income - decrease (increase) Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Contingent consideration Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] All Currencies [Domain] All Currencies [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Revolving credit facility, Due 2024 Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 [Member] Schedule of Long-term Debt Obligations, Net of Current Maturities Schedule of Debt [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Lease, Cost Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Geographical [Axis] Geographical [Axis] Derivative, forward point components, (gain) loss, recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Segment [Domain] Segments [Domain] Service cost Defined Benefit Plan, Service Cost Net Investment Hedges: Net Investment Hedging [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Interest expense Interest Expense [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Severance and benefits Employee Severance [Member] Deferred income, December 31, 2020 Deferred income, September 30, 2021 Deferred income Contract with Customer, Liability Loss on investment activity Unrealized Gain (Loss) on Investments SmartDose SmartDose [Member] SmartDose [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost (1.2 million and 1.3 million shares, respectively) Treasury Stock, Value Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] 2018 Restructuring Plan 2018 Restructuring Plan [Member] 2018 Restructuring Plan [Member] SGD Singapore, Dollars Deferred income taxes Deferred Income Tax Liabilities, Net Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Fair Value Measurements Fair Value Disclosures [Text Block] Restructuring and severance related charges Restructuring Charges Accounts payable Accounts Payable, Current Contract-Manufactured Products Delivery Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Standard Packaging Delivery Devices [Member] Delivery Devices [Member] Contract assets, December 31, 2020 Contract assets, September 30, 2021 Contract with Customer, Asset, after Allowance for Credit Loss Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Other items Other Operating Income (Expense), Net Derivative [Table] Derivative [Table] Long Long [Member] Other expense (income) Total other expense (income) Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Purchase of intangibles Payments to Acquire Intangible Assets Stock repurchase program, shares authorized (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Total lease cost Lease, Cost Income Statement Location [Domain] Income Statement Location [Domain] Derivative, nonmonetary notional amount, volume Derivative, Nonmonetary Notional Amount, Volume Cost investment activity Cost Investment Impairment Cost Investment Impairment Property, plant and equipment, net Property, Plant and Equipment, Net Other long-term liabilities Other Liabilities, Noncurrent Share purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Debt Instrument [Line Items] Debt Instrument [Line Items] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Repayments of long-term debt Repayments of Other Long-term Debt Property, plant and equipment Property, Plant and Equipment, Gross Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Document Quarterly Report Document Quarterly Report Net sales Revenues Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Long-term debt Long-term debt, net Long-term Debt, Excluding Current Maturities Liabilities: Liabilities, Fair Value Disclosure [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expense Document Fiscal Period Focus Document Fiscal Period Focus Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Notes payable and other current debt Long-term debt, current Debt, Current Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Balance (in shares) Balance (in shares) Shares, Issued Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] U.S. plans UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Current assets: Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Leases [Abstract] Leases [Abstract] Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name Commodity call options Commodity Option [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Amortization Amortization Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Business combination, contingent consideration, measurement input Business Combination, Contingent Consideration, Measurement Input Business Combination, Contingent Consideration, Measurement Input Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Derivative (gain) loss recognized in income, fair value hedges Gain (Loss) on Fair Value Hedges Recognized in Earnings Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] (Losses) gains on derivatives Gains (losses) on derivatives: Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cross-currency swap Currency Swap [Member] Other expense (income) Foreign Currency Gain (Loss) [Member] Class of Stock [Line Items] Class of Stock [Line Items] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Credit Facility [Axis] Credit Facility [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Segment Information Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Derivative (gain) loss on hedged item, fair value hedges Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Shares repurchased for employee tax withholdings Payment, Tax Withholding, Share-based Payment Arrangement Intersegment sales elimination Intersegment Eliminations [Member] Foreign Exchange Forward Foreign Exchange Forward [Member] Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Position [Domain] Position [Domain] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Title of each class Title of 12(b) Security Purchases and royalty payments made to affiliates Purchases and Royalty Payments from Equity Method Investees Purchases and Royalty Payments from Equity Method Investees Other current assets Other Assets, Current New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Proprietary Products Packaging Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Restructuring and related cost, cumulative cost incurred Restructuring and Related Cost, Cost Incurred to Date Statistical Measurement [Axis] Statistical Measurement [Axis] Cover [Abstract] Goodwill Goodwill Cost of goods and services sold Cost of Sales [Member] Income taxes payable Accrued Income Taxes, Current USD United States of America, Dollars Development and licensing income Development And Licensing Income The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer. Biologics Biologics Customers [Member] Biologics Customers [Member] Forward Contracts Forward Contracts [Member] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Pension benefits Pension Plan [Member] Operating lease cost Operating Lease, Cost Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Nature of Expense [Axis] Nature of Expense [Axis] Accounting Standards Update 2016-13 [Member] EX-101.PRE 11 wst-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 wst-20210930_htm.xml IDEA: XBRL DOCUMENT 0000105770 2021-01-01 2021-09-30 0000105770 2021-10-18 0000105770 2021-07-01 2021-09-30 0000105770 2020-07-01 2020-09-30 0000105770 2020-01-01 2020-09-30 0000105770 2021-09-30 0000105770 2020-12-31 0000105770 2019-12-31 0000105770 2020-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 srt:MinimumMember 2021-01-01 2021-09-30 0000105770 srt:MaximumMember 2021-01-01 2021-09-30 0000105770 wst:SmartDoseMember 2013-06-30 0000105770 wst:SmartDoseMember 2021-09-30 0000105770 wst:TermLoanDue2024Member 2021-09-30 0000105770 wst:TermLoanDue2024Member 2020-12-31 0000105770 wst:SeniorNotesDue2022Member 2021-09-30 0000105770 wst:SeniorNotesDue2022Member 2020-12-31 0000105770 wst:SeniorBNotesDue2024Member 2021-09-30 0000105770 wst:SeniorBNotesDue2024Member 2020-12-31 0000105770 wst:SeniorCNotesDue2027Member 2021-09-30 0000105770 wst:SeniorCNotesDue2027Member 2020-12-31 0000105770 wst:Revolvingcreditfacilitydue2024Member 2021-09-30 0000105770 us-gaap:LetterOfCreditMember wst:Revolvingcreditfacilitydue2024Member 2021-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember 2020-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember 2021-09-30 0000105770 currency:USD us-gaap:ForwardContractsMember 2020-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember 2021-09-30 0000105770 us-gaap:ForeignExchangeForwardMember 2021-01-01 2021-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 us-gaap:OptionMember 2017-11-01 2021-09-30 0000105770 us-gaap:OptionMember 2021-01-01 2021-09-30 0000105770 us-gaap:OptionMember 2021-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:FairValueHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:FairValueHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:FairValueHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:FairValueHedgingMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000105770 us-gaap:CashFlowHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:CashFlowHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2020-01-01 2020-09-30 0000105770 wst:NetSalesMember 2020-07-01 2020-09-30 0000105770 wst:NetSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2021-01-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000105770 us-gaap:CashFlowHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-09-30 0000105770 wst:NetSalesMember 2021-07-01 2021-09-30 0000105770 wst:NetSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0000105770 us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000105770 us-gaap:InterestExpenseMember 2021-01-01 2021-09-30 0000105770 us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:NondesignatedMember 2021-07-01 2021-09-30 0000105770 us-gaap:NondesignatedMember 2020-07-01 2020-09-30 0000105770 us-gaap:NondesignatedMember 2021-01-01 2021-09-30 0000105770 us-gaap:NondesignatedMember 2020-01-01 2020-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000105770 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000105770 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0000105770 us-gaap:CurrencySwapMember 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000105770 us-gaap:CurrencySwapMember 2020-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2020-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000105770 srt:MinimumMember wst:SalesProjectionsMember 2021-09-30 0000105770 srt:MaximumMember wst:SalesProjectionsMember 2021-09-30 0000105770 srt:WeightedAverageMember wst:SalesProjectionsMember 2021-09-30 0000105770 srt:MinimumMember wst:ProbabilitiesOfSuccessfulFDAApprovalMember 2021-09-30 0000105770 srt:MaximumMember wst:ProbabilitiesOfSuccessfulFDAApprovalMember 2021-09-30 0000105770 srt:MinimumMember wst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember 2021-09-30 0000105770 srt:MaximumMember wst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember 2021-09-30 0000105770 us-gaap:MeasurementInputDiscountRateMember 2021-09-30 0000105770 2020-01-01 2020-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000105770 us-gaap:CommonStockMember 2020-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000105770 us-gaap:TreasuryStockMember 2020-12-31 0000105770 us-gaap:RetainedEarningsMember 2020-12-31 0000105770 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000105770 2021-01-01 2021-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000105770 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000105770 us-gaap:CommonStockMember 2021-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000105770 us-gaap:TreasuryStockMember 2021-03-31 0000105770 us-gaap:RetainedEarningsMember 2021-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000105770 2021-03-31 0000105770 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000105770 2021-04-01 2021-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000105770 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000105770 us-gaap:CommonStockMember 2021-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000105770 us-gaap:TreasuryStockMember 2021-06-30 0000105770 us-gaap:RetainedEarningsMember 2021-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000105770 2021-06-30 0000105770 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000105770 us-gaap:CommonStockMember 2021-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000105770 us-gaap:TreasuryStockMember 2021-09-30 0000105770 us-gaap:RetainedEarningsMember 2021-09-30 0000105770 us-gaap:CommonStockMember 2019-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000105770 us-gaap:TreasuryStockMember 2019-12-31 0000105770 us-gaap:RetainedEarningsMember 2019-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000105770 2019-01-01 2019-12-31 0000105770 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000105770 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000105770 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000105770 2020-01-01 2020-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000105770 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000105770 us-gaap:CommonStockMember 2020-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000105770 us-gaap:TreasuryStockMember 2020-03-31 0000105770 us-gaap:RetainedEarningsMember 2020-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000105770 2020-03-31 0000105770 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000105770 2020-04-01 2020-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000105770 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000105770 us-gaap:CommonStockMember 2020-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000105770 us-gaap:TreasuryStockMember 2020-06-30 0000105770 us-gaap:RetainedEarningsMember 2020-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000105770 2020-06-30 0000105770 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000105770 us-gaap:CommonStockMember 2020-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000105770 us-gaap:TreasuryStockMember 2020-09-30 0000105770 us-gaap:RetainedEarningsMember 2020-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000105770 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0000105770 us-gaap:PerformanceSharesMember 2021-09-30 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 country:US 2021-07-01 2021-09-30 0000105770 country:US 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember 2020-07-01 2020-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 country:US 2021-01-01 2021-09-30 0000105770 country:US 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember 2020-01-01 2020-09-30 0000105770 wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2021-09-30 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2021-09-30 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2021-07-01 2021-09-30 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2021-07-01 2021-09-30 0000105770 wst:A2020RestructuringPlanMember 2020-07-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2020-12-31 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2020-12-31 0000105770 wst:A2020RestructuringPlanMember 2020-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2021-01-01 2021-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2021-01-01 2021-09-30 0000105770 wst:A2020RestructuringPlanMember 2021-01-01 2021-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2021-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2021-09-30 0000105770 wst:A2020RestructuringPlanMember 2021-09-30 0000105770 wst:A2018RestructuringPlanMember 2018-02-01 2018-02-28 0000105770 wst:A2018RestructuringPlanMember 2018-02-28 0000105770 wst:A2018RestructuringPlanMember 2021-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2020-12-31 0000105770 wst:A2018RestructuringPlanMember 2020-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2021-01-01 2021-09-30 0000105770 wst:A2018RestructuringPlanMember 2021-01-01 2021-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2021-09-30 0000105770 wst:SmartDoseMember 2021-07-01 2021-09-30 0000105770 wst:SmartDoseMember 2020-07-01 2020-09-30 0000105770 wst:SmartDoseMember 2020-01-01 2020-09-30 0000105770 wst:SmartDoseMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2020-07-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2020-01-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2020-07-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2020-01-01 2020-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2021-07-01 2021-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:segment 0000105770 --12-31 2021 Q3 false http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member 10-Q true 2021-09-30 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-0645 610 594-2900 Common Stock, par value $0.25 per share WST NYSE Yes Yes Large Accelerated Filer false false false 74079715 706500000 548000000.0 2100800000 1566700000 418300000 353400000 1225600000 1010000000 288200000 194600000 875200000 556700000 13100000 12500000 39100000 34000000.0 91900000 76200000 264800000 225700000 -1800000 -6700000 -3000000.0 -6200000 181400000 99200000 568300000 290800000 1800000 2100000 5600000 6100000 400000 200000 700000 1200000 1100000 400000 3600000 300000 181100000 97700000 567000000.0 286200000 12000000.0 21100000 73000000.0 52100000 6500000 5700000 20100000 13700000 175600000 82300000 514100000 247800000 2.37 1.11 6.95 3.35 2.31 1.09 6.78 3.28 74100000 73900000 74000000.0 73900000 76000000.0 75800000 75800000 75600000 175600000 82300000 514100000 247800000 -24200000 29400000 -46900000 -4900000 200000 -100000 400000 -1200000 -400000 200000 -1100000 4000000.0 -400000 -200000 -400000 -400000 1300000 -900000 700000 -1000000.0 -22500000 28300000 -45100000 -9900000 153100000 110600000 469000000.0 237900000 688000000.0 615500000 476400000 385300000 353800000 321300000 80100000 51600000 1598300000 1373700000 2146100000 2035500000 1139600000 1092300000 1006500000 943200000 58500000 68300000 215700000 214700000 108900000 111100000 26100000 30500000 80000000.0 16000000.0 17000000.0 12900000 31600000 23400000 3142600000 2793800000 44200000 2300000 207700000 213100000 2400000 2300000 114000000.0 106000000.0 39500000 26000000.0 8100000 10100000 142700000 143600000 558600000 503400000 209900000 252900000 11600000 10400000 52100000 57500000 53400000 60400000 26900000 22900000 27800000 31800000 940300000 939300000 3000000 3000000 0 0 0 0 0 0 0.25 0.25 200000000 200000000 75300000 75300000 74100000 74000000 18800000 18800000 251200000 267300000 2335800000 1846700000 -155700000 -110600000 1200000 1300000 247800000 167700000 2202300000 1854500000 3142600000 2793800000 514100000 247800000 84600000 77300000 3300000 3300000 27500000 27600000 700000 3400000 1000000.0 700000 17500000 9500000 188500000 25400000 423200000 323800000 176900000 116700000 0 3800000 -1200000 1400000 -175700000 -121900000 1100000 1700000 37800000 35500000 23100000 22000000.0 5700000 4600000 137100000 115500000 14700000 2300000 -161900000 -128400000 -13100000 6800000 72500000 80300000 615500000 439100000 688000000.0 519400000 Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2021, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Throughout the COVID-19 pandemic, production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2021, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Throughout the COVID-19 pandemic, production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance, and where applicable, the Company has made contract amendments to reflect the removal of the LIBOR rate.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance, and where applicable, the Company has made contract amendments to reflect the removal of the LIBOR rate.</span></div> RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. <div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in the third quarter of 2020, the Company entered into new capacity reservation agreements, which include the receipt of up-front cash. The decrease in the deferred income balance is primarily due to the revenue recognition associated with the capacity reservation agreements, which is to be recognized over the next 1 to 2 years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, $30.0 million of revenue was recognized that was included in deferred income at the beginning of the year. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. As of September 30, 2021, there was $4.1 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $3.2 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div> <div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div> 0.40 0.32 0.40 0.29 0.18 0.18 0.17 0.19 0.24 0.27 0.24 0.28 0.18 0.23 0.19 0.24 1 1 1 1 0.55 0.47 0.54 0.45 0.05 0.05 0.04 0.05 0.22 0.25 0.23 0.26 0.18 0.23 0.19 0.24 1 1 1 1 0.45 0.49 0.45 0.49 0.45 0.42 0.45 0.43 0.10 0.09 0.10 0.08 1 1 1 1 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 10900000 12800000 1900000 57100000 38100000 19000000.0 P1Y P2Y 30000000 20000000 4100000 900000 3200000 Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, there were 0.0 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.0 million and 0.2 million antidilutive shares outstanding during the nine months ended September 30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced a share repurchase program for calendar-year 2021 authorizing the repurchase of up to 631,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2021. During the nine months ended September 30, 2021, we purchased 479,000 shares of our common stock under the program at a cost of $137.1 million, or an average price of $286.23 per share. This share repurchase program is expected to be completed by December 31, 2021.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 175600000 82300000 514100000 247800000 74100000 73900000 74000000.0 73900000 1900000 1900000 1800000 1700000 76000000.0 75800000 75800000 75600000 0 0 0 200000 631000 0 479000 137100000 286.23 Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 140400000 133500000 71100000 54900000 142300000 132900000 353800000 321300000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the weighted average remaining lease term for operating leases was 10.9 and 11.1 years, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the weighted average discount rate was 3.67% and 3.68%, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining period as of )</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3300000 3100000 9500000 9300000 400000 300000 900000 600000 1100000 1200000 3300000 2800000 4800000 4600000 13700000 12700000 2900000 3200000 9200000 9600000 0 300000 800000 4600000 P10Y10M24D P11Y1M6D 0.0367 0.0368 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining period as of )</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 3000000.0 12400000 10300000 10400000 9300000 9300000 8500000 8700000 6800000 6900000 36200000 37500000 74100000 85200000 12600000 14700000 61500000 70500000 Affiliated Companies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $207.1 million and $201.9 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $8.6 million and $12.8 million, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases from, and royalty payments made to, affiliates totaled $34.0 million and $119.6 million for the three and nine months ended September 30, 2021, respectively, as compared to $36.6 million and $97.0 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the payable balance due to affiliates was $13.8 million and $33.6 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to affiliates were $2.8 million and $8.8 million, respectively, for the three and nine months ended September 30, 2021, as compared to $2.7 million and $7.7 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the receivable balance due from affiliates was $2.2 million and $1.4 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 7, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Companies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div> 207100000 201900000 8600000 12800000 34000000 119600000 36600000 97000000.0 13800000 33600000 2800000 8800000 2700000 7700000 2200000 1400000 Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (1.01%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 8, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details regarding our debt agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement - Credit Facility </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $297.6 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement Amendment - Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, we had $86.6 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $84.4 million was classified as long-term. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (1.01%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0101 86600000 87700000 0.0367 42000000.0 42000000.0 0.0382 53000000.0 53000000.0 0.0402 73000000.0 73000000.0 254600000 255700000 500000 500000 254100000 255200000 44200000 2300000 209900000 252900000 300000000 2400000 297600000 86600000 2200000 84400000 Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2021 and December 31, 2020, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2021, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.4 billion ($86.1 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From November 2017 through September 2021, we purchased several series of call options for a total of 596,367 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had outstanding contracts to purchase 182,495 barrels of crude oil from October 2021 to March 2023, at a weighted-average strike price of $70.40 per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of September 30, 2021 and December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2021 and 2020 were $0.6 million, $1.9 million, and $1.3 million, $5.0 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021 and 2020, there was no material ineffectiveness related to our hedges.</span></div> 601500000 601500000 13400000 13400000 P18M As of September 30, 2021, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 28800000 0 24000000.0 6131700000 24600000 27700000 28700000 17800000 3000000.0 90000000 9400000000 86100000 596367 182495 70.40 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> 5900000 -9300000 11000000.0 -25100000 -5900000 9300000 -11000000.0 25100000 900000 1900000 2100000 5900000 900000 1900000 2100000 5900000 600000 1900000 -1300000 -5000000 -200000 -100000 -100000 700000 -200000 -100000 -100000 700000 100000 -500000 -100000 -200000 1400000 0 300000 -100000 0 0 -100000 -100000 1500000 -500000 100000 -400000 600000 -3000000.0 0 0 600000 -3000000.0 0 0 -600000 2800000 -900000 3300000 -600000 2800000 -900000 3300000 -500000 0 0 -900000 300000 300000 -1400000 -300000 -300000 -1200000 100000 100000 0 0 -200000 -200000 -1900000 -300000 -2300000 200000 6000000.0 -2000000.0 0 0 6000000.0 -2000000.0 0 0 100000 200000 900000 -300000 -300000 100000 1200000 -100000 100000 100000 200000 200000 100000 -700000 900000 -3300000 500000 100000 1600000 300000 500000 100000 1600000 300000 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets and long-term liabilities, is valued using a market approach. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives. All derivatives are recognized on a gross basis as either assets or liabilities in the balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the contingent consideration liability related to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> technology platform (the “SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in an increase or decrease to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> contingent consideration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of changes in our Level 3 fair value measurements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value recorded in earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.</span></div>The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2021, the estimated fair value of long-term debt was $220.3 million compared to a carrying amount of $209.9 million. At December 31, 2020, the estimated fair value of long-term debt was $265.7 million and the carrying amount was $252.9 million. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14400000 14400000 0 0 12000000.0 0 12000000.0 0 2200000 0 2200000 0 1800000 0 1800000 0 30400000 14400000 16000000.0 0 3500000 0 0 3500000 15700000 15700000 0 0 2800000 0 2800000 0 22000000.0 15700000 2800000 3500000 12800000 12800000 0 0 3000000.0 0 3000000.0 0 300000 300000 16100000 12800000 3300000 0 3600000 0 0 3600000 14500000 14500000 0 0 5600000 0 0 5600000 0 9700000 0 9700000 0 33400000 14500000 15300000 3600000 0.10 0.50 0.40 0.19 1 0.25 1 0.19 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of changes in our Level 3 fair value measurements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value recorded in earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3300000 -1200000 900000 3600000 -900000 1000000.0 3500000 220300000 209900000 265700000 252900000 Accumulated Other Comprehensive Loss <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.269%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -1900000 600000 -40500000 -68800000 -110600000 -2500000 0 600000 -46900000 -48800000 -3200000 0 -500000 0 -3700000 700000 0 1100000 -46900000 -45100000 -1200000 600000 -39400000 -115700000 -155700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.269%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> -100000 -300000 -1100000 300000 -400000 100000 1900000 -300000 -900000 1100000 -2100000 5100000 100000 100000 300000 300000 -700000 600000 -5400000 5400000 -700000 300000 -2200000 1900000 0 300000 -3200000 3500000 -100000 -100000 -200000 -400000 100000 200000 -100000 0 0 -1100000 -700000 -3400000 200000 -800000 -600000 -3000000.0 100000 -300000 -100000 -800000 100000 -500000 -500000 -2200000 100000 -200000 -3700000 1300000 Shareholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.431%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"/><td style="width:32.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM2MTFmNjQ2NWJhZDRjMzVhNDk5MmQ2YzJiMDQ1MmJhL3NlYzpjNjExZjY0NjViYWQ0YzM1YTQ5OTJkNmMyYjA0NTJiYV82Ny9mcmFnOmJiNjRlYzBhNTg2NTRmZWE4Nzg0M2ZjNmY2ODRmNTZjL3RhYmxlOmRhOTZlOGIxMTc1NzQ3ZDViNGNkMmQ1MDlhYmFhYjA2L3RhYmxlcmFuZ2U6ZGE5NmU4YjExNzU3NDdkNWI0Y2QyZDUwOWFiYWFiMDZfNC0wLTEtMS0w_0d9a6415-b49d-43e7-b297-907e0d1bfb23">Effect of modified retrospective application of a new accounting standard</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.431%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"/><td style="width:32.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM2MTFmNjQ2NWJhZDRjMzVhNDk5MmQ2YzJiMDQ1MmJhL3NlYzpjNjExZjY0NjViYWQ0YzM1YTQ5OTJkNmMyYjA0NTJiYV82Ny9mcmFnOmJiNjRlYzBhNTg2NTRmZWE4Nzg0M2ZjNmY2ODRmNTZjL3RhYmxlOmRhOTZlOGIxMTc1NzQ3ZDViNGNkMmQ1MDlhYmFhYjA2L3RhYmxlcmFuZ2U6ZGE5NmU4YjExNzU3NDdkNWI0Y2QyZDUwOWFiYWFiMDZfNC0wLTEtMS0w_0d9a6415-b49d-43e7-b297-907e0d1bfb23">Effect of modified retrospective application of a new accounting standard</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 75300000 18800000 267300000 1300000 -167700000 1846700000 -110600000 1854500000 151200000 151200000 -20600000 -300000 23100000 2500000 500000 137100000 137100000 0.17 12500000 12500000 -29600000 -29600000 75300000 18800000 246700000 1500000 -281700000 1985400000 -140200000 1829000000 187300000 187300000 1300000 -200000 20500000 21800000 0.17 12500000 12500000 7000000.0 7000000.0 75300000 18800000 248000000.0 1300000 -261200000 2160200000 -133200000 2032600000 175600000 175600000 3200000 -100000 13400000 16600000 -22500000 -22500000 75300000 18800000 251200000 1200000 -247800000 2335800000 -155700000 2202300000 75300000 18800000 272700000 1200000 -118100000 1549400000 -149600000 1573200000 -100000 -100000 74300000 74300000 -5100000 -300000 17900000 12800000 800000 115500000 115500000 0.16 11800000 11800000 -42700000 -42700000 75300000 18800000 267600000 1700000 -215700000 1611800000 -192300000 1490200000 91200000 91200000 -4500000 -200000 24900000 20400000 4500000 4500000 75300000 18800000 263100000 1500000 -190800000 1703000000 -187800000 1606300000 82300000 82300000 5100000 -100000 8800000 13900000 0.16 11900000 11900000 28300000 28300000 75300000 18800000 268200000 1400000 -182000000.0 1773400000 -159500000 1718900000 Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2021, there were 2,485,724 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we granted 159,932 stock options at a weighted average exercise price of $277.23 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $63.72 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 0.7%; expected life of 5.6 years based on prior experience; stock volatility of 23.9% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we granted 36,902 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $331.56 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we granted 5,109 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $292.42 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div>Stock-based compensation expense was $11.4 million and $27.5 million for the three and nine months ended September 30, 2021, respectively. For the three and nine months ended September 30, 2020, stock-based compensation expense was $10.0 million and $27.6 million, respectively. 2485724 159932 277.23 63.72 0.007 P5Y7M6D 0.239 0.003 36902 331.56 0 2 5109 292.42 11400000 27500000 10000000.0 27600000 Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 100000 400000 0 0 100000 400000 1600000 1700000 0 0 1600000 1700000 2900000 2800000 0 0 2900000 2800000 0 100000 -100000 -200000 -100000 -100000 -500000 -400000 300000 600000 -200000 200000 0 -1100000 0 0 0 -1100000 -700000 900000 -400000 -800000 -1100000 100000 -900000 500000 -400000 -800000 -1300000 -300000 200000 400000 0 0 200000 400000 -700000 900000 -400000 -800000 -1100000 100000 900000 1000000.0 0 0 900000 1000000.0 4500000 5500000 100000 100000 4600000 5600000 9000000.0 8800000 0 0 9000000.0 8800000 100000 100000 -300000 -500000 -200000 -400000 -1500000 -1400000 1200000 1400000 -300000 0 -700000 -3400000 0 0 -700000 -3400000 -1300000 2600000 -1400000 -1800000 -2700000 800000 -2400000 1500000 -1400000 -1800000 -3800000 -300000 1100000 1100000 0 0 1100000 1100000 -1300000 2600000 -1400000 -1800000 -2700000 800000 -700000 Other Expense (Income) <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairments and loss (gain) on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was originally expected to require restructuring and related charges of approximately $15 million to $17 million, with annualized savings being in the range of $3.5 million to $4.5 million. Due to the recent increase in customer demand, the Company will no longer proceed with certain portions of the plan, thus reducing the total expected charges to be approximately $9 million to $11 million. Similarly, annualized savings are now expected to be in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $7.1 million in restructuring and related charges associated with this plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Items</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss in our cost investment activity of $1.8 million, inclusive of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an impairment charge of $2.2 million for one of the Company's cost investments. For the three and nine months ended September 30, 2020, there was no activity related to our cost investments. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During both the three and nine months ended September 30, 2021 and 2020, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. Please refer to Note 3, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue</a></span>, for additional information. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairments and loss (gain) on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 400000 4500000 2500000 4500000 200000 900000 600000 7200000 100000 800000 900000 900000 -400000 -1000000.0 2500000 4500000 -700000 500000 -1500000 1900000 -1800000 -6700000 -3000000.0 -6200000 P24M 15000000 17000000 3500000 4500000 9000000 11000000 900000 1600000 7100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4600000 0 4600000 1000000.0 1500000 2500000 1400000 900000 2300000 4200000 600000 4800000 P24M 16000000 13700000 100000 100000 100000 100000 0 0 -900000 -1800000 2200000 200000 200000 600000 600000 20000000 Income TaxesThe tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.The provision for income taxes was $12.0 million and $21.1 million for the three months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 6.6% and 21.6%, respectively. The provision for income taxes was $73.0 million and $52.1 million for the nine months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 12.9% and 18.2%, respectively. The reduction in effective tax rates for the three and nine months ended September 30, 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit. 12000000 21100000 0.066 0.216 73000000.0 52100000 0.129 0.182 20400000 20400000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the commitments and contingencies included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577021000008/wst-20201231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> Segment InformationOur business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total business and segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and severance related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of Acquisition-related Intangible Assets (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic611f6465bad4c35a4992d6c2b0452ba_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of these items.</span></div> 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total business and segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and severance related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of Acquisition-related Intangible Assets (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div> 577000000.0 421500000 1708000000 1194500000 129700000 126600000 393200000 372500000 -200000 -100000 -400000 -300000 706500000 548000000.0 2100800000 1566700000 195500000 107500000 594300000 312900000 16800000 18800000 51900000 52100000 212300000 126300000 646200000 365000000.0 11400000 10000000.0 27500000 27600000 18100000 12400000 45500000 39500000 300000 4500000 2500000 6700000 200000 200000 600000 400000 900000 0 1800000 0 -30900000 -27100000 -77900000 -74200000 181400000 99200000 568300000 290800000 -300000 -1500000 -1300000 -4600000 181100000 97700000 567000000.0 286200000 200000 600000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Oct. 18, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 1-8036  
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 23-1210010  
Entity Address, Address Line One 530 Herman O. West Drive  
Entity Address, City or Town Exton  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19341-0645  
City Area Code 610  
Local Phone Number 594-2900  
Title of each class Common Stock, par value $0.25 per share  
Trading Symbol WST  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   74,079,715
Entity Central Index Key 0000105770  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Net sales $ 706.5 $ 548.0 $ 2,100.8 $ 1,566.7
Cost of goods and services sold 418.3 353.4 1,225.6 1,010.0
Gross profit 288.2 194.6 875.2 556.7
Research and development 13.1 12.5 39.1 34.0
Selling, general and administrative expenses 91.9 76.2 264.8 225.7
Other expense (income) 1.8 6.7 3.0 6.2
Operating profit 181.4 99.2 568.3 290.8
Interest expense 1.8 2.1 5.6 6.1
Interest income (0.4) (0.2) (0.7) (1.2)
Other nonoperating (income) expense (1.1) (0.4) (3.6) (0.3)
Income before income taxes 181.1 97.7 567.0 286.2
Income tax expense 12.0 21.1 73.0 52.1
Equity in net income of affiliated companies (6.5) (5.7) (20.1) (13.7)
Net income $ 175.6 $ 82.3 $ 514.1 $ 247.8
Net income per share:        
Basic (in dollars per share) $ 2.37 $ 1.11 $ 6.95 $ 3.35
Diluted (in dollars per share) $ 2.31 $ 1.09 $ 6.78 $ 3.28
Weighted average shares outstanding:        
Basic (in shares) 74.1 73.9 74.0 73.9
Diluted (in shares) 76.0 75.8 75.8 75.6
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net income $ 175.6 $ 82.3 $ 514.1 $ 247.8
Other comprehensive (loss) income, net of tax:        
Foreign currency translation adjustments (24.2) 29.4 (46.9) (4.9)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.2, $(0.1), $0.4, and $(1.2), respectively 0.4 (0.2) 1.1 (4.0)
Net gain (loss) on derivatives, net of tax of $(0.4), $(0.2), $(0.4) and $(0.4), respectively 1.3 (0.9) 0.7 (1.0)
Other comprehensive (loss) income, net of tax (22.5) 28.3 (45.1) (9.9)
Comprehensive income $ 153.1 $ 110.6 $ 469.0 $ 237.9
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Defined benefit pension and other postretirement plan adjustments, tax $ 0.2 $ (0.1) $ 0.4 $ (1.2)
Net gain (loss) on derivatives, tax $ (0.4) $ (0.2) $ (0.4) $ (0.4)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 688.0 $ 615.5
Accounts receivable, net 476.4 385.3
Inventories 353.8 321.3
Other current assets 80.1 51.6
Total current assets 1,598.3 1,373.7
Property, plant and equipment 2,146.1 2,035.5
Less: accumulated depreciation and amortization 1,139.6 1,092.3
Property, plant and equipment, net 1,006.5 943.2
Operating lease right-of-use assets 58.5 68.3
Investments in affiliated companies 215.7 214.7
Goodwill 108.9 111.1
Intangible assets, net 26.1 30.5
Deferred income taxes 80.0 16.0
Pension and other postretirement benefits 17.0 12.9
Other noncurrent assets 31.6 23.4
Total Assets 3,142.6 2,793.8
Current liabilities:    
Notes payable and other current debt 44.2 2.3
Accounts payable 207.7 213.1
Pension and other postretirement benefits 2.4 2.3
Accrued salaries, wages and benefits 114.0 106.0
Income taxes payable 39.5 26.0
Operating lease liabilities 8.1 10.1
Other current liabilities 142.7 143.6
Total current liabilities 558.6 503.4
Long-term debt 209.9 252.9
Deferred income taxes 11.6 10.4
Pension and other postretirement benefits 52.1 57.5
Operating lease liabilities 53.4 60.4
Deferred compensation benefits 26.9 22.9
Other long-term liabilities 27.8 31.8
Total Liabilities 940.3 939.3
Commitments and contingencies (Note 17)
Equity:    
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding 0.0 0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.1 million and 74.0 million, respectively 18.8 18.8
Capital in excess of par value 251.2 267.3
Retained earnings 2,335.8 1,846.7
Accumulated other comprehensive loss (155.7) (110.6)
Treasury stock, at cost (1.2 million and 1.3 million shares, respectively) (247.8) (167.7)
Total Equity 2,202.3 1,854.5
Total Liabilities and Equity $ 3,142.6 $ 2,793.8
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 3,000,000 3,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.25 $ 0.25
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 75,300,000 75,300,000
Common stock, shares outstanding (in shares) 74,100,000 74,000,000
Treasury stock, at cost (in shares) 1,200,000 1,300,000
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net income $ 514.1 $ 247.8
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 84.6 77.3
Amortization 3.3 3.3
Stock-based compensation 27.5 27.6
Pension settlement charge 0.7 3.4
Contingent consideration payments in excess of acquisition-date liability (1.0) (0.7)
Other non-cash items, net (17.5) (9.5)
Changes in assets and liabilities (188.5) (25.4)
Net cash provided by operating activities 423.2 323.8
Cash flows from investing activities:    
Capital expenditures (176.9) (116.7)
Purchase of intangibles 0.0 (3.8)
Other, net 1.2 (1.4)
Net cash used in investing activities (175.7) (121.9)
Cash flows from financing activities:    
Repayments of long-term debt (1.1) (1.7)
Dividend payments (37.8) (35.5)
Proceeds from stock-based compensation awards 23.1 22.0
Employee stock purchase plan contributions 5.7 4.6
Shares purchased under share repurchase programs (137.1) (115.5)
Shares repurchased for employee tax withholdings (14.7) (2.3)
Net cash used in financing activities (161.9) (128.4)
Effect of exchange rates on cash (13.1) 6.8
Net increase (decrease) in cash and cash equivalents 72.5 80.3
Cash, including cash equivalents at beginning of period 615.5 439.1
Cash, including cash equivalents at end of period $ 688.0 $ 519.4
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2021, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Throughout the COVID-19 pandemic, production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
New Accounting Standards
 9 Months Ended
Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards New Accounting Standards
Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance, and where applicable, the Company has made contract amendments to reflect the removal of the LIBOR rate.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Biologics
40 %
32 %
40 %
29 %
Generics
 18 %
18 %
17 %
19 %
Pharma
24 %
27 %
24 %
28 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
High-Value Product Components
55 %
47 %
54 %
45 %
High-Value Product Delivery Devices
5 %
5 %
4 %
5 %
Standard Packaging
22 %
25 %
23 %
26 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Americas
45 %
49 %
45 %
49 %
Europe, Middle East, Africa
45 %
42 %
45 %
43 %
Asia Pacific
10 %
9 %
10 %
8 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2020$10.9 
Contract assets, September 30, 2021
12.8 
Change in contract assets - increase (decrease)$1.9 
Deferred income, December 31, 2020$(57.1)
Deferred income, September 30, 2021
(38.1)
Change in deferred income - decrease (increase)$19.0 

Starting in the third quarter of 2020, the Company entered into new capacity reservation agreements, which include the receipt of up-front cash. The decrease in the deferred income balance is primarily due to the revenue recognition associated with the capacity reservation agreements, which is to be recognized over the next 1 to 2 years.
During the nine months ended September 30, 2021, $30.0 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2021, there was $4.1 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $3.2 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income Per Share
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2021202020212020
Net income$175.6 $82.3 $514.1 $247.8 
Weighted average common shares outstanding74.1 73.9 74.0 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.9 1.8 1.7 
Weighted average shares assuming dilution76.0 75.8 75.8 75.6 

During the three months ended September 30, 2021 and 2020, there were 0.0 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.0 million and 0.2 million antidilutive shares outstanding during the nine months ended September 30, 2021 and 2020, respectively.

In December 2020, we announced a share repurchase program for calendar-year 2021 authorizing the repurchase of up to 631,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2021. During the nine months ended September 30, 2021, we purchased 479,000 shares of our common stock under the program at a cost of $137.1 million, or an average price of $286.23 per share. This share repurchase program is expected to be completed by December 31, 2021.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2021		December 31,
2020
Raw materials$140.4 $133.5 
Work in process71.1 54.9 
Finished goods142.3 132.9 
 $353.8 $321.3 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
 9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Leases Leases
A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating lease cost$3.3 $3.1 $9.5 $9.3 
Short-term lease cost0.4 0.3 0.9 0.6 
Variable lease cost1.1 1.2 3.3 2.8 
Total lease cost$4.8 $4.6 $13.7 $12.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2.9 $3.2 $9.2 $9.6 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $0.3 $0.8 $4.6 

As of September 30, 2021 and December 31, 2020, the weighted average remaining lease term for operating leases was 10.9 and 11.1 years, respectively.

As of September 30, 2021 and December 31, 2020, the weighted average discount rate was 3.67% and 3.68%, respectively.
Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20212020
2021 (remaining period as of )$3.0 $12.4 
202210.3 10.4 
20239.3 9.3 
20248.5 8.7 
20256.8 6.9 
Thereafter36.2 37.5 
74.1 85.2 
Less: imputed lease interest(12.6)(14.7)
Total lease liabilities$61.5 $70.5 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Affiliated Companies
 9 Months Ended
Sep. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]  
Affiliated Companies Affiliated Companies
At September 30, 2021 and December 31, 2020, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $207.1 million and $201.9 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $8.6 million and $12.8 million, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $34.0 million and $119.6 million for the three and nine months ended September 30, 2021, respectively, as compared to $36.6 million and $97.0 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the payable balance due to affiliates was $13.8 million and $33.6 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.8 million and $8.8 million, respectively, for the three and nine months ended September 30, 2021, as compared to $2.7 million and $7.7 million, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, the receivable balance due from affiliates was $2.2 million and $1.4 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2020 Annual Report for additional details.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2021.
($ in millions)September 30,
2021		December 31,
2020
Term Loan, due December 31, 2024 (1.01%)
$86.6 $87.7 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
254.6 255.7 
Less: unamortized debt issuance costs0.5 0.5 
Total debt254.1 255.2 
Less: current portion of long-term debt44.2 2.3 
Long-term debt, net$209.9 $252.9 

Please refer to Note 8, Debt, to the consolidated financial statements in our 2020 Annual Report for additional details regarding our debt agreements.

Credit Agreement - Credit Facility

At September 30, 2021, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $297.6 million.

Credit Agreement Amendment - Term Loan

At September 30, 2021, we had $86.6 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $84.4 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2021 and December 31, 2020, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.
In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2021, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD28.8 — 24.0 
Yen6,131.7 24.6 27.7 
SGD28.7 17.8 3.0 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.4 billion ($86.1 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2021, we purchased several series of call options for a total of 596,367 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.

As of September 30, 2021, we had outstanding contracts to purchase 182,495 barrels of crude oil from October 2021 to March 2023, at a weighted-average strike price of $70.40 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2021 and December 31, 2020.
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of (Gain) Loss Recognized in Income for theAmount of (Gain) Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Fair Value Hedges:
Hedged item (intercompany loan)
$(5.9)$9.3 $(11.0)$25.1 Other expense (income)
Derivative designated as hedging instrument
5.9 (9.3)11.0 (25.1)Other expense (income)
Amount excluded from effectiveness testing
(0.9)(1.9)(2.1)(5.9)Other expense (income)
Total$(0.9)$(1.9)$(2.1)$(5.9)

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2021 and 2020 were $0.6 million, $1.9 million, and $1.3 million, $5.0 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.2)$(0.1)$0.1 $(0.7)Other expense (income)
Total$(0.2)$(0.1)$0.1 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$0.1 $(0.5)$0.1 $0.2 Net sales
Foreign currency hedge contracts1.4 — (0.3)0.1 Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$1.5 $(0.5)$(0.1)$0.4  
Net Investment Hedges:     
Cross-currency swap$0.6 $(3.0)$— $— Other expense (income)
Total$0.6 $(3.0)$— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.6)$2.8 $0.9 $(3.3)Other expense (income)
Total$(0.6)$2.8 $0.9 $(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$— $0.9 $(0.3)Net sales
Foreign currency hedge contracts(1.4)(0.3)1.2 (0.1)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(1.9)$(0.3)$2.3 $(0.2) 
Net Investment Hedges:     
Cross-currency swap$6.0 $(2.0)$— $— Other expense (income)
Total$6.0 $(2.0)$— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales$0.1 $0.2 $0.9 $(0.3)
Cost of goods and services sold(0.3)0.1 1.2 (0.1)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)0.1 (0.7)0.9 (3.3)

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Commodity call options$0.5 $0.1 $1.6 $0.3 Other expense (income)
Total$0.5 $0.1 $1.6 $0.3 

For the three and nine months ended September 30, 2021 and 2020, there was no material ineffectiveness related to our hedges.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$14.4 $14.4 $— $— 
Foreign currency contracts12.0 — 12.0 — 
Cross-currency swap2.2 — 2.2 — 
Commodity call options1.8 — 1.8 — 
 $30.4 $14.4 $16.0 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities15.7 15.7 — — 
Foreign currency contracts2.8 — 2.8 — 
 $22.0 $15.7 $2.8 $3.5 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.8 $12.8 $— $— 
Foreign currency contracts3.0 — 3.0 — 
Commodity call options0.3 0.3 
 $16.1 $12.8 $3.3 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities14.5 14.5 — — 
Cross-currency swap5.6 — 5.6 — 
Foreign currency contracts9.7 — 9.7 — 
 $33.4 $14.5 $15.3 $3.6 
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets and long-term liabilities, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. All derivatives are recognized on a gross basis as either assets or liabilities in the balance sheet.

Level 3 Fair Value Measurements

The fair value of the contingent consideration liability related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose® contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose® technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in an increase or decrease to the SmartDose® contingent consideration.

The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2019$3.3 
Increase in fair value recorded in earnings1.2 
Payments(0.9)
Balance, December 31, 20203.6 
Increase in fair value recorded in earnings0.9 
Payments(1.0)
Balance, September 30, 2021$3.5 

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.
The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2021, the estimated fair value of long-term debt was $220.3 million compared to a carrying amount of $209.9 million. At December 31, 2020, the estimated fair value of long-term debt was $265.7 million and the carrying amount was $252.9 million.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Accumulated Other Comprehensive Loss
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive income (loss) before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive income (loss)3.2 — 0.5 — 3.7 
Other comprehensive income (loss), net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2021202020212020
Gains (losses) on derivatives:
Foreign currency contracts$(0.1)$(0.3)$(1.1)$0.3 Net sales
Foreign currency contracts0.4 (0.1)(1.9)0.3 Cost of goods and services sold
Foreign currency contracts(0.9)1.1 (2.1)5.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(0.7)0.6 (5.4)5.4 
Tax benefit (expense)0.7 (0.3)2.2 (1.9)
Net of tax$— $0.3 $(3.2)$3.5 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.2 $0.4 (a)
Actuarial losses0.1 0.2 (0.1)— (a)
Settlements— (1.1)(0.7)(3.4)(a)
Total before tax0.2 (0.8)(0.6)(3.0)
Tax benefit (expense)(0.1)0.3 0.1 0.8 
Net of tax$0.1 $(0.5)$(0.5)$(2.2)
Total reclassifications for the period, net of tax$0.1 $(0.2)$(3.7)$1.3 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2021, there were 2,485,724 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2021, we granted 159,932 stock options at a weighted average exercise price of $277.23 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $63.72 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 0.7%; expected life of 5.6 years based on prior experience; stock volatility of 23.9% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2021, we granted 36,902 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $331.56 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2021, we granted 5,109 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $292.42 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.
Stock-based compensation expense was $11.4 million and $27.5 million for the three and nine months ended September 30, 2021, respectively. For the three and nine months ended September 30, 2020, stock-based compensation expense was $10.0 million and $27.6 million, respectively.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans
 9 Months Ended
Sep. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Benefit Plans Benefit Plans
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.1 $0.4 $— $— $0.1 $0.4 
Interest cost1.6 1.7 — — 1.6 1.7 
Expected return on assets(2.9)(2.8)— — (2.9)(2.8)
Amortization of prior service credit— 0.1 (0.1)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.5 0.4 (0.3)(0.6)0.2 (0.2)
Settlements— 1.1 — — — 1.1 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(0.9)$0.5 $(0.4)$(0.8)$(1.3)$(0.3)
International plans0.2 0.4 — — 0.2 0.4 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.9 $1.0 $— $— $0.9 $1.0 
Interest cost4.5 5.5 0.1 0.1 4.6 5.6 
Expected return on assets(9.0)(8.8)— — (9.0)(8.8)
Amortization of prior service credit0.1 0.1 (0.3)(0.5)(0.2)(0.4)
Recognized actuarial losses (gains)1.5 1.4 (1.2)(1.4)0.3 — 
Settlements0.7 3.4 — — 0.7 3.4 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(2.4)$1.5 $(1.4)$(1.8)$(3.8)$(0.3)
International plans1.1 1.1 — — 1.1 1.1 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 

During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Other Expense (Income)
 9 Months Ended
Sep. 30, 2021
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Restructuring and related charges$0.4 $4.5 $2.5 $4.5 
Fixed asset impairments and loss (gain) on sale of equipment0.2 0.9 0.6 7.2 
Contingent consideration0.1 0.8 0.9 0.9 
Foreign exchange transaction losses (gains)0.4 1.0 (2.5)(4.5)
Other items0.7 (0.5)1.5 (1.9)
Total other expense (income)$1.8 $6.7 $3.0 $6.2 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was originally expected to require restructuring and related charges of approximately $15 million to $17 million, with annualized savings being in the range of $3.5 million to $4.5 million. Due to the recent increase in customer demand, the Company will no longer proceed with certain portions of the plan, thus reducing the total expected charges to be approximately $9 million to $11 million. Similarly, annualized savings are now expected to be in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $7.1 million in restructuring and related charges associated with this plan.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2020$4.6 $— $4.6 
Charges1.0 1.5 2.5 
Cash payments(1.4)(0.9)(2.3)
Balance, September 30, 2021$4.2 $0.6 $4.8 

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2020$0.1 $0.1 
Cash payments(0.1)(0.1)
Balance, September 30, 2021$— $— 
Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Other Items

During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a net loss in our cost investment activity of $1.8 million, inclusive of an impairment charge of $2.2 million for one of the Company's cost investments. For the three and nine months ended September 30, 2020, there was no activity related to our cost investments.
During both the three and nine months ended September 30, 2021 and 2020, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.The provision for income taxes was $12.0 million and $21.1 million for the three months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 6.6% and 21.6%, respectively. The provision for income taxes was $73.0 million and $52.1 million for the nine months ended September 30, 2021 and 2020, respectively, and the effective tax rate was 12.9% and 18.2%, respectively. The reduction in effective tax rates for the three and nine months ended September 30, 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2020 Annual Report.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Information Segment InformationOur business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.
The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales:    
Proprietary Products$577.0 $421.5 $1,708.0 $1,194.5 
Contract-Manufactured Products129.7 126.6 393.2 372.5 
Intersegment sales elimination(0.2)(0.1)(0.4)(0.3)
Consolidated net sales$706.5 $548.0 $2,100.8 $1,566.7 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating profit (loss):
Proprietary Products$195.5 $107.5 $594.3 $312.9 
Contract-Manufactured Products16.8 18.8 51.9 52.1 
Total business and segment operating profit$212.3 $126.3 $646.2 $365.0 
Corporate and Unallocated
Stock-based compensation expense$(11.4)$(10.0)$(27.5)$(27.6)
Corporate general costs (1)(18.1)(12.4)(45.5)(39.5)
Unallocated Items:
Restructuring and severance related charges(0.3)(4.5)(2.5)(6.7)
Amortization of Acquisition-related Intangible Assets (2)(0.2)(0.2)(0.6)(0.4)
Cost investment activity(0.9)— (1.8)— 
Total Corporate and Unallocated(30.9)(27.1)(77.9)(74.2)
Total consolidated operating profit$181.4 $99.2 $568.3 $290.8 
Other expense, net0.3 1.5 1.3 4.6 
Income before income taxes$181.1 $97.7 $567.0 $286.2 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other Expense (Income), for further discussion of these items.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2021, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Throughout the COVID-19 pandemic, production facilities have continued to operate as they had prior to the pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments have had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.
New Accounting Standards New Accounting Standards
Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance, and where applicable, the Company has made contract amendments to reflect the removal of the LIBOR rate.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Biologics
40 %
32 %
40 %
29 %
Generics
 18 %
18 %
17 %
19 %
Pharma
24 %
27 %
24 %
28 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
High-Value Product Components
55 %
47 %
54 %
45 %
High-Value Product Delivery Devices
5 %
5 %
4 %
5 %
Standard Packaging
22 %
25 %
23 %
26 %
Contract-Manufactured Products
18 %
23 %
19 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Americas
45 %
49 %
45 %
49 %
Europe, Middle East, Africa
45 %
42 %
45 %
43 %
Asia Pacific
10 %
9 %
10 %
8 %
100 %
100 %
100 %
100 %
Schedule of Change in Contract with Customer, Asset and Liability The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2020$10.9 
Contract assets, September 30, 2021
12.8 
Change in contract assets - increase (decrease)$1.9 
Deferred income, December 31, 2020$(57.1)
Deferred income, September 30, 2021
(38.1)
Change in deferred income - decrease (increase)$19.0 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income Per Share (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic to Diluted Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2021202020212020
Net income$175.6 $82.3 $514.1 $247.8 
Weighted average common shares outstanding74.1 73.9 74.0 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.9 1.8 1.7 
Weighted average shares assuming dilution76.0 75.8 75.8 75.6 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2021		December 31,
2020
Raw materials$140.4 $133.5 
Work in process71.1 54.9 
Finished goods142.3 132.9 
 $353.8 $321.3 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Schedule of Lease, Cost
The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating lease cost$3.3 $3.1 $9.5 $9.3 
Short-term lease cost0.4 0.3 0.9 0.6 
Variable lease cost1.1 1.2 3.3 2.8 
Total lease cost$4.8 $4.6 $13.7 $12.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2.9 $3.2 $9.2 $9.6 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $0.3 $0.8 $4.6 
Schedule of Lessee, Operating Lease, Liability, Maturity Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20212020
2021 (remaining period as of )$3.0 $12.4 
202210.3 10.4 
20239.3 9.3 
20248.5 8.7 
20256.8 6.9 
Thereafter36.2 37.5 
74.1 85.2 
Less: imputed lease interest(12.6)(14.7)
Total lease liabilities$61.5 $70.5 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Obligations, Net of Current Maturities
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2021.
($ in millions)September 30,
2021		December 31,
2020
Term Loan, due December 31, 2024 (1.01%)
$86.6 $87.7 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
254.6 255.7 
Less: unamortized debt issuance costs0.5 0.5 
Total debt254.1 255.2 
Less: current portion of long-term debt44.2 2.3 
Long-term debt, net$209.9 $252.9 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Contracts As of September 30, 2021, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEuro
USD28.8 — 24.0 
Yen6,131.7 24.6 27.7 
SGD28.7 17.8 3.0 
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of (Gain) Loss Recognized in Income for theAmount of (Gain) Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Fair Value Hedges:
Hedged item (intercompany loan)
$(5.9)$9.3 $(11.0)$25.1 Other expense (income)
Derivative designated as hedging instrument
5.9 (9.3)11.0 (25.1)Other expense (income)
Amount excluded from effectiveness testing
(0.9)(1.9)(2.1)(5.9)Other expense (income)
Total$(0.9)$(1.9)$(2.1)$(5.9)
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.2)$(0.1)$0.1 $(0.7)Other expense (income)
Total$(0.2)$(0.1)$0.1 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$0.1 $(0.5)$0.1 $0.2 Net sales
Foreign currency hedge contracts1.4 — (0.3)0.1 Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$1.5 $(0.5)$(0.1)$0.4  
Net Investment Hedges:     
Cross-currency swap$0.6 $(3.0)$— $— Other expense (income)
Total$0.6 $(3.0)$— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020 
Fair Value Hedges
Foreign currency hedge contracts$(0.6)$2.8 $0.9 $(3.3)Other expense (income)
Total$(0.6)$2.8 $0.9 $(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$— $0.9 $(0.3)Net sales
Foreign currency hedge contracts(1.4)(0.3)1.2 (0.1)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(1.9)$(0.3)$2.3 $(0.2) 
Net Investment Hedges:     
Cross-currency swap$6.0 $(2.0)$— $— Other expense (income)
Total$6.0 $(2.0)$— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales$0.1 $0.2 $0.9 $(0.3)
Cost of goods and services sold(0.3)0.1 1.2 (0.1)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)0.1 (0.7)0.9 (3.3)

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2021202020212020
Commodity call options$0.5 $0.1 $1.6 $0.3 Other expense (income)
Total$0.5 $0.1 $1.6 $0.3 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$14.4 $14.4 $— $— 
Foreign currency contracts12.0 — 12.0 — 
Cross-currency swap2.2 — 2.2 — 
Commodity call options1.8 — 1.8 — 
 $30.4 $14.4 $16.0 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities15.7 15.7 — — 
Foreign currency contracts2.8 — 2.8 — 
 $22.0 $15.7 $2.8 $3.5 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.8 $12.8 $— $— 
Foreign currency contracts3.0 — 3.0 — 
Commodity call options0.3 0.3 
 $16.1 $12.8 $3.3 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities14.5 14.5 — — 
Cross-currency swap5.6 — 5.6 — 
Foreign currency contracts9.7 — 9.7 — 
 $33.4 $14.5 $15.3 $3.6 
Schedule of Changes in Level 3 Fair Value Measurements The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2019$3.3 
Increase in fair value recorded in earnings1.2 
Payments(0.9)
Balance, December 31, 20203.6 
Increase in fair value recorded in earnings0.9 
Payments(1.0)
Balance, September 30, 2021$3.5 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Accumulated Other Comprehensive Loss (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive income (loss) before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive income (loss)3.2 — 0.5 — 3.7 
Other comprehensive income (loss), net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)
Schedule of Reclassification out of Accumulated Other Comprehensive Loss
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2021202020212020
Gains (losses) on derivatives:
Foreign currency contracts$(0.1)$(0.3)$(1.1)$0.3 Net sales
Foreign currency contracts0.4 (0.1)(1.9)0.3 Cost of goods and services sold
Foreign currency contracts(0.9)1.1 (2.1)5.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(0.7)0.6 (5.4)5.4 
Tax benefit (expense)0.7 (0.3)2.2 (1.9)
Net of tax$— $0.3 $(3.2)$3.5 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.2 $0.4 (a)
Actuarial losses0.1 0.2 (0.1)— (a)
Settlements— (1.1)(0.7)(3.4)(a)
Total before tax0.2 (0.8)(0.6)(3.0)
Tax benefit (expense)(0.1)0.3 0.1 0.8 
Net of tax$0.1 $(0.5)$(0.5)$(2.2)
Total reclassifications for the period, net of tax$0.1 $(0.2)$(3.7)$1.3 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Stockholders Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.1 $0.4 $— $— $0.1 $0.4 
Interest cost1.6 1.7 — — 1.6 1.7 
Expected return on assets(2.9)(2.8)— — (2.9)(2.8)
Amortization of prior service credit— 0.1 (0.1)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.5 0.4 (0.3)(0.6)0.2 (0.2)
Settlements— 1.1 — — — 1.1 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(0.9)$0.5 $(0.4)$(0.8)$(1.3)$(0.3)
International plans0.2 0.4 — — 0.2 0.4 
Net periodic benefit cost$(0.7)$0.9 $(0.4)$(0.8)$(1.1)$0.1 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
Service cost$0.9 $1.0 $— $— $0.9 $1.0 
Interest cost4.5 5.5 0.1 0.1 4.6 5.6 
Expected return on assets(9.0)(8.8)— — (9.0)(8.8)
Amortization of prior service credit0.1 0.1 (0.3)(0.5)(0.2)(0.4)
Recognized actuarial losses (gains)1.5 1.4 (1.2)(1.4)0.3 — 
Settlements0.7 3.4 — — 0.7 3.4 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202120202021202020212020
U.S. plans$(2.4)$1.5 $(1.4)$(1.8)$(3.8)$(0.3)
International plans1.1 1.1 — — 1.1 1.1 
Net periodic benefit cost$(1.3)$2.6 $(1.4)$(1.8)$(2.7)$0.8 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Other Expense (Income) (Tables)
 9 Months Ended
Sep. 30, 2021
Other Income and Expenses [Abstract]  
Schedule of Other Expense (Income)
Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Restructuring and related charges$0.4 $4.5 $2.5 $4.5 
Fixed asset impairments and loss (gain) on sale of equipment0.2 0.9 0.6 7.2 
Contingent consideration0.1 0.8 0.9 0.9 
Foreign exchange transaction losses (gains)0.4 1.0 (2.5)(4.5)
Other items0.7 (0.5)1.5 (1.9)
Total other expense (income)$1.8 $6.7 $3.0 $6.2 
Schedule of Restructuring Reserve
The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2020$4.6 $— $4.6 
Charges1.0 1.5 2.5 
Cash payments(1.4)(0.9)(2.3)
Balance, September 30, 2021$4.2 $0.6 $4.8 
The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2020$0.1 $0.1 
Cash payments(0.1)(0.1)
Balance, September 30, 2021$— $— 
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Net sales:    
Proprietary Products$577.0 $421.5 $1,708.0 $1,194.5 
Contract-Manufactured Products129.7 126.6 393.2 372.5 
Intersegment sales elimination(0.2)(0.1)(0.4)(0.3)
Consolidated net sales$706.5 $548.0 $2,100.8 $1,566.7 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2021202020212020
Operating profit (loss):
Proprietary Products$195.5 $107.5 $594.3 $312.9 
Contract-Manufactured Products16.8 18.8 51.9 52.1 
Total business and segment operating profit$212.3 $126.3 $646.2 $365.0 
Corporate and Unallocated
Stock-based compensation expense$(11.4)$(10.0)$(27.5)$(27.6)
Corporate general costs (1)(18.1)(12.4)(45.5)(39.5)
Unallocated Items:
Restructuring and severance related charges(0.3)(4.5)(2.5)(6.7)
Amortization of Acquisition-related Intangible Assets (2)(0.2)(0.2)(0.6)(0.4)
Cost investment activity(0.9)— (1.8)— 
Total Corporate and Unallocated(30.9)(27.1)(77.9)(74.2)
Total consolidated operating profit$181.4 $99.2 $568.3 $290.8 
Other expense, net0.3 1.5 1.3 4.6 
Income before income taxes$181.1 $97.7 $567.0 $286.2 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Revenue Recognition (Details) - Revenue Benchmark
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Customer Concentration Risk | Biologics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 40.00% 32.00% 40.00% 29.00%
Customer Concentration Risk | Generics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 18.00% 18.00% 17.00% 19.00%
Customer Concentration Risk | Pharma        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 24.00% 27.00% 24.00% 28.00%
Customer Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 18.00% 23.00% 19.00% 24.00%
Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Product Concentration Risk | High-Value Product Components        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 55.00% 47.00% 54.00% 45.00%
Product Concentration Risk | High-Value Product Delivery Devices        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 5.00% 5.00% 4.00% 5.00%
Product Concentration Risk | Standard Packaging        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 22.00% 25.00% 23.00% 26.00%
Product Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 18.00% 23.00% 19.00% 24.00%
Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Geographic Concentration Risk | Americas        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 45.00% 49.00% 45.00% 49.00%
Geographic Concentration Risk | Europe, Middle East, Africa        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 45.00% 42.00% 45.00% 43.00%
Geographic Concentration Risk | Asia Pacific        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 10.00% 9.00% 10.00% 8.00%
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Contracts and Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2021
USD ($)
Contract With Customer, Asset [Roll Forward]  
Contract assets, December 31, 2020 $ 10.9
Contract assets, September 30, 2021 12.8
Change in contract assets - increase (decrease) 1.9
Contract With Customer, Liability [Roll Forward]  
Deferred income, December 31, 2020 (57.1)
Deferred income, September 30, 2021 (38.1)
Change in deferred income - decrease (increase) $ 19.0
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Contracts and Liabilities, Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Jun. 30, 2013
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in the deferred income balance $ 30.0    
Deferred income 38.1 $ 57.1  
SmartDose      
Disaggregation of Revenue [Line Items]      
Deferred income 4.1   $ 20.0
Deferred income, current 0.9    
Deferred income, noncurrent $ 3.2    
Minimum      
Disaggregation of Revenue [Line Items]      
Contract with customer liability recognized 1 year    
Maximum      
Disaggregation of Revenue [Line Items]      
Contract with customer liability recognized 2 years    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Earnings Per Share [Abstract]                  
Net income $ 175.6 $ 187.3 $ 151.2 $ 82.3 $ 91.2 $ 74.3 $ 514.1 $ 247.8  
Weighted average common shares outstanding (in shares) 74,100,000     73,900,000     74,000,000.0 73,900,000  
Dilutive effect of equity awards, based on the treasury stock method (in shares) 1,900,000     1,900,000     1,800,000 1,700,000  
Weighted average shares assuming dilution (in shares) 76,000,000.0     75,800,000     75,800,000 75,600,000  
Antidilutive options excluded from computation of diluted net income per share (in shares) 0     0     0 200,000  
Stock repurchase program, shares authorized (in shares)                 631,000
Share purchased under share repurchase program (in shares) 0           479,000    
Stock purchase program, cost of shares purchased     $ 137.1     $ 115.5 $ 137.1    
Stock repurchase program, average price per share (in dollars per share)             $ 286.23    
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 140.4 $ 133.5
Work in process 71.1 54.9
Finished goods 142.3 132.9
Total inventories $ 353.8 $ 321.3
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Lease Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Leases [Abstract]        
Operating lease cost $ 3.3 $ 3.1 $ 9.5 $ 9.3
Short-term lease cost 0.4 0.3 0.9 0.6
Variable lease cost 1.1 1.2 3.3 2.8
Total lease cost $ 4.8 $ 4.6 $ 13.7 $ 12.7
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases $ 2.9 $ 3.2 $ 9.2 $ 9.6
Right-of-use assets obtained in exchange for new operating lease liabilities $ 0.0 $ 0.3 $ 0.8 $ 4.6
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Lease Weighted Average (Details)
Sep. 30, 2021
Dec. 31, 2020
Leases [Abstract]    
Weighted average remaining lease term 10 years 10 months 24 days 11 years 1 month 6 days
Weighted average discount rate 3.67% 3.68%
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Leases [Abstract]    
Remainder of fiscal year $ 3.0  
Year one 10.3 $ 12.4
Year two 9.3 10.4
Year three 8.5 9.3
Year four 6.8 8.7
Thereafter 36.2  
Year five   6.9
Thereafter   37.5
Operating leases liabilities payments due 74.1 85.2
Less: imputed lease interest (12.6) (14.7)
Total lease liabilities $ 61.5 $ 70.5
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Affiliated Companies (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]          
Carrying amount, equity-method investments $ 207.1   $ 207.1   $ 201.9
Carrying amount, investments not accounted for under the equity method 8.6   8.6   12.8
Purchases and royalty payments made to affiliates 34.0 $ 36.6 119.6 $ 97.0  
Amount due and payable to affiliates 13.8   13.8   33.6
Sales to affiliates 2.8 $ 2.7 8.8 $ 7.7  
Amount receivable from affiliates $ 2.2   $ 2.2   $ 1.4
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Long-term debt, gross $ 254.6 $ 255.7
Less: unamortized debt issuance costs 0.5 0.5
Total debt 254.1 255.2
Less: current portion of long-term debt 44.2 2.3
Long-term debt, net $ 209.9 252.9
Term Loan, due December 31, 2024 (1.01%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 1.01%  
Long-term debt, gross $ 86.6 87.7
Long-term debt, net $ 84.4  
Series A notes, due July 5, 2022 (3.67%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.67%  
Long-term debt, gross $ 42.0 42.0
Series B notes, due July 5, 2024 (3.82%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.82%  
Long-term debt, gross $ 53.0 53.0
Series C notes, due July 5, 2027 (4.02%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 4.02%  
Long-term debt, gross $ 73.0 $ 73.0
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Credit Agreement (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Line of Credit Facility [Line Items]    
Long-term debt, gross $ 254.6 $ 255.7
Long-term debt, current 44.2 2.3
Long-term debt 209.9 252.9
Revolving credit facility, Due 2024    
Line of Credit Facility [Line Items]    
Line of credit facility, current borrowing capacity 300.0  
Line of credit Facility, unused commitment level 297.6  
Revolving credit facility, Due 2024 | Letter of Credit    
Line of Credit Facility [Line Items]    
Long-term line of credit 2.4  
Term Loan Due 2024    
Line of Credit Facility [Line Items]    
Long-term debt, gross 86.6 $ 87.7
Long-term debt, current 2.2  
Long-term debt $ 84.4  
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)
€ in Millions, ¥ in Millions, $ in Millions, $ in Millions
 9 Months Ended 47 Months Ended
Sep. 30, 2021
SGD ($)
$ / bbl
bbl
Sep. 30, 2021
SGD ($)
$ / bbl
bbl
Sep. 30, 2021
USD ($)
$ / bbl
Sep. 30, 2021
EUR (€)
$ / bbl
Sep. 30, 2021
JPY (¥)
$ / bbl
Dec. 31, 2020
SGD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
JPY (¥)
Foreign Exchange Forward                  
Derivative [Line Items]                  
Derivative contract term 18 months                
Options Held                  
Derivative [Line Items]                  
Derivative, nonmonetary notional amount, volume | bbl 182,495 596,367              
Derivative, average price risk option strike price | $ / bbl 70.40 70.40 70.40 70.40 70.40        
USD | Forward Contracts                  
Derivative [Line Items]                  
Derivative, notional amount     $ 13.4       $ 13.4    
USD | Foreign Exchange Forward | Long | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount     28.8            
USD | Foreign Exchange Forward | Short | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount     0.0 € 24.0          
USD | Cross Currency Interest Rate Contract                  
Derivative [Line Items]                  
Derivative, notional amount               $ 86.1  
USD | Cross Currency Interest Rate Contract | Net Investment Hedges:                  
Derivative [Line Items]                  
Derivative, notional amount               $ 90.0  
Yen | Foreign Exchange Forward | Long | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount | ¥         ¥ 6,131.7        
Yen | Foreign Exchange Forward | Short | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount     24.6 27.7          
Yen | Cross Currency Interest Rate Contract                  
Derivative [Line Items]                  
Derivative, notional amount | ¥                 ¥ 9,400.0
SGD | Forward Contracts                  
Derivative [Line Items]                  
Derivative, notional amount $ 601.5 $ 601.5       $ 601.5      
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount $ 28.7 $ 28.7              
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument                  
Derivative [Line Items]                  
Derivative, notional amount     $ 17.8 € 3.0          
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss recognized in income, fair value hedges $ (0.9) $ (1.9) $ (2.1) $ (5.9)
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net 0.5 0.1 1.6 0.3
Fair Value Hedges        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, forward point components, (gain) loss, recognized in earnings (0.6) 1.3 (1.9) 5.0
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.2) (0.1) (0.6) 2.8
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 (0.7) 0.9 (3.3)
Cash Flow Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 1.5 (0.5) (1.9) (0.3)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income (0.1) 0.4 2.3 (0.2)
Net Investment Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 0.6 (3.0) 6.0 (2.0)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Other expense (income)        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss on hedged item, fair value hedges (5.9) 9.3 (11.0) 25.1
Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges 5.9 (9.3) 11.0 (25.1)
Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges (0.9) (1.9) (2.1) (5.9)
Gain (loss) on derivative instruments, net, pretax 0.1 (0.7) 0.9 (3.3)
Other expense (income) | Commodity call options | Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net 0.5 0.1 1.6 0.3
Other expense (income) | Fair Value Hedges | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.2) (0.1) (0.6) 2.8
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 (0.7) 0.9 (3.3)
Other expense (income) | Net Investment Hedges: | Cross-currency swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 0.6 (3.0) 6.0 (2.0)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0   0.0 0.0
Net sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI   0.0    
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income       (0.3)
Gain (loss) on derivative instruments, net, pretax 0.1 0.2 0.9 (0.3)
Net sales | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.1 (0.5) (0.5) 0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 0.2 0.9 (0.3)
Cost of goods and services sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI       (0.3)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income       (0.1)
Gain (loss) on derivative instruments, net, pretax (0.3) 0.1 1.2 (0.1)
Cost of goods and services sold | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 1.4 0.0 (1.4) (0.3)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income (0.3) 0.1 1.2 (0.1)
Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 0.1 0.1 0.2 0.2
Interest expense | Cash Flow Hedges: | Forward treasury locks        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.0 0.0 0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income $ 0.1 $ 0.1 $ 0.2 $ 0.2
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Assets:    
Deferred compensation assets $ 14.4 $ 12.8
Foreign currency contracts   3.0
Commodity call options 1.8 0.3
Total assets at fair value 30.4 16.1
Liabilities:    
Contingent consideration 3.5 3.6
Deferred compensation liabilities 15.7 14.5
Total liabilities at fair value 22.0 33.4
Foreign currency contracts    
Assets:    
Foreign currency contracts 12.0  
Liabilities:    
Foreign currency contracts 2.8 9.7
Cross-currency swap    
Assets:    
Foreign currency contracts 2.2  
Liabilities:    
Foreign currency contracts   5.6
Level 1    
Assets:    
Deferred compensation assets 14.4 12.8
Foreign currency contracts   0.0
Commodity call options 0.0
Total assets at fair value 14.4 12.8
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 15.7 14.5
Total liabilities at fair value 15.7 14.5
Level 1 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0  
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 1 | Cross-currency swap    
Assets:    
Foreign currency contracts 0.0  
Liabilities:    
Foreign currency contracts   0.0
Level 2    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts   3.0
Commodity call options 1.8 0.3
Total assets at fair value 16.0 3.3
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 2.8 15.3
Level 2 | Foreign currency contracts    
Assets:    
Foreign currency contracts 12.0  
Liabilities:    
Foreign currency contracts 2.8 9.7
Level 2 | Cross-currency swap    
Assets:    
Foreign currency contracts 2.2  
Liabilities:    
Foreign currency contracts   5.6
Level 3    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts   0.0
Commodity call options 0.0
Total assets at fair value 0.0 0.0
Liabilities:    
Contingent consideration 3.5 3.6
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 3.5 3.6
Level 3 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0  
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 3 | Cross-currency swap    
Assets:    
Foreign currency contracts $ 0.0  
Liabilities:    
Foreign currency contracts   $ 0.0
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurement - Level 3 Fair Value Measurements (Details) - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Level 3 Fair Value Measurements [Roll Forward]    
Balance, beginning of period $ 3.6 $ 3.3
Increase in fair value recorded in earnings 0.9 1.2
Payments (1.0) (0.9)
Balance, end of period $ 3.5 $ 3.6
Sales Projections | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 10.00%  
Sales Projections | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 50.00%  
Sales Projections | Weighted Average    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 40.00%  
Probabilities of Successful FDA Approval | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 19.00%  
Probabilities of Successful FDA Approval | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 100.00%  
Probabilities of Successful Execution of Agreement | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 25.00%  
Probabilities of Successful Execution of Agreement | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 100.00%  
Measurement Input, Discount Rate    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 19.00%  
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurement - Other Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Other Financial Instruments [Abstract]    
Long-term debt, fair value $ 220.3 $ 265.7
Long-term debt $ 209.9 $ 252.9
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance $ 2,032.6 $ 1,829.0 $ 1,854.5 $ 1,606.3 $ 1,490.2 $ 1,573.2 $ 1,854.5 $ 1,573.2
Other comprehensive income (loss) before reclassifications             (48.8)  
Amounts reclassified out from accumulated other comprehensive income (loss)             3.7  
Other comprehensive (loss) income, net of tax (22.5) 7.0 (29.6) 28.3 4.5 (42.7) (45.1) (9.9)
Ending balance 2,202.3 2,032.6 1,829.0 1,718.9 1,606.3 1,490.2 2,202.3 1,718.9
(Losses) gains on derivatives                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (1.9)       (1.9)  
Other comprehensive income (loss) before reclassifications             (2.5)  
Amounts reclassified out from accumulated other comprehensive income (loss)             3.2  
Other comprehensive (loss) income, net of tax             0.7  
Ending balance (1.2)           (1.2)  
Change in equity affiliate investment AOCI                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     0.6       0.6  
Other comprehensive income (loss) before reclassifications             0.0  
Amounts reclassified out from accumulated other comprehensive income (loss)             0.0  
Other comprehensive (loss) income, net of tax             0.0  
Ending balance 0.6           0.6  
Defined benefit pension and other postretirement plans                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (40.5)       (40.5)  
Other comprehensive income (loss) before reclassifications             0.6  
Amounts reclassified out from accumulated other comprehensive income (loss)             0.5  
Other comprehensive (loss) income, net of tax             1.1  
Ending balance (39.4)           (39.4)  
Foreign currency translation                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (68.8)       (68.8)  
Other comprehensive income (loss) before reclassifications             (46.9)  
Amounts reclassified out from accumulated other comprehensive income (loss)             0.0  
Other comprehensive (loss) income, net of tax             (46.9)  
Ending balance (115.7)           (115.7)  
Accumulated other comprehensive loss                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance (133.2) (140.2) (110.6) (187.8) (192.3) (149.6) (110.6) (149.6)
Other comprehensive (loss) income, net of tax (22.5) 7.0 (29.6) 28.3 4.5 (42.7)    
Ending balance $ (155.7) $ (133.2) $ (140.2) $ (159.5) $ (187.8) $ (192.3) $ (155.7) $ (159.5)
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Cost of goods and services sold $ (418.3)     $ (353.4)     $ (1,225.6) $ (1,010.0)
Interest expense (1.8)     (2.1)     (5.6) (6.1)
Prior service credit 0.1     0.1     0.2 0.4
Actuarial losses (0.2)     0.2     (0.3) 0.0
Settlements 0.0     (1.1)     (0.7) (3.4)
Income before income taxes 181.1     97.7     567.0 286.2
Tax benefit (expense) (12.0)     (21.1)     (73.0) (52.1)
Total reclassifications for the period, net of tax 175.6 $ 187.3 $ 151.2 82.3 $ 91.2 $ 74.3 514.1 247.8
Reclassification out of Accumulated Other Comprehensive Loss                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Total reclassifications for the period, net of tax 0.1     (0.2)     (3.7) 1.3
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Income before income taxes (0.7)     0.6     (5.4) 5.4
Tax benefit (expense) 0.7     (0.3)     2.2 (1.9)
Total reclassifications for the period, net of tax 0.0     0.3     (3.2) 3.5
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net sales (0.1)     (0.3)     (1.1) 0.3
Cost of goods and services sold 0.4     (0.1)     (1.9) 0.3
Other expense (income) (0.9)     1.1     (2.1) 5.1
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Interest expense (0.1)     (0.1)     (0.3) (0.3)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Prior service credit 0.1     0.1     0.2 0.4
Actuarial losses 0.1     0.2     (0.1) 0.0
Settlements 0.0     (1.1)     (0.7) (3.4)
Income before income taxes 0.2     (0.8)     (0.6) (3.0)
Tax benefit (expense) (0.1)     0.3     0.1 0.8
Total reclassifications for the period, net of tax $ 0.1     $ (0.5)     $ (0.5) $ (2.2)
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholder's Equity - Change in Shareholders' Equity (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Class of Stock [Line Items]                  
Accounting Standards Update [Extensible Enumeration]                 Accounting Standards Update 2016-13 [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance $ 2,032.6 $ 1,829.0 $ 1,854.5 $ 1,606.3 $ 1,490.2 $ 1,573.2 $ 1,854.5 $ 1,573.2  
Net income 175.6 187.3 151.2 82.3 91.2 74.3 $ 514.1 247.8  
Activity related to stock-based compensation $ 16.6 21.8 2.5 13.9 20.4 12.8      
Share purchased under share repurchase program (in shares) 0           479,000    
Shares purchased under share repurchase program     (137.1)     (115.5) $ (137.1)    
Dividends declared   (12.5) (12.5) (11.9)   (11.8)      
Other comprehensive (loss) income, net of tax $ (22.5) 7.0 (29.6) 28.3 4.5 (42.7) (45.1) (9.9)  
Ending balance $ 2,202.3 $ 2,032.6 $ 1,829.0 $ 1,718.9 $ 1,606.3 1,490.2 $ 2,202.3 1,718.9 $ 1,573.2
Cumulative Effect, Period of Adoption, Adjustment                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance           $ (0.1)   $ (0.1)  
Ending balance                 $ (0.1)
Common Stock                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000  
Beginning balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8  
Balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Ending balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Capital in Excess of Par Value                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 248.0 246.7 267.3 263.1 267.6 272.7 267.3 272.7  
Activity related to stock-based compensation 3.2 1.3 (20.6) 5.1 (4.5) (5.1)      
Ending balance $ 251.2 $ 248.0 $ 246.7 $ 268.2 $ 263.1 $ 267.6 $ 251.2 $ 268.2 $ 272.7
Treasury Stock                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Balance (in shares) 1,300,000 1,500,000 1,300,000 1,500,000 1,700,000 1,200,000 1,300,000 1,200,000  
Beginning balance $ (261.2) $ (281.7) $ (167.7) $ (190.8) $ (215.7) $ (118.1) $ (167.7) $ (118.1)  
Activity related to stock -based compensation (in shares) (100,000) (200,000) (300,000) (100,000) (200,000) (300,000)      
Activity related to stock-based compensation $ 13.4 $ 20.5 $ 23.1 $ 8.8 $ 24.9 $ 17.9      
Share purchased under share repurchase program (in shares)     500,000     800,000      
Shares purchased under share repurchase program     $ (137.1)     $ (115.5)      
Balance (in shares) 1,200,000 1,300,000 1,500,000 1,400,000 1,500,000 1,700,000 1,200,000 1,400,000 1,200,000
Ending balance $ (247.8) $ (261.2) $ (281.7) $ (182.0) $ (190.8) $ (215.7) $ (247.8) $ (182.0) $ (118.1)
Retained earnings                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 2,160.2 1,985.4 1,846.7 1,703.0 1,611.8 1,549.4 1,846.7 1,549.4  
Net income 175.6 187.3 151.2 82.3 91.2 74.3      
Dividends declared   (12.5) (12.5) (11.9)   (11.8)      
Ending balance 2,335.8 2,160.2 1,985.4 1,773.4 1,703.0 1,611.8 2,335.8 1,773.4 1,549.4
Retained earnings | Cumulative Effect, Period of Adoption, Adjustment                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance           (0.1)   (0.1)  
Ending balance                 (0.1)
Accumulated other comprehensive loss                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance (133.2) (140.2) (110.6) (187.8) (192.3) (149.6) (110.6) (149.6)  
Other comprehensive (loss) income, net of tax (22.5) 7.0 (29.6) 28.3 4.5 (42.7)      
Ending balance $ (155.7) $ (133.2) $ (140.2) $ (159.5) $ (187.8) $ (192.3) $ (155.7) $ (159.5) $ (149.6)
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholder's Equity - Supplemental Equity Information (Details) - $ / shares
 3 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Equity [Abstract]        
Dividends declared per share (in dollars per share) $ 0.17 $ 0.17 $ 0.16 $ 0.16
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares available for issuance under the 2016 Plan (in shares) 2,485,724   2,485,724  
Stock options, granted (in shares)     159,932  
Stock options, weighted average exercise price (in dollars per share)     $ 277.23  
Stock options, weighted average grant date fair value (in dollars per share)     $ 63.72  
Risk-free interest rate (in hundredths)     0.70%  
Expected life (in years)     5 years 7 months 6 days  
Stock volatility (in hundredths)     23.90%  
Dividend yield (in hundredths)     0.30%  
Stock-based compensation expense $ 11.4 $ 10.0 $ 27.5 $ 27.6
Performance Share Unit (PSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     36,902  
Grant date fair value (in dollars per share)     $ 331.56  
PSU payout, minimum (in hundredths) 0.00%   0.00%  
PSU payout, maximum (in hundredths) 200.00%   200.00%  
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     5,109  
Grant date fair value (in dollars per share)     $ 292.42  
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost $ 0.1 $ 0.4 $ 0.9 $ 1.0
Interest cost 1.6 1.7 4.6 5.6
Expected return on assets (2.9) (2.8) (9.0) (8.8)
Amortization of prior service credit (0.1) (0.1) (0.2) (0.4)
Recognized actuarial losses (gains) 0.2 (0.2) 0.3 0.0
Settlements 0.0 1.1 0.7 3.4
Net periodic benefit cost (1.1) 0.1 (2.7) 0.8
U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (1.3) (0.3) (3.8) (0.3)
International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.2 0.4 1.1 1.1
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.1 0.4 0.9 1.0
Interest cost 1.6 1.7 4.5 5.5
Expected return on assets (2.9) (2.8) (9.0) (8.8)
Amortization of prior service credit 0.0 0.1 0.1 0.1
Recognized actuarial losses (gains) 0.5 0.4 1.5 1.4
Settlements 0.0 1.1 0.7 3.4
Net periodic benefit cost (0.7) 0.9 (1.3) 2.6
Pension benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.9) 0.5 (2.4) 1.5
Pension benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.2 0.4 1.1 1.1
Other retirement benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.0 0.0 0.0 0.0
Interest cost 0.0 0.0 0.1 0.1
Expected return on assets 0.0 0.0 0.0 0.0
Amortization of prior service credit (0.1) (0.2) (0.3) (0.5)
Recognized actuarial losses (gains) (0.3) (0.6) (1.2) (1.4)
Settlements 0.0 0.0 0.0 0.0
Net periodic benefit cost (0.4) (0.8) (1.4) (1.8)
Other retirement benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.4) (0.8) (1.4) (1.8)
Other retirement benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 0.0 $ 1.1 $ 0.7 $ 3.4
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 0.0 $ 1.1 $ 0.7 $ 3.4
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Other Expense (Income) - Other Expense (Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Other Income and Expenses [Abstract]        
Restructuring and related charges $ 0.4 $ 4.5 $ 2.5 $ 4.5
Fixed asset impairments and loss (gain) on sale of equipment 0.2 0.9 0.6 7.2
Contingent consideration 0.1 0.8 0.9 0.9
Foreign exchange transaction losses (gains) 0.4 1.0 (2.5) (4.5)
Other items 0.7 (0.5) 1.5 (1.9)
Total other expense (income) $ 1.8 $ 6.7 $ 3.0 $ 6.2
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Other Expense (Income) - Restructuring and Related Charges (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2020
Feb. 28, 2018
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Restructuring Reserve [Roll Forward]            
Charges     $ 0.4 $ 4.5 $ 2.5 $ 4.5
2020 Restructuring Plan            
Restructuring Cost and Reserve [Line Items]            
Restructuring and related activities, period of implementation 24 months          
Restructuring and related cost, cumulative cost incurred $ 7.1          
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2020         4.6  
Charges         2.5  
Cash payments         (2.3)  
Balance, September 30, 2021     4.8   4.8  
2020 Restructuring Plan | Severance and benefits            
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2020         4.6  
Charges         1.0  
Cash payments         (1.4)  
Balance, September 30, 2021     4.2   4.2  
2020 Restructuring Plan | Other charges            
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2020         0.0  
Charges         1.5  
Cash payments         (0.9)  
Balance, September 30, 2021     0.6   0.6  
2020 Restructuring Plan | Minimum            
Restructuring Cost and Reserve [Line Items]            
Restructuring and related cost, expected cost 15.0   9.0   9.0  
Effect on future earnings, amount 3.5   0.9      
2020 Restructuring Plan | Maximum            
Restructuring Cost and Reserve [Line Items]            
Restructuring and related cost, expected cost 17.0   11.0   11.0  
Effect on future earnings, amount $ 4.5   1.6      
2018 Restructuring Plan            
Restructuring Cost and Reserve [Line Items]            
Restructuring and related activities, period of implementation   24 months        
Restructuring and related cost, expected cost   $ 16.0        
Restructuring and related cost, cumulative cost incurred     13.7   13.7  
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2020         0.1  
Cash payments         (0.1)  
Balance, September 30, 2021     0.0   0.0  
2018 Restructuring Plan | Severance and benefits            
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2020         0.1  
Cash payments         (0.1)  
Balance, September 30, 2021     $ 0.0   $ 0.0  
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Other Expense (Income) - Other Items (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Development and licensing income [Line Items]          
Loss on sale of investments $ 0.9        
Loss on investment activity     $ 1.8    
Impairment charge     2.2    
Deferred income 38.1   38.1   $ 57.1
SmartDose          
Development and licensing income [Line Items]          
Development and licensing income $ 0.2 $ 0.2 $ 0.6 $ 0.6  
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 12.0 $ 21.1 $ 73.0 $ 52.1
Effective income tax rate 6.60% 21.60% 12.90% 18.20%
Effective income tax rate reconciliation, deduction, amount $ 20.4   $ 20.4  
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales $ 706.5 $ 548.0 $ 2,100.8 $ 1,566.7
Operating profit 181.4 99.2 568.3 290.8
Stock-based compensation expense     (27.5) (27.6)
Other expense, net 0.3 1.5 1.3 4.6
Income before income taxes 181.1 97.7 567.0 286.2
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit 212.3 126.3 646.2 365.0
Intersegment sales elimination        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales (0.2) (0.1) (0.4) (0.3)
Corporate and Unallocated        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit (30.9) (27.1) (77.9) (74.2)
Stock-based compensation expense (11.4) (10.0) (27.5) (27.6)
Corporate general costs (18.1) (12.4) (45.5) (39.5)
Restructuring and severance related charges (0.3) (4.5) (2.5) (6.7)
Amortization of Acquisition-related Intangible Assets (0.2) (0.2) (0.6) (0.4)
Cost investment activity (0.9) 0.0 (1.8) 0.0
Proprietary Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 577.0 421.5 1,708.0 1,194.5
Operating profit 195.5 107.5 594.3 312.9
Contract-Manufactured Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 129.7 126.6 393.2 372.5
Operating profit $ 16.8 $ 18.8 $ 51.9 $ 52.1
EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 376 360 1 false 81 0 false 10 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.westpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103102 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 2104103 - Disclosure - Revenue Sheet http://www.westpharma.com/role/Revenue Revenue Notes 10 false false R11.htm 2109104 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 11 false false R12.htm 2112105 - Disclosure - Inventories Sheet http://www.westpharma.com/role/Inventories Inventories Notes 12 false false R13.htm 2115106 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 13 false false R14.htm 2121107 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 14 false false R15.htm 2123108 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 15 false false R16.htm 2127109 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 16 false false R17.htm 2131110 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 2136111 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 18 false false R19.htm 2140112 - Disclosure - Shareholders' Equity Sheet http://www.westpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 2144113 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 2146114 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 21 false false R22.htm 2150115 - Disclosure - Other Expense (Income) Sheet http://www.westpharma.com/role/OtherExpenseIncome Other Expense (Income) Notes 22 false false R23.htm 2155116 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2157117 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 2158118 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 25 false false R26.htm 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 26 false false R27.htm 2305301 - Disclosure - Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueTables Revenue (Tables) Tables http://www.westpharma.com/role/Revenue 27 false false R28.htm 2310302 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 28 false false R29.htm 2313303 - Disclosure - Inventories (Tables) Sheet http://www.westpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.westpharma.com/role/Inventories 29 false false R30.htm 2316304 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 30 false false R31.htm 2324305 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 31 false false R32.htm 2328306 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 32 false false R33.htm 2332307 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 33 false false R34.htm 2337308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 34 false false R35.htm 2341309 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.westpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.westpharma.com/role/ShareholdersEquity 35 false false R36.htm 2347310 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 36 false false R37.htm 2351311 - Disclosure - Other Expense (Income) (Tables) Sheet http://www.westpharma.com/role/OtherExpenseIncomeTables Other Expense (Income) (Tables) Tables http://www.westpharma.com/role/OtherExpenseIncome 37 false false R38.htm 2359312 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 38 false false R39.htm 2406401 - Disclosure - Revenue - Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue - Revenue Recognition (Details) Details 39 false false R40.htm 2407402 - Disclosure - Revenue - Contracts and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails Revenue - Contracts and Liabilities (Details) Details 40 false false R41.htm 2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails Revenue - Contracts and Liabilities, Narrative (Details) Details 41 false false R42.htm 2411404 - Disclosure - Net Income Per Share (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Details http://www.westpharma.com/role/NetIncomePerShareTables 42 false false R43.htm 2414405 - Disclosure - Inventories (Details) Sheet http://www.westpharma.com/role/InventoriesDetails Inventories (Details) Details http://www.westpharma.com/role/InventoriesTables 43 false false R44.htm 2417406 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 44 false false R45.htm 2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails Leases - Lease Cash Flow and Supplemental Information (Details) Details 45 false false R46.htm 2419408 - Disclosure - Leases - Lease Weighted Average (Details) Sheet http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails Leases - Lease Weighted Average (Details) Details 46 false false R47.htm 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 47 false false R48.htm 2422410 - Disclosure - Affiliated Companies (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesDetails Affiliated Companies (Details) Details http://www.westpharma.com/role/AffiliatedCompanies 48 false false R49.htm 2425411 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.westpharma.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 49 false false R50.htm 2426412 - Disclosure - Debt - Credit Agreement (Details) Sheet http://www.westpharma.com/role/DebtCreditAgreementDetails Debt - Credit Agreement (Details) Details 50 false false R51.htm 2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Details 51 false false R52.htm 2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Details 52 false false R53.htm 2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Details 53 false false R54.htm 2434416 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails Fair Value Measurement - Level 3 Fair Value Measurements (Details) Details 54 false false R55.htm 2435417 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails Fair Value Measurement - Other Financial Instruments (Details) Details 55 false false R56.htm 2438418 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Details 56 false false R57.htm 2439419 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Details 57 false false R58.htm 2442420 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) Sheet http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails Shareholder's Equity - Change in Shareholders' Equity (Details) Details 58 false false R59.htm 2443421 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) Sheet http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails Shareholder's Equity - Supplemental Equity Information (Details) Details 59 false false R60.htm 2445422 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.westpharma.com/role/StockBasedCompensation 60 false false R61.htm 2448423 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Sheet http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Details 61 false false R62.htm 2449424 - Disclosure - Benefit Plans - Narrative (Details) Sheet http://www.westpharma.com/role/BenefitPlansNarrativeDetails Benefit Plans - Narrative (Details) Details 62 false false R63.htm 2452425 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails Other Expense (Income) - Other Expense (Income) (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 63 false false R64.htm 2453426 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails Other Expense (Income) - Restructuring and Related Charges (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 64 false false R65.htm 2454427 - Disclosure - Other Expense (Income) - Other Items (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails Other Expense (Income) - Other Items (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 65 false false R66.htm 2456428 - Disclosure - Income Taxes (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.westpharma.com/role/IncomeTaxes 66 false false R67.htm 2460429 - Disclosure - Segment Information (Details) Sheet http://www.westpharma.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.westpharma.com/role/SegmentInformationTables 67 false false All Reports Book All Reports wst-20210930.htm char1-1826719v3xlibortrans.htm ex311q32021.htm ex312q32021.htm ex321q32021.htm ex322q32021.htm wst-20210930.xsd wst-20210930_cal.xml wst-20210930_def.xml wst-20210930_lab.xml wst-20210930_pre.xml http://xbrl.sec.gov/currency/2021 http://xbrl.sec.gov/country/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wst-20210930.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 376, "dts": { "calculationLink": { "local": [ "wst-20210930_cal.xml" ] }, "definitionLink": { "local": [ "wst-20210930_def.xml" ] }, "inline": { "local": [ "wst-20210930.htm" ] }, "labelLink": { "local": [ "wst-20210930_lab.xml" ] }, "presentationLink": { "local": [ "wst-20210930_pre.xml" ] }, "schema": { "local": [ "wst-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 499, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 1, "http://xbrl.sec.gov/dei/2021": 5, "total": 6 }, "keyCustom": 14, "keyStandard": 346, "memberCustom": 22, "memberStandard": 58, "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.westpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Revenue", "role": "http://www.westpharma.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Net Income Per Share", "role": "http://www.westpharma.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112105 - Disclosure - Inventories", "role": "http://www.westpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115106 - Disclosure - Leases", "role": "http://www.westpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Affiliated Companies", "role": "http://www.westpharma.com/role/AffiliatedCompanies", "shortName": "Affiliated Companies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123108 - Disclosure - Debt", "role": "http://www.westpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127109 - Disclosure - Derivative Financial Instruments", "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - Fair Value Measurements", "role": "http://www.westpharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136111 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140112 - Disclosure - Shareholders' Equity", "role": "http://www.westpharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144113 - Disclosure - Stock-Based Compensation", "role": "http://www.westpharma.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146114 - Disclosure - Benefit Plans", "role": "http://www.westpharma.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150115 - Disclosure - Other Expense (Income)", "role": "http://www.westpharma.com/role/OtherExpenseIncome", "shortName": "Other Expense (Income)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - Income Taxes", "role": "http://www.westpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157117 - Disclosure - Commitments and Contingencies", "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158118 - Disclosure - Segment Information", "role": "http://www.westpharma.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Revenue (Tables)", "role": "http://www.westpharma.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Inventories (Tables)", "role": "http://www.westpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - Leases (Tables)", "role": "http://www.westpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Debt (Tables)", "role": "http://www.westpharma.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332307 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341309 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.westpharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347310 - Disclosure - Benefit Plans (Tables)", "role": "http://www.westpharma.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351311 - Disclosure - Other Expense (Income) (Tables)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables", "shortName": "Other Expense (Income) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359312 - Disclosure - Segment Information (Tables)", "role": "http://www.westpharma.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i42b82abc76ec435b969c86e95c4cbc74_D20210701-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Revenue - Revenue Recognition (Details)", "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "shortName": "Revenue - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i42b82abc76ec435b969c86e95c4cbc74_D20210701-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia14ead9df9114c8298eac622f1f15cb0_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Revenue - Contracts and Liabilities (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "shortName": "Revenue - Contracts and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia14ead9df9114c8298eac622f1f15cb0_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "shortName": "Revenue - Contracts and Liabilities, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Net Income Per Share (Details)", "role": "http://www.westpharma.com/role/NetIncomePerShareDetails", "shortName": "Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Inventories (Details)", "role": "http://www.westpharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417406 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Leases - Lease Weighted Average (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "shortName": "Leases - Lease Weighted Average (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Affiliated Companies (Details)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "shortName": "Affiliated Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia14ead9df9114c8298eac622f1f15cb0_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - Debt - Long-term Debt (Details)", "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails", "shortName": "Debt - Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426412 - Disclosure - Debt - Credit Agreement (Details)", "role": "http://www.westpharma.com/role/DebtCreditAgreementDetails", "shortName": "Debt - Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "iad066d083cea48a4b9b9cf9e9a294550_I20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i8692ad00038349378532774b05be24bb_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i8692ad00038349378532774b05be24bb_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia14ead9df9114c8298eac622f1f15cb0_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "shortName": "Fair Value Measurement - Level 3 Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i2840d000cd24413d9cd3a18bc00751ae_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails", "shortName": "Fair Value Measurement - Other Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i3157da0a0357470c984ae839083c40bc_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i560ff85be09d4d5880d767dc15df8f65_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i3157da0a0357470c984ae839083c40bc_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442420 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "shortName": "Shareholder's Equity - Change in Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ida4536fef0b743ff844556083be09dc0_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443421 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails", "shortName": "Shareholder's Equity - Supplemental Equity Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ida4536fef0b743ff844556083be09dc0_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ia52201e23330462bba8965a0120833f7_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445422 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448423 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails", "shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449424 - Disclosure - Benefit Plans - Narrative (Details)", "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "shortName": "Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452425 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "shortName": "Other Expense (Income) - Other Expense (Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453426 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "shortName": "Other Expense (Income) - Restructuring and Related Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i929ea5d3a0a640fab1235ec151690df2_D20200701-20200731", "decimals": null, "lang": "en-US", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454427 - Disclosure - Other Expense (Income) - Other Items (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails", "shortName": "Other Expense (Income) - Other Items (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456428 - Disclosure - Income Taxes (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "ic7330cbb651e4a00a3c36d240c2b99a2_D20210701-20210930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460429 - Disclosure - Segment Information (Details)", "role": "http://www.westpharma.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - New Accounting Standards", "role": "http://www.westpharma.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20210930.htm", "contextRef": "i6985b9193e3b47d89944a84b7de7e462_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 81, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. plans" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Japan, Yen", "terseLabel": "Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Singapore, Dollars", "terseLabel": "SGD" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r119", "r173", "r185", "r186", "r187", "r188", "r189", "r191", "r195", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r268", "r270", "r271" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r119", "r173", "r185", "r186", "r187", "r188", "r189", "r191", "r195", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r268", "r270", "r271" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r124", "r134", "r140", "r219", "r480", "r481", "r482", "r497", "r498", "r563", "r566", "r569", "r570", "r731" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r124", "r134", "r140", "r219", "r480", "r481", "r482", "r497", "r498", "r563", "r566", "r569", "r570", "r731" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r124", "r134", "r140", "r219", "r480", "r481", "r482", "r497", "r498", "r563", "r566", "r569", "r570", "r731" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r202", "r351", "r357", "r692" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r276", "r313", "r454", "r459", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r689", "r693", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r276", "r313", "r454", "r459", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r689", "r693", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r202", "r351", "r357", "r692" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r198", "r351", "r355", "r648", "r688", "r690" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r198", "r351", "r355", "r648", "r688", "r690" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r276", "r313", "r395", "r454", "r459", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r689", "r693", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r276", "r313", "r395", "r454", "r459", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r689", "r693", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r199", "r200", "r351", "r356", "r691", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r199", "r200", "r351", "r356", "r691", "r708", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r640", "r642", "r645", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "verboseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r127", "r128", "r129", "r131", "r207", "r208", "r216", "r217", "r218", "r219", "r222", "r223", "r257", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r497", "r498", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r586", "r587", "r588", "r589", "r590", "r591", "r595", "r596", "r629", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r42", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r24", "r204", "r205" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r655", "r672" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r65", "r70", "r78", "r79", "r80", "r518" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans:" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r235" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r70", "r78", "r79", "r80", "r81", "r517" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "(Losses) gains on derivatives", "verboseLabel": "Gains (losses) on derivatives:" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r62", "r63", "r64", "r70", "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Change in equity affiliate investment AOCI" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r68", "r69", "r70", "r674", "r701", "r705" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r78", "r79", "r602", "r603", "r604", "r605", "r606", "r608" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r67", "r70", "r78", "r79", "r80", "r121", "r122", "r123", "r518", "r696", "r697", "r733" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r59", "r70", "r78", "r79", "r80", "r518", "r603", "r604", "r605", "r606", "r608" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r484", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r121", "r122", "r123", "r480", "r481", "r482", "r569" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r108", "r232" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r462", "r473", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r108", "r230", "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of Acquisition-related Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r116", "r181", "r187", "r193", "r214", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r515", "r519", "r585", "r634", "r636", "r654", "r671" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r57", "r116", "r214", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r515", "r519", "r585", "r634", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r573" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r464", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r107", "r512" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 3.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r509", "r510", "r511" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r37", "r110" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, including cash equivalents at end of period", "periodStartLabel": "Cash, including cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r105", "r601" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges:" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r556" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 2.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r556" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 1.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Derivative (gain) loss on hedged item, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r254", "r659", "r678" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r251", "r252", "r253", "r255", "r710" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option contract in which the underlying asset is a commodity.", "label": "Commodity Option [Member]", "terseLabel": "Commodity call options" } } }, "localname": "CommodityOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r121", "r122", "r569" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3\u00a0million and 75.3 million, respectively; shares outstanding: 74.1\u00a0million and 74.0 million, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r74", "r76", "r77", "r87", "r663", "r684" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r86", "r96", "r662", "r683" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r166", "r167", "r202", "r583", "r584", "r709" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r166", "r167", "r202", "r583", "r584", "r706", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r166", "r167", "r202", "r583", "r584", "r706", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r166", "r167", "r202", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of net sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r166", "r167", "r202", "r583", "r584", "r709" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r338", "r340", "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract assets, September\u00a030, 2021", "periodStartLabel": "Contract assets, December 31, 2020" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r338", "r339", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "negatedPeriodEndLabel": "Deferred income, September\u00a030, 2021", "negatedPeriodStartLabel": "Deferred income, December 31, 2020", "terseLabel": "Deferred income" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Change in deferred income - decrease (increase)" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r338", "r339", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred income, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r338", "r339", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred income, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in the deferred income balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r185", "r186", "r187", "r188", "r189", "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate and Unallocated" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r90", "r648" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedTerseLabel": "Cost of goods and services sold", "verboseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r396", "r547" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r163", "r202" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Long-term debt, current", "verboseLabel": "Notes payable and other current debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r112", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r290", "r297", "r298", "r300", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r301", "r656", "r669" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48", "r274" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r115", "r119", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r303", "r304", "r305", "r306", "r328", "r331", "r332", "r333", "r610", "r611", "r613", "r614", "r668" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "verboseLabel": "Deferred compensation benefits" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r41" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r490", "r491" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r490", "r491" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r379" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Recognized actuarial losses (gains)", "terseLabel": "Actuarial losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r372", "r412", "r439", "r444", "r445" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "negatedTerseLabel": "Prior service credit", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r18", "r370", "r371", "r394", "r444", "r653", "r670" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r372", "r410", "r437", "r444", "r445" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r372", "r377", "r409", "r436", "r444", "r445" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r407", "r434", "r444", "r445" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r373", "r414", "r441" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Settlements", "negatedTerseLabel": "Settlements", "terseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r375", "r408", "r435", "r444", "r445" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r428", "r429", "r432", "r433", "r444" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r108", "r233" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average strike price on the group of price risk option contracts such as put options or call options.", "label": "Derivative, Average Price Risk Option Strike Price", "terseLabel": "Derivative, average price risk option strike price" } } }, "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r538", "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "negatedTerseLabel": "Derivative, forward point components, (gain) loss, recognized in earnings" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r58", "r531", "r533", "r541", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r559", "r572" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r529", "r531", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r529", "r531", "r541", "r549", "r550", "r553", "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r539", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nominal volume used to calculate payments on a derivative instrument.", "label": "Derivative, Nonmonetary Notional Amount, Volume", "terseLabel": "Derivative, nonmonetary notional amount, volume" } } }, "localname": "DerivativeNonmonetaryNotionalAmountVolume", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "volumeItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r523", "r525" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r522", "r524", "r525", "r529", "r530", "r534", "r541", "r551", "r552", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative contract term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r351", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r631", "r632", "r680" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Amount receivable from affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrentAndNoncurrent": { "auth_ref": [ "r631", "r633", "r658", "r679", "r707" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due to Affiliate", "terseLabel": "Amount due and payable to affiliates" } } }, "localname": "DueToAffiliateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East, Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r88", "r132", "r133", "r134", "r135", "r136", "r143", "r145", "r150", "r151", "r152", "r156", "r157", "r570", "r571", "r664", "r685" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r88", "r132", "r133", "r134", "r135", "r136", "r145", "r150", "r151", "r152", "r156", "r157", "r570", "r571", "r664", "r685" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r601" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOnFutureEarningsAmount": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on earnings.", "label": "Effect on Future Earnings, Amount", "terseLabel": "Effect on future earnings, amount" } } }, "localname": "EffectOnFutureEarningsAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r78", "r79", "r80", "r121", "r122", "r123", "r128", "r137", "r139", "r160", "r219", "r327", "r334", "r480", "r481", "r482", "r497", "r498", "r569", "r602", "r603", "r604", "r605", "r606", "r608", "r696", "r697", "r698", "r733" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r38", "r182", "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying amount, equity-method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Affiliated Companies" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Carrying amount, investments not accounted for under the equity method" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r573", "r574", "r575", "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r288", "r303", "r304", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r444", "r574", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r288", "r396", "r398", "r403", "r444", "r574", "r637" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r288", "r303", "r304", "r396", "r398", "r403", "r444", "r574", "r638" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r288", "r303", "r304", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r444", "r574", "r639" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Level 3 Fair Value Measurements [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r577", "r582" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Changes in Level 3 Fair Value Measurements" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Increase in fair value recorded in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r288", "r303", "r304", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r444", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Other expense (income)" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r597", "r598", "r599", "r600" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 4.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange transaction losses (gains)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r58", "r396", "r546" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r449", "r453", "r458" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International plans" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "auth_ref": [ "r538", "r557" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 3.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "negatedTerseLabel": "Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges" } } }, "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r531" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (loss) on derivative instruments, net, pretax" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r535" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "negatedTotalLabel": "Derivative (gain) loss recognized in income, fair value hedges" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedTerseLabel": "Loss on sale of investments" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedTerseLabel": "Corporate general costs" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r165", "r709" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r226", "r227", "r636", "r652" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r89", "r116", "r181", "r186", "r189", "r192", "r195", "r214", "r258", "r259", "r260", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r585" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r529", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairment charge" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r181", "r186", "r189", "r192", "r195" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r84", "r108", "r178", "r213", "r660", "r681" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net income of affiliated companies" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r238", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r117", "r494", "r495", "r496", "r502", "r504", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r138", "r139", "r179", "r492", "r503", "r505", "r686" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Tax benefit (expense)", "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDeductions": { "auth_ref": [ "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Amount", "terseLabel": "Effective income tax rate reconciliation, deduction, amount" } } }, "localname": "IncomeTaxReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r107" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other non-cash items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r146", "r147", "r148", "r152" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r229", "r231" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r82", "r175", "r609", "r612", "r665" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r173", "r185", "r186", "r187", "r188", "r189", "r191", "r195" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment sales elimination" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r224" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r55", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.westpharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r224" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r224" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r92", "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedTerseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r38" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in affiliated companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r625", "r627" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating leases liabilities payments due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year one" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of fiscal year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r626" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed lease interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r116", "r188", "r214", "r258", "r259", "r260", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r516", "r519", "r520", "r585", "r634", "r635" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r116", "r214", "r585", "r636", "r657", "r676" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r47", "r116", "r214", "r258", "r259", "r260", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r516", "r519", "r520", "r585", "r634", "r635", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r573" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r20", "r656", "r669" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit Facility, unused commitment level" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r43", "r115" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r287", "r302", "r303", "r304", "r656", "r673" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less: current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "verboseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r49", "r256" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r105", "r106", "r109" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r7", "r72", "r75", "r80", "r85", "r109", "r116", "r127", "r132", "r133", "r134", "r135", "r138", "r139", "r149", "r181", "r186", "r189", "r192", "r195", "r214", "r258", "r259", "r260", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r571", "r585", "r661", "r682" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Total reclassifications for the period, net of tax" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedges:" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r5", "r125", "r126", "r129", "r130", "r140", "r141", "r142", "r209", "r210", "r220", "r221", "r362", "r363", "r364", "r365", "r483", "r499", "r500", "r501", "r567", "r592", "r593", "r594", "r630", "r649", "r650", "r651", "r700", "r701", "r702", "r703", "r705", "r734" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.westpharma.com/role/SegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r70", "r81" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r181", "r186", "r189", "r192", "r195" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating profit", "totalLabel": "Operating profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r618", "r627" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r616" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r616" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r616" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r617", "r621" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r615" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r624", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r623", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r185", "r186", "r187", "r188", "r189", "r195" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Options Held" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r108", "r237" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 5.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Fixed asset impairments and loss (gain) on sale of equipment" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r56", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Commodity call options" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r66", "r68", "r513", "r517" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $0.2, $(0.1), $0.4, and $(1.2), respectively" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "auth_ref": [ "r513", "r514", "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "terseLabel": "Defined benefit pension and other postretirement plan adjustments, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r513", "r514", "r517" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r60", "r68", "r532", "r536", "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "auth_ref": [ "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "auth_ref": [ "r61", "r68", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "terseLabel": "Net gain (loss) on derivatives, tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r61", "r537" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Net gain (loss) on derivatives, net of tax of $(0.4), $(0.2), $(0.4) and $(0.4), respectively" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r73", "r76", "r513", "r514", "r517" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive (loss) income, net of tax", "totalLabel": "Other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liabilities" } } }, "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Employee-related Liabilities, Current", "terseLabel": "Accrued salaries, wages and benefits" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r687" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other expense (income)" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r367", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "Other Expense (Income)" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r46", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r109" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Changes in assets and liabilities" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other nonoperating (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 2.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other items" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r369", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r422", "r425", "r429", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other retirement benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r241", "r242", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other charges" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Contingent consideration payments in excess of acquisition-date liability" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r97", "r99" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r101" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares purchased under share repurchase programs" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r104", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r101" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividend payments" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r101" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Shares repurchased for employee tax withholdings" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r98" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangibles" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r98" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r395", "r397", "r403", "r421", "r423", "r424", "r425", "r426", "r427", "r444", "r446", "r447", "r448", "r460" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r19", "r370", "r371", "r394", "r444" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "verboseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r21", "r370", "r371", "r394", "r444" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r368", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r422", "r425", "r429", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r455", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension benefits" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Unit (PSUs)" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r22", "r311" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r100", "r475" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Employee stock purchase plan contributions" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r100", "r475" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock-based compensation awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r234" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r236", "r636", "r667", "r677" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r70", "r81" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified out from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r186", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r186", "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Segment Information" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r102" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r489", "r647", "r722" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r241", "r244", "r248", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Restructuring and related cost, cumulative cost incurred" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r241", "r244", "r248", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r241", "r244", "r248", "r250" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 1.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Charges", "verboseLabel": "Restructuring and related charges" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r108", "r240", "r245", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedTerseLabel": "Restructuring and severance related charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r241", "r242", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r242", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance, September 30, 2021", "periodStartLabel": "Balance, December 31, 2020" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r334", "r484", "r636", "r675", "r700", "r705" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r121", "r122", "r123", "r128", "r137", "r139", "r219", "r480", "r481", "r482", "r497", "r498", "r569", "r696", "r698" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r425", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r449", "r453", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r425", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r449", "r453", "r458" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r368", "r369", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r422", "r425", "r429", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r368", "r369", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r422", "r425", "r429", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r172", "r173", "r185", "r190", "r191", "r198", "r199", "r202", "r350", "r351", "r648" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r354", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r83", "r116", "r172", "r173", "r185", "r190", "r191", "r198", "r199", "r202", "r214", "r258", "r259", "r260", "r263", "r264", "r265", "r267", "r269", "r271", "r272", "r585", "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r622", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r166", "r202" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r70", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r531", "r541", "r550" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r522", "r524", "r525", "r529", "r530", "r534", "r541", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Foreign Currency Contracts" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r15", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r241", "r242", "r243", "r244", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r242", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r464", "r474" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r52", "r113", "r161", "r162", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r320", "r325", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r168", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r202", "r244", "r250", "r688" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r168", "r170", "r171", "r181", "r184", "r189", "r193", "r194", "r195", "r196", "r198", "r201", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r107" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "negatedTerseLabel": "Stock-based compensation expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Stock volatility (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r461", "r465" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Stock options, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r469", "r485" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r619", "r627" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r111", "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r6", "r168", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r202", "r228", "r239", "r244", "r250", "r688" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r54", "r78", "r79", "r80", "r121", "r122", "r123", "r128", "r137", "r139", "r160", "r219", "r327", "r334", "r480", "r481", "r482", "r497", "r498", "r569", "r602", "r603", "r604", "r605", "r606", "r608", "r696", "r697", "r698", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r327", "r334" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock -based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r334", "r463", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Stock repurchase program, shares authorized (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r28", "r29", "r116", "r206", "r214", "r585", "r636" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r114", "r312", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Forward treasury locks" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Stock repurchase program, average price per share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r53", "r335" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r53", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r23", "r327", "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Share purchased under share repurchase program (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r53", "r335", "r336" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost (1.2\u00a0million and 1.3 million shares, respectively)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r327", "r334", "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Shares purchased under share repurchase program", "terseLabel": "Stock purchase program, cost of shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r241", "r242", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Less: unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Loss on investment activity" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r620", "r627" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r152" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r152" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "wst_A2018RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Restructuring Plan [Member]", "label": "2018 Restructuring Plan [Member]", "terseLabel": "2018 Restructuring Plan" } } }, "localname": "A2018RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_A2020RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Restructuring Plan [Member]", "label": "2020 Restructuring Plan [Member]", "terseLabel": "2020 Restructuring Plan" } } }, "localname": "A2020RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_BiologicsCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biologics Customers [Member]", "label": "Biologics Customers [Member]", "terseLabel": "Biologics" } } }, "localname": "BiologicsCustomersMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_BusinessCombinationContingentConsiderationMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Measurement Input", "label": "Business Combination, Contingent Consideration, Measurement Input", "terseLabel": "Business combination, contingent consideration, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationMeasurementInput", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "wst_ContractManufacturedCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract-Manufactured Customers [Member]", "label": "Contract-Manufactured Customers [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedCustomersMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractManufacturedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Manufactured Products [Member]", "label": "Contract Manufactured Products [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedProductsMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractWithCustomerAssetIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Increase (Decrease)", "label": "Contract With Customer, Asset, Increase (Decrease)", "terseLabel": "Change in contract assets - increase (decrease)" } } }, "localname": "ContractWithCustomerAssetIncreaseDecrease", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract With Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_ContractWithCustomerLiabilityRecognitionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Recognition Period", "label": "Contract With Customer, Liability, Recognition Period", "terseLabel": "Contract with customer liability recognized" } } }, "localname": "ContractWithCustomerLiabilityRecognitionPeriod", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "wst_ContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability [Roll Forward]", "label": "Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilityRollForward", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_CostInvestmentImpairment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cost Investment Impairment", "label": "Cost Investment Impairment", "negatedTerseLabel": "Cost investment activity" } } }, "localname": "CostInvestmentImpairment", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "wst_DeliveryDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delivery Devices [Member]", "label": "Delivery Devices [Member]", "terseLabel": "Standard Packaging" } } }, "localname": "DeliveryDevicesMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_DeliverySystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Delivery Systems [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "DeliverySystemsMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_DevelopmentAndLicensingIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer.", "label": "Development And Licensing Income", "terseLabel": "Development and licensing income" } } }, "localname": "DevelopmentAndLicensingIncome", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "wst_DevelopmentandlicensingincomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Development and licensing income [Table]", "label": "Development and licensing income [Line Items]", "terseLabel": "Development and licensing income [Line Items]" } } }, "localname": "DevelopmentandlicensingincomeLineItems", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "stringItemType" }, "wst_DevelopmentandlicensingincomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development and licensing income [Table]", "label": "Development and licensing income [Table]", "terseLabel": "Development and licensing income [Table]" } } }, "localname": "DevelopmentandlicensingincomeTable", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails" ], "xbrltype": "stringItemType" }, "wst_GenericsCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generics Customers [Member]", "label": "Generics Customers [Member]", "terseLabel": "Generics" } } }, "localname": "GenericsCustomersMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_HighValueComponentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High-Value Components [Member]", "label": "High-Value Components [Member]", "terseLabel": "High-Value Product Components" } } }, "localname": "HighValueComponentsMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_NetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net sales member", "label": "Net Sales [Member]", "terseLabel": "Net sales" } } }, "localname": "NetSalesMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "wst_OtherFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Financial Instruments [Abstract]", "terseLabel": "Other Financial Instruments [Abstract]" } } }, "localname": "OtherFinancialInstrumentsAbstract", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "wst_OtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Income (Expense)", "negatedTerseLabel": "Other expense (income)", "negatedTotalLabel": "Total other expense (income)" } } }, "localname": "OtherIncomeExpense", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "wst_PackagingSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Packaging Systems [Member]", "terseLabel": "Proprietary Products" } } }, "localname": "PackagingSystemsMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_PensionSettlementCharge": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits.", "label": "Pension Settlement Charge", "terseLabel": "Pension settlement charge" } } }, "localname": "PensionSettlementCharge", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "wst_PharmaCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharma Customers [Member]", "label": "Pharma Customers [Member]", "terseLabel": "Pharma" } } }, "localname": "PharmaCustomersMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ProbabilitiesOfSuccessfulExecutionOfAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probabilities of Successful Execution of Agreement", "label": "Probabilities of Successful Execution of Agreement [Member]", "terseLabel": "Probabilities of Successful Execution of Agreement" } } }, "localname": "ProbabilitiesOfSuccessfulExecutionOfAgreementMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_ProbabilitiesOfSuccessfulFDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probabilities of Successful FDA Approval", "label": "Probabilities of Successful FDA Approval [Member]", "terseLabel": "Probabilities of Successful FDA Approval" } } }, "localname": "ProbabilitiesOfSuccessfulFDAApprovalMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases and Royalty Payments from Equity Method Investees", "label": "Purchases and Royalty Payments from Equity Method Investees", "terseLabel": "Purchases and royalty payments made to affiliates" } } }, "localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_PvsPayoutMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Maximum.", "label": "PVS Payout Maximum", "verboseLabel": "PSU payout, maximum (in hundredths)" } } }, "localname": "PvsPayoutMaximum", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_PvsPayoutMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Minimum.", "label": "PVS Payout Minimum", "verboseLabel": "PSU payout, minimum (in hundredths)" } } }, "localname": "PvsPayoutMinimum", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Activities, Period of Implementation", "label": "Restructuring and Related Activities, Period of Implementation", "terseLabel": "Restructuring and related activities, period of implementation" } } }, "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "durationItemType" }, "wst_Revolvingcreditfacilitydue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving credit facility, due 2024 [Member]", "label": "Revolving credit facility, due 2024 [Member]", "terseLabel": "Revolving credit facility, Due 2024" } } }, "localname": "Revolvingcreditfacilitydue2024Member", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "wst_SalesProjectionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Projections", "label": "Sales Projections [Member]", "terseLabel": "Sales Projections" } } }, "localname": "SalesProjectionsMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_SalesToEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales to Equity Method Investees", "label": "Sales to Equity Method Investees", "terseLabel": "Sales to affiliates" } } }, "localname": "SalesToEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Income And Expense, By Component", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "terseLabel": "Schedule of Other Expense (Income)" } } }, "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "xbrltype": "textBlockItemType" }, "wst_SeniorBNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior B Notes Due 2024 [Member]", "label": "Senior B Notes Due 2024 [Member]", "terseLabel": "Series B notes, due July 5, 2024 (3.82%)" } } }, "localname": "SeniorBNotesDue2024Member", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorCNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior C Notes Due 2027 [Member]", "label": "Senior C Notes Due 2027 [Member]", "terseLabel": "Series C notes, due July 5, 2027 (4.02%)" } } }, "localname": "SeniorCNotesDue2027Member", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior A Notes Due 2022 [Member]", "label": "Senior A Notes Due 2022 [Member]", "terseLabel": "Series A notes, due July 5, 2022 (3.67%)" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SmartDoseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SmartDose [Member]", "label": "SmartDose [Member]", "terseLabel": "SmartDose" } } }, "localname": "SmartDoseMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherItemsDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_StandardPackagingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Packaging [Member]", "label": "Standard Packaging [Member]", "terseLabel": "High-Value Product Delivery Devices" } } }, "localname": "StandardPackagingMember", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_TermLoanDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Due 2024", "label": "Term Loan Due 2024 [Member]", "terseLabel": "Term Loan, due December 31, 2024 (1.01%)", "verboseLabel": "Term Loan Due 2024" } } }, "localname": "TermLoanDue2024Member", "nsuri": "http://www.westpharma.com/20210930", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r487": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r488": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498357-110258" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r628": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r723": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r724": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r725": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r726": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r727": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r728": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 86 0000105770-21-000083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-21-000083-xbrl.zip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�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�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